<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD000535.pub3" GROUP_ID="PVD" ID="493299081014434644" MERGED_FROM="" MODIFIED="2015-02-18 15:12:36 +0000" MODIFIED_BY="Marlene Stewart" REVIEW_NO="02" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="8.0">
<COVER_SHEET MODIFIED="2015-02-18 15:12:36 +0000" MODIFIED_BY="Marlene Stewart">
<TITLE>Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery</TITLE>
<CONTACT MODIFIED="2015-02-18 15:12:36 +0000" MODIFIED_BY="Marlene Stewart"><PERSON ID="z1308221148098966495610632139453" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Rachel</FIRST_NAME><LAST_NAME>Bedenis</LAST_NAME><EMAIL_1>rbedenis@gmail.com</EMAIL_1><EMAIL_2>rbedenis@staffmail.ed.ac.uk</EMAIL_2><ADDRESS><DEPARTMENT>Centre for Population Health Sciences</DEPARTMENT><ORGANISATION>University of Edinburgh</ORGANISATION><CITY>Edinburgh</CITY><ZIP>EH8 9AG</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2015-02-18 15:12:36 +0000" MODIFIED_BY="Marlene Stewart"><PERSON ID="z1308221148098966495610632139453" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Rachel</FIRST_NAME><LAST_NAME>Bedenis</LAST_NAME><EMAIL_1>rbedenis@gmail.com</EMAIL_1><EMAIL_2>rbedenis@staffmail.ed.ac.uk</EMAIL_2><ADDRESS><DEPARTMENT>Centre for Population Health Sciences</DEPARTMENT><ORGANISATION>University of Edinburgh</ORGANISATION><CITY>Edinburgh</CITY><ZIP>EH8 9AG</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON><PERSON ID="4773" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Anne</FIRST_NAME><LAST_NAME>Lethaby</LAST_NAME><POSITION>Systematic reviewer</POSITION><EMAIL_1>a.lethaby@auckland.ac.nz</EMAIL_1><ADDRESS><DEPARTMENT>Department of Obstetrics and Gynaecology</DEPARTMENT><ORGANISATION>University of Auckland</ORGANISATION><ADDRESS_1>Private Bag 92019</ADDRESS_1><CITY>Auckland</CITY><ZIP>1142</ZIP><COUNTRY CODE="NZ">New Zealand</COUNTRY><PHONE_1>+64 9 373 7599 ext 86333</PHONE_1><FAX_1>+64 9 373 7503</FAX_1></ADDRESS></PERSON><PERSON ID="9127" ROLE="AUTHOR"><PREFIX>Mrs</PREFIX><FIRST_NAME>Heather</FIRST_NAME><LAST_NAME>Maxwell</LAST_NAME><EMAIL_1>hgmaxwell@aol.com</EMAIL_1><ADDRESS><ORGANISATION/><ADDRESS_1>15 Orchard Road</ADDRESS_1><CITY>Edinburgh</CITY><ZIP>EH4 2EP</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 131 3322604</PHONE_1></ADDRESS></PERSON><PERSON ID="z1211201151457955566166328882258" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Stefan</FIRST_NAME><LAST_NAME>Acosta</LAST_NAME><EMAIL_1>stefan.acosta@telia.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Vascular Diseases</DEPARTMENT><ORGANISATION>Malmö University Hospital</ORGANISATION><CITY>Malmö</CITY><ZIP>S205 02</ZIP><COUNTRY CODE="SE">Sweden</COUNTRY></ADDRESS></PERSON><PERSON ID="15784" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Martin</FIRST_NAME><MIDDLE_INITIALS>H</MIDDLE_INITIALS><LAST_NAME>Prins</LAST_NAME><EMAIL_1>Mh.Prins@maastrichtuniversity.nl</EMAIL_1><EMAIL_2>mh.prins@maastrichtuniversity.nl</EMAIL_2><ADDRESS><DEPARTMENT>Department of Epidemiology</DEPARTMENT><ORGANISATION>CAPHRI Research School, Maastricht University</ORGANISATION><CITY>Maastricht</CITY><ZIP>6200 MD</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 43 3882901</PHONE_1><FAX_1>+31 43 3884128</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2014-09-02 14:07:39 +0100" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="13" MONTH="6" YEAR="2014"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="13" MONTH="6" YEAR="2014"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="13" MONTH="6" YEAR="2016"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="1997"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2003"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2015"/>
</DATES>
<WHATS_NEW MODIFIED="2014-10-02 15:40:55 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-10-02 15:40:55 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="2" MONTH="9" YEAR="2014"/>
<DESCRIPTION>
<P>Searches rerun, one new study included, three new studies excluded</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2014-10-02 15:40:54 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="2" MONTH="9" YEAR="2014"/>
<DESCRIPTION>
<P>Searches rerun, one new study included, three new studies excluded, risk of bias tables completed, two new authors joined review team. Conclusions not changed</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2014-09-02 14:01:14 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2014-09-02 14:01:14 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="14" MONTH="2" YEAR="2011"/>
<DESCRIPTION>
<P>Link to anticoagulant feedback added</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2011-02-14 11:08:41 +0000" MODIFIED_BY="Marlene Stewart">
<DATE DAY="23" MONTH="4" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format. </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2011-02-14 11:08:38 +0000" MODIFIED_BY="Marlene Stewart">
<DATE DAY="23" MONTH="4" YEAR="2008"/>
<DESCRIPTION>
<P>This review was updated in 2008. New studies were identified and added to the included and excluded tables.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-05-07 12:08:39 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="26" MONTH="5" YEAR="2004"/>
<DESCRIPTION>
<P>Graph created and text amended</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-05-07 12:08:35 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="18" MONTH="8" YEAR="2003"/>
<DESCRIPTION>
<P>Published note added to effect that Donald Adam wrote protocol but did not have any involvement with the review</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2014-04-01 15:07:19 +0100" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES MODIFIED="2014-04-01 15:07:19 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2014-04-01 15:07:19 +0100" MODIFIED_BY="[Empty name]">
<NAME>Chief Scientist Office, Scottish Government Health Directorates, The Scottish Government</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>The PVD Group editorial base is supported by the Chief Scientist Office.</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2015-02-18 14:53:32 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2015-01-27 13:59:50 +0000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-04-30 13:59:00 +0100" MODIFIED_BY="[Empty name]">Antiplatelet agents for preventing failure of peripheral arterial grafts</TITLE>
<SUMMARY_BODY MODIFIED="2015-01-27 13:59:50 +0000" MODIFIED_BY="[Empty name]">
<P>Background</P>
<P>Symptomatic peripheral arterial disease in people with atherosclerosis can present as intermittent claudication, disabling pain on walking, or as critical limb ischaemia with pain at rest, ulceration, gangrene and the risk of losing a leg. One treatment option is to implant a graft or makeshift blood vessel to bypass a blockage in the main artery of the thigh. Using a section of the vein from the patient's leg is often better than artificial or prosthetic materials such as Dacron or polytetrafluoroethylene, which take up platelets that could lead to clotting that could block the graft. Other factors affecting the patency of the graft (how long the bypass remains open) include length of the bypass, site where the graft connects to the existing artery and blood flow out of the graft. Stenosis (narrowing) of the graft most frequently occurs at the surgical connections because of hyperplasia, or an increase in the number of smooth muscle cells, into the inner layer of the vessel, often followed by the formation of a thrombosis (clot) at the stenotic site.</P>
<P>Study characteristics</P>
<P>We include 16 studies in this review with 5683 randomised participants. Nine different treatment groups were evaluated: Aspirin (ASA) or aspirin and dipyridamole (ASA/DIP) versus placebo or nothing (six studies); ASA or ASA/DIP versus pentoxifylline (two studies); ASA/DIP versus indobufen (one study); ASA or ASA/DIP versus vitamin K antagonists (two studies); ASA/DIP versus low molecular weight heparin (one study); ticlopidine versus placebo (one study); ASA versus prostaglandin E1 (one study); ASA versus naftidrofuryl (one study); and clopidogrel and ASA versus ASA alone (one study). We evaluated the different treatment comparisons separately, and, where possible, we evaluated separately those participants who received different types of grafts, venous or prosthetic.</P>
<P>Quality of the evidence</P>
<P>The quality of evidence from the review was low to moderate, as there were few studies to provide evidence for the different comparisons; several of the included studies randomised and analysed participants in a way that could introduce bias; and many of the prespecified outcomes of the review were not addressed within the studies, or were reported on in different ways between studies. Also, the treatment dosages varied between studies. Overall study quality was moderate, with the largest problem being that the majority of studies did not described their methods of randomisation or blinding of those that evaluated the outcomes. The other main issue with study quality was not blinding participants or personnel to the treatment received.</P>
<P>Key results</P>
<P>The comparison of ASA or ASA and dipyridamole (ASA/DIP) versus placebo or nothing, included the most studies (six), which allowed for robust analysis. For this treatment group, there was improved graft patency in the ASA or ASA/DIP treatment group. There was an improvement in those that received prosthetic grafts, but not in those that received venous grafts. Only a single study evaluated secondary patency, for which there was no difference between treatment groups. For this comparison there was no difference for any of the side effects, including general, gastrointestinal, bleeding and wound/graft infection. Amputations, cardiovascular events and death from any cause were also similar between the treatment groups. The comparison of ASA or ASA/DIP versus vitamin K antagonists included two studies, one of which was very large, with over 2000 participants. There were no differences between treatment for primary graft patency at three, six, 12 or 24 months, and there was also no evidence of a difference for limb amputation, cardiovascular events or mortality. One large study evaluated clopidogrel and ASA versus ASA alone, and for all grafts (including prosthetic and venous grafts) there was no evidence of a difference of primary patency at 24 months. There was evidence of increased total bleeding in the clopidogrel and ASA group, from an increase in mild and moderate bleeding, but there was no difference in severe or fatal bleeding. There was no difference between the treatment groups for limb amputation or death from any cause. For the remaining treatment comparisons there is not currently enough evidence to draw any robust conclusions about the efficacy or safety of the treatment on graft patency after peripheral bypass.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2015-01-27 13:57:55 +0000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2015-01-13 09:46:29 +0000" MODIFIED_BY="[Empty name]">
<P>Peripheral arterial disease (PAD) may cause occlusions (blockages) in the main arteries of lower limbs. One treatment option is bypass surgery using autologous (the patient's own tissue) vein graft or prosthetic (artificial) graft. A number of factors influence occlusion rates in these patients, including the material used. To prevent graft occlusion patients are usually treated with antiplatelet, antithrombotic drugs, or a combination of both.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2015-01-27 13:55:25 +0000" MODIFIED_BY="[Empty name]">
<P>To determine the effects of antiplatelet agents for the prevention of thrombosis in people with lower limb atherosclerosis who were undergoing femoropopliteal or femorodistal bypass grafting. Outcomes included the overall success of therapy (graft patency and limb salvage rates) and complications of treatment.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2015-01-27 13:55:35 +0000" MODIFIED_BY="[Empty name]">
<P>For this update the Cochrane Peripheral Vascular Diseases Group Trials Search Co-ordinator searched the Specialised Register (last searched June 2014) and the Cochrane Central Register of Controlled Trials (CENTRAL) (2014, Issue 5). We sought additional trials through screening the reference lists of relevant papers.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2015-01-27 13:55:48 +0000" MODIFIED_BY="[Empty name]">
<P>Two review authors, RB and AL, independently reviewed studies found in the search and evaluated them based on the inclusion and exclusion criteria, resolving disagreements through discussion.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2015-01-27 13:56:10 +0000" MODIFIED_BY="[Empty name]">
<P>RB and AL independently extracted details of the selected studies for the update. We compared the treatment and control groups for important prognostic factors and differences described. If any data were unavailable, we sought further information from study authors. We synthesised data by comparing group results. We addressed unit of analysis issues by subgroup analysis.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2015-01-27 13:57:17 +0000" MODIFIED_BY="[Empty name]">
<P>We include 16 studies with 5683 randomised participants. Nine different treatment groups were evaluated: aspirin (ASA) or aspirin and dipyridamole (ASA/DIP) versus placebo or nothing (six studies); ASA or ASA/DIP versus pentoxifylline (two studies); ASA/DIP versus indobufen (one study); ASA or ASA/DIP versus vitamin K antagonists (two studies); ASA/DIP versus low molecular weight heparin (one study); ticlopidine versus placebo (one study); ASA versus prostaglandin E1 (one study); ASA versus naftidrofuryl (one study); and clopidogrel and ASA versus ASA alone (one study). The treatment comparisons were evaluated separately, and, where possible, we performed subgroup analysis for venous grafts and prosthetic grafts and at different follow-up time points. The quality of evidence was low to moderate as many of the treatment comparisons had very few studies to contribute data, several of the included studies had unit of analysis issues, the treatment dosages varied between studies, and data for many outcomes important to this review were not given in any of the studies, or differed greatly between studies. Overall study quality was moderate, with the largest problem being that the majority of studies did not describe their methods of randomisation, allocation concealment or blinding of outcome assessors, leading to risk ratings of 'unclear'. The other main issue with study quality was studies not blinding participants or personnel.</P>
<P>The treatment comparison with the most number of included studies, which allowed for robust conclusions, was that of aspirin (ASA) or ASA and dipyridamole (ASA/DIP) versus placebo or nothing, covered by six studies. For this treatment group, there was improved graft patency in the ASA or ASA/DIP treatment group, odds ratio (OR) 0.42 (95% confidence interval (CI) 0.22 to 0.83; P = 0.01; 952 participants). This effect was not seen for venous grafts alone at any of the time points, but was observed for all time points in prosthetic grafts, including the final time point of 12 months (OR 0.19, 95% CI 0.10 to 0.36; P &lt; 0.00001; 222 participants). Only a single study evaluated secondary patency, for which there was no difference between treatment groups. For the comparison ASA or ASA/DIP versus placebo or nothing there was no difference for any of the side effects, including general, gastrointestinal, bleeding and wound/graft infection. Amputations, cardiovascular events and mortality were also similar between the treatment groups. The comparison of ASA or ASA/DIP versus vitamin K antagonists included two studies, one of which was very large, with over 2000 participants. There were no differences between treatment for primary graft patency at three, six, 12 or 24 months, and there was also no evidence of a difference for limb amputation, cardiovascular events or mortality. One large study (851 participants) evaluated clopidogrel and ASA versus ASA alone, and for all grafts there was no evidence of a difference of primary patency at 24 months. There was evidence of increased total bleeding in the clopidogrel and ASA group (OR 2.65, 95% CI 1.69 to 4.15) from an increase in mild (OR 2.34, 95% CI 1.37 to 4.00), and moderate bleeding (OR 4.13, 95% CI 1.37 to 12.45), but no difference in severe or fatal bleeding. There was no difference between the treatment groups for limb amputation or mortality. For the remaining treatment comparisons there is not currently enough evidence to draw any robust conclusions about the efficacy or safety of the treatment on graft patency after peripheral bypass.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2015-01-27 13:57:55 +0000" MODIFIED_BY="[Empty name]">
<P>Antiplatelet therapy with aspirin or with aspirin plus dipyridamole had a beneficial effect on primary patency of peripheral bypass grafts compared to placebo or no treatment. This effect was not evident when evaluating venous grafts alone, but antiplatelet therapy did have a beneficial effect on patency in those who had prosthetic grafts. There was no evidence of differences in side effects (including general, gastrointestinal, bleeding or infection), amputation, cardiovascular events or mortality between the treatment groups. However, the number of participants included in this analysis might be too small to detect a statistically significant effect for side effects, amputation, cardiovascular morbidity or mortality. We found no difference in primary graft patency when aspirin or aspirin with dipyridamole was compared to a vitamin K antagonist or when clopidogrel with aspirin was compared to aspirin alone. However, there was evidence of increase bleeding in the clopidogrel with aspirin group for the latter comparison. The remaining six treatment comparisons did not include enough data to draw any robust conclusions about their efficacy or safety at this time.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2015-01-28 08:39:54 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2015-01-27 14:00:10 +0000" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2015-01-27 14:00:07 +0000" MODIFIED_BY="[Empty name]">
<P>Symptomatic, chronic peripheral arterial disease (PAD) of the lower extremities may present either as intermittent claudication (IC), pain on walking, or as critical limb ischaemia (CLI), which is a more progressive stage with pain at rest, ulceration and gangrene (<LINK REF="REF-Becker-2011" TYPE="REFERENCE">Becker 2011</LINK>). The implantation of a femoropopliteal or femorodistal bypass graft (a makeshift blood vessel used to bypass a blockage in the main artery of the thigh) is one treatment option for people who are at risk of losing a limb or whose walking ability is greatly impaired because of the disease. By placing a graft in the groin area (an infrainguinal graft) the blocked arterial segment is bypassed, thereby improving blood flow in the limb. This then relieves the symptoms of claudication or rest pain and decreases the potential for amputation due to ulceration and gangrene, termed limb salvage.</P>
<P>The patency rate for femoropopliteal and femorodistal grafts, or the number of bypasses remaining open after a certain period of time, depends on several risk factors. These include whether or not the patient has acute lower limb ischaemia (<LINK REF="REF-Baril-2013" TYPE="REFERENCE">Baril 2013</LINK>), graft material, length of the bypass, site of the distal anastomosis (surgical connection of the graft to the existing artery), outflow conditions in the calf (flow of blood out of the graft) and female gender (<LINK REF="REF-Cooper-1990" TYPE="REFERENCE">Cooper 1990</LINK>; <LINK REF="REF-Tangelder-2000" TYPE="REFERENCE">Tangelder 2000</LINK>). Autologous saphenous vein (using a vein from the patient's calf or thigh or both) is superior to prosthetic (artificial) materials such as Dacron or polytetrafluoroethylene (PTFE) (<LINK REF="REF-Rutherford-1988" TYPE="REFERENCE">Rutherford 1988</LINK>). Where the distal anastomosis is above the knee there is a lower risk of graft failure, and patients with two or three patent calf arteries have a better outcome than those with only one patent artery. Graft failure most frequently occurs at the site of either the distal or proximal anastomosis, when smooth muscle cells of the medial (middle) layer of the vessel wall grow into the intimal (inner) layer, which is known as intimal hyperplasia. This in turn causes the diameter of the perfused graft to become smaller, known as stenosis. When blood flow through the vessel is significantly reduced intermittent claudication may be experienced. Graft occlusion (closure) can occur by formation of a thrombosis (clot) at the stenotic site. If blood flow in the failed graft cannot be restored and further bypass surgery is not possible, then blood flow may be so poor that the limb cannot remain viable and amputation is required. Successful prevention of graft failure and thus the need for surgical re-intervention is of major clinical and economic importance. Occlusion rates one year after the operation vary between 15% and 75% depending on the various risk factors described above (<LINK REF="REF-Abbott-1997" TYPE="REFERENCE">Abbott 1997</LINK>; <LINK REF="REF-Consensus-1991" TYPE="REFERENCE">Consensus 1991</LINK>). In addition, patients with lower limb atherosclerosis (progressive hardening of the arteries) frequently experience increased platelet aggregation, leading to clot formation. Moreover, the body's physiological stress response to surgery is a prothrombotic state (where the body is preparing to form a blood clot).</P>
</CONDITION>
<INTERVENTION MODIFIED="2015-01-27 14:00:10 +0000" MODIFIED_BY="[Empty name]">
<P>Antiplatelet treatment is used to prevent formation of blood clots by preventing platelet aggregation (<LINK REF="REF-NICE-2013" TYPE="REFERENCE">NICE 2013</LINK>). Antiplatelet agents work by improving blood rheology and also by suppressing the advancement of in- and outflow atherosclerosis (reducing the rate of development of stenosis) as well as coronary artery atherosclerosis, indirectly optimising cardiac function and circulation.</P>
<P>For patients receiving bypass surgery, the intensity of platelet uptake by the graft material has been shown to be inversely related to graft patency at one year, indicating the need for antiplatelet intervention. In animal experiments, antiplatelet drug administration started before bypass surgery has been shown to increase patency in prosthetic grafts when compared to no treatment (<LINK REF="REF-Fujitani-1988" TYPE="REFERENCE">Fujitani 1988</LINK>).</P>
<P>To prevent graft occlusion patients are usually treated with either an antiplatelet or an anticoagulant drug, or a combination of both. It is not known which regimen is best to prevent infrainguinal graft occlusion. The aim of this review was to evaluate whether antiplatelet treatment improves graft patency, limb salvage and survival in patients with chronic PAD who are undergoing infrainguinal bypass surgery.</P>
</INTERVENTION>
<IMPORTANCE MODIFIED="2014-07-22 17:13:58 +0100" MODIFIED_BY="[Empty name]">
<P>Another Cochrane review was recently undertaken to also evaluate the prevention of thrombosis after infrainguinal arterial bypass, but this review focused on the use of antithrombotic therapies (<LINK REF="REF-Geraghty-2011" TYPE="REFERENCE">Geraghty 2011</LINK>). Overall their findings were inconclusive, with a possible benefit of antithrombotics for autologous vein grafts. Also, there may be higher economic costs and adverse haemorrhagic events associated with the use of anticoagulants compared with antiplatelet therapy. If the efficacy of antiplatelets is acceptable then it may be a more economical alternative to anticoagulant therapy following bypass graft surgery in the legs.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2015-01-27 14:00:11 +0000" MODIFIED_BY="[Empty name]">
<P>To determine the effects of antiplatelet agents for the prevention of thrombosis in patients with lower limb atherosclerosis who were undergoing femoropopliteal or femorodistal bypass grafting. Outcomes include the overall success of therapy (graft patency and limb salvage rates) and complications of treatment.</P>
</OBJECTIVES>
<METHODS MODIFIED="2015-01-27 14:02:50 +0000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2015-01-27 14:00:42 +0000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2015-01-27 14:00:15 +0000" MODIFIED_BY="[Empty name]">
<P>Trials in which participants were randomly allocated to receive either antiplatelet therapy versus placebo, one antiplatelet regimen versus another or antiplatelet therapy versus an alternative treatment. We include trials using alternation (allocation of treatment alternating between two interventions) and consider them as quasi-randomised clinical trials (qRCTs).</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2015-01-27 14:00:22 +0000" MODIFIED_BY="[Empty name]">
<P>All people undergoing femoropopliteal or femorodistal bypass grafting for the treatment of intermittent claudication and critical limb ischaemia. We excluded people undergoing bypass surgery for trauma.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2015-01-27 14:00:34 +0000" MODIFIED_BY="[Empty name]">
<P>Antiplatelet therapy versus placebo, one antiplatelet regimen versus another, or antiplatelet therapy versus an alternative treatment. We excluded studies that included the same antiplatelet agent in both treatment groups, unless another antiplatelet was also used, but in only one treatment arm. We recorded the type of therapy, dosage, time of starting compared to surgery (pre- or postoperatively) and duration of the therapy.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2015-01-27 14:00:42 +0000" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2015-01-27 14:00:36 +0000" MODIFIED_BY="[Empty name]">
<P>(1) Primary graft patency: patency rates after surgery with no further intervention, as determined by clinical examination, measurement of the ankle-brachial pressure index (ABPI), duplex ultrasonography, angiography.<BR/>(2) Assisted primary patency: patency rates after intervention to improve blood flow in a graft which has not occluded.</P>
<P>We analysed primary patency and primary assisted patency for all grafts and for venous or prosthetic (artificial) grafts separately.</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2015-01-27 14:00:42 +0000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Secondary graft patency: patency rates following secondary intervention to restore blood flow to the graft</LI>
<LI>Objective assessment of lower limb blood flow: ABPI, exercise tolerance test</LI>
<LI>Side effects of treatment and complications</LI>
<LI>Limb salvage rate: survival rates with limb intact (or limb amputation)</LI>
<LI>Incidence of other cardiovascular events and mortality</LI>
<LI>Participants' quality of life</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2015-01-27 14:00:48 +0000" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2015-01-27 14:00:45 +0000" MODIFIED_BY="[Empty name]">
<P>For this update the Cochrane Peripheral Vascular Diseases Group Trials Search Co-ordinator (TSC) searched the Specialised Register (last searched June 2014) and the Cochrane Central Register of Controlled Trials (CENTRAL) 2014, Issue 5, part of <I>The Cochrane Library</I> (<A HREF="http://www.thecochranelibrary.com">www.thecochranelibrary.com</A>). See <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> for details of the search strategy used to search CENTRAL. The Specialised Register is maintained by the TSC and is constructed from weekly electronic searches of MEDLINE, EMBASE, CINAHL, AMED, and through handsearching relevant journals. The full list of the databases, journals and conference proceedings which have been searched, as well as the search strategies used, are described in the <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/PVD/frame.html">Specialised Register</A> section of the Cochrane Peripheral Vascular Diseases Group module in <I>The Cochrane Library</I>.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2015-01-27 14:00:48 +0000" MODIFIED_BY="[Empty name]">
<P>We scanned reference lists of studies and reviews identified by the search for relevant studies.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2015-01-27 14:02:50 +0000" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2015-01-27 14:00:56 +0000" MODIFIED_BY="[Empty name]">
<P>In this update, Rachel Bedenis (RB) and Anne Lethaby (AL) independently selected trials for inclusion or exclusion, resolving disagreements by discussion between them.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2015-01-27 14:01:05 +0000" MODIFIED_BY="[Empty name]">
<P>For newly-included studies RB and AL independently extracted the number of participants originally allocated to each treatment group and performed an intention-to-treat analysis. Data collection on each trial consisted of: inclusion and exclusion criteria; participant details (age, gender, co-morbidity); severity of arterial occlusive disease (as determined by the ABPI and the European Consensus (<LINK REF="REF-Consensus-1991" TYPE="REFERENCE">Consensus 1991</LINK>) definition of critical limb ischaemia); type of graft (autologous vein, prosthetic, human umbilical vein, composite graft); level of proximal graft anastomosis (common superficial femoral artery) and distal anastomosis (above-knee popliteal, below-knee popliteal, distal arteries); type of antiplatelet therapy used (dose, commencement of therapy relative to surgery, duration of therapy, compliance); and outcome (as mentioned in the section '<LINK TAG="SELECTION_CRITERIA" TYPE="SECTION">Criteria for considering studies for this review</LINK>'). We compared the treatment and control groups for important prognostic factors. If any of the above data were not available, we sought further information from the authors.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2015-01-27 14:01:21 +0000" MODIFIED_BY="[Empty name]">
<P>RB and AL independently assessed the methodological quality of included trials, using the 'Risk of bias' tool from The Cochrane Collaboration (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We assessed the following five domains: selection bias (random sequence generation, allocation concealment), performance bias (blinding of participants and personnel and blinding of outcome assessment), attrition bias (incomplete outcome data), reporting bias (selective reporting) and other potential sources of bias. We classified the domains as being at low risk of bias, high risk of bias or unclear risk of bias according to the guidelines in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). The two review authors assessing bias resolved disagreements by discussion.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2015-01-27 14:01:24 +0000" MODIFIED_BY="[Empty name]">
<P>We extracted dichotomous data and transformed them into odds ratios (ORs) with 95% confidence intervals (CIs) in the meta-analysis.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2015-01-27 14:02:10 +0000" MODIFIED_BY="[Empty name]">
<P>The majority of the included studies use individual participants as the unit of analysis, although four studies were not consistent in this method (<LINK REF="STD-Clyne-1987" TYPE="STUDY">Clyne 1987</LINK>; <LINK REF="STD-Donaldson-1985" TYPE="STUDY">Donaldson 1985</LINK>; <LINK REF="STD-Kohler-1984" TYPE="STUDY">Kohler 1984</LINK>; <LINK REF="STD-Lucas-1984" TYPE="STUDY">Lucas 1984</LINK>). <LINK REF="STD-Kohler-1984" TYPE="STUDY">Kohler 1984</LINK> reported on grafts rather than participants: 14 participants were re-entered and re-randomised after graft failure; participants with bilateral reconstructions were followed for patency of both grafts but were randomised only after the first reconstruction. There were 102 grafts in 88 participants in this study. In <LINK REF="STD-Donaldson-1985" TYPE="STUDY">Donaldson 1985</LINK>, the aspirin group recorded 35 grafts in 33 participants and the placebo group recorded 38 grafts in 32 participants. These additional grafts were due to bilateral grafts. In <LINK REF="STD-Clyne-1987" TYPE="STUDY">Clyne 1987</LINK>, 148 grafts were undertaken in 140 participants. <LINK REF="STD-Lucas-1984" TYPE="STUDY">Lucas 1984</LINK>

 
examined a mixture of single and multiple bypasses, using different materials, and also included thromboendarterectomy; there were considerable sources of heterogeneity within this study. The remaining papers appeared to report on one graft per individual.</P>
<P>For the meta-analyses, we used the number of participants randomised where possible and not the number of grafts, in order to maintain consistency with the majority of included studies. We have included the four studies using grafts as the unit of analysis (<LINK REF="STD-Clyne-1987" TYPE="STUDY">Clyne 1987</LINK>; <LINK REF="STD-Donaldson-1985" TYPE="STUDY">Donaldson 1985</LINK>; <LINK REF="STD-Kohler-1984" TYPE="STUDY">Kohler 1984</LINK>; <LINK REF="STD-Lucas-1984" TYPE="STUDY">Lucas 1984</LINK>) in the meta-analysis, but we have excluded them from a subsequent sensitivity analysis, to assess the influence these studies may have on the overall results.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2015-01-27 14:02:16 +0000" MODIFIED_BY="[Empty name]">
<P>Where data were missing, we contacted study authors for more information. Where possible, we performed analyses on an intention-to-treat basis.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2015-01-27 14:02:26 +0000" MODIFIED_BY="[Empty name]">
<P>To test for heterogeneity, we used the I² statistic (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). Where heterogeneity was high (I² &gt; 50%), we used a random-effects model for data synthesis.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2015-01-27 14:02:31 +0000" MODIFIED_BY="[Empty name]">
<P>We obtained data from full papers, conference abstracts and unpublished sources, where found. If at least ten studies were included in a meta-analysis, we constructed a funnel plot to look at issues around publication bias.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2015-01-27 14:02:38 +0000" MODIFIED_BY="[Empty name]">
<P>Where possible, we calculated the number of events occurring within the sample for each of the outcomes. We generated ORs with 95% CIs to evaluate the effect of treatment, using a fixed-effect model. Where heterogeneity was high (I² &gt; 50%) we used a random-effects model for data synthesis.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2015-01-27 14:02:42 +0000" MODIFIED_BY="[Empty name]">
<P>We subgrouped data for graft patency at follow-up (that is, at 1, 3, 6, 9, 12 and 24 months, where data were available) and for whether the graft was venous or prosthetic.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2015-01-27 14:02:50 +0000" MODIFIED_BY="[Empty name]">
<P>We performed sensitivity analysis to evaluate the effect of studies with unit of analysis concerns. Please see <LINK TAG="UNIT_OF_ANALYSIS" TYPE="SECTION">Unit of analysis issues</LINK> for more detail.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2015-01-28 08:39:54 +0000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2015-01-27 14:04:05 +0000" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2015-01-27 14:03:03 +0000" MODIFIED_BY="[Empty name]">
<P>See <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> for study flow diagram.</P>
<P>For the current update of the review, we considered 19 reports of 12 studies retrieved by the search. We included one additional study with four reports (<LINK REF="STD-CASPAR-2010" TYPE="STUDY">CASPAR 2010</LINK>). We deemed six studies with six citations not to be relevant, and we added another three studies with four reports to the excluded studies (<LINK REF="STD-Burdess-2010" TYPE="STUDY">Burdess 2010</LINK>; <LINK REF="STD-EUCTR2007-2008" TYPE="STUDY">EUCTR2007 2008</LINK>; <LINK REF="STD-Monaco-2012" TYPE="STUDY">Monaco 2012</LINK>). We added five new reports of two studies to previously included studies (<LINK REF="STD-BOA-2000" TYPE="STUDY">BOA 2000</LINK>; <LINK REF="STD-McCollum-1991" TYPE="STUDY">McCollum 1991</LINK>) and eight previously excluded reports to two included studies (<LINK REF="STD-BOA-2000" TYPE="STUDY">BOA 2000</LINK>; <LINK REF="STD-McCollum-1991" TYPE="STUDY">McCollum 1991</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2015-01-27 14:03:57 +0000" MODIFIED_BY="[Empty name]">
<P>For this update there was one additional study included (<LINK REF="STD-CASPAR-2010" TYPE="STUDY">CASPAR 2010</LINK>) making a total of 16 studies (<LINK REF="STD-Becquemin-1997" TYPE="STUDY">Becquemin 1997</LINK>; <LINK REF="STD-BOA-2000" TYPE="STUDY">BOA 2000</LINK>; <LINK REF="STD-CASPAR-2010" TYPE="STUDY">CASPAR 2010</LINK>; <LINK REF="STD-Clyne-1987" TYPE="STUDY">Clyne 1987</LINK>; <LINK REF="STD-D_x0027_Addato-1992" TYPE="STUDY">D'Addato 1992</LINK>; <LINK REF="STD-Donaldson-1985" TYPE="STUDY">Donaldson 1985</LINK>; <LINK REF="STD-Edmondson-1994" TYPE="STUDY">Edmondson 1994</LINK>; <LINK REF="STD-Goldman-1984" TYPE="STUDY">Goldman 1984</LINK>; <LINK REF="STD-Green-1982" TYPE="STUDY">Green 1982</LINK>; <LINK REF="STD-Gruss-1991" TYPE="STUDY">Gruss 1991</LINK>; <LINK REF="STD-Kohler-1984" TYPE="STUDY">Kohler 1984</LINK>; <LINK REF="STD-Lucas-1984" TYPE="STUDY">Lucas 1984</LINK>; <LINK REF="STD-McCollum-1991" TYPE="STUDY">McCollum 1991</LINK>; <LINK REF="STD-Noppeney-1988" TYPE="STUDY">Noppeney 1988</LINK>; <LINK REF="STD-Raithel-1987" TYPE="STUDY">Raithel 1987</LINK>; <LINK REF="STD-Schneider-1979" TYPE="STUDY">Schneider 1979</LINK>) which were included in this analysis. See <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> for full details.</P>
<P>We conducted comparisons of the following interventions:</P>
<OL>
<LI>Aspirin (ASA) or aspirin and dipyridamole (ASA/DIP) versus placebo or nothing (<LINK REF="STD-Clyne-1987" TYPE="STUDY">Clyne 1987</LINK>; <LINK REF="STD-Donaldson-1985" TYPE="STUDY">Donaldson 1985</LINK>; <LINK REF="STD-Goldman-1984" TYPE="STUDY">Goldman 1984</LINK>; <LINK REF="STD-Green-1982" TYPE="STUDY">Green 1982</LINK>; <LINK REF="STD-Kohler-1984" TYPE="STUDY">Kohler 1984</LINK>; <LINK REF="STD-McCollum-1991" TYPE="STUDY">McCollum 1991</LINK>)</LI>
<LI>ASA or ASA/DIP versus pentoxifylline (PTX) (<LINK REF="STD-Lucas-1984" TYPE="STUDY">Lucas 1984</LINK>; <LINK REF="STD-Raithel-1987" TYPE="STUDY">Raithel 1987</LINK>)</LI>
<LI>ASA/DIP versus indobufen (IND), a reversible cyclo-oxygenase inhibitor (<LINK REF="STD-D_x0027_Addato-1992" TYPE="STUDY">D'Addato 1992</LINK>)</LI>
<LI>ASA or ASA/DIP versus vitamin K antagonists (VKA) (<LINK REF="STD-BOA-2000" TYPE="STUDY">BOA 2000</LINK>; <LINK REF="STD-Schneider-1979" TYPE="STUDY">Schneider 1979</LINK>)</LI>
<LI>ASA/DIP versus low molecular weight heparin (LMWH) (<LINK REF="STD-Edmondson-1994" TYPE="STUDY">Edmondson 1994</LINK>)</LI>
<LI>Ticlopidine (TIC) versus placebo (<LINK REF="STD-Becquemin-1997" TYPE="STUDY">Becquemin 1997</LINK>)</LI>
<LI>ASA versus prostaglandin E1 (<LINK REF="STD-Gruss-1991" TYPE="STUDY">Gruss 1991</LINK>)</LI>
<LI>ASA versus naftidrofuryl (<LINK REF="STD-Noppeney-1988" TYPE="STUDY">Noppeney 1988</LINK>)</LI>
<LI>Clopidogrel and ASA versus ASA alone (<LINK REF="STD-CASPAR-2010" TYPE="STUDY">CASPAR 2010</LINK>)</LI>
</OL>
<P>Details of the study designs are shown in the table '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>' and in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="4">Aspirin (ASA) or aspirin and dipyridamole (ASA/DIP) versus placebo or nothing</HEADING>
<P>In all six trials study medication was started prior to bypass surgery, mostly 48 hours before the operation (<LINK REF="STD-Clyne-1987" TYPE="STUDY">Clyne 1987</LINK>; <LINK REF="STD-Donaldson-1985" TYPE="STUDY">Donaldson 1985</LINK>; <LINK REF="STD-Goldman-1984" TYPE="STUDY">Goldman 1984</LINK>; <LINK REF="STD-Green-1982" TYPE="STUDY">Green 1982</LINK>; <LINK REF="STD-Kohler-1984" TYPE="STUDY">Kohler 1984</LINK>; <LINK REF="STD-McCollum-1991" TYPE="STUDY">McCollum 1991</LINK>). Doses ranged from 300 mg to 325 mg ASA and 75 mg DIP, given two and three times daily. Participants were randomised before surgery. Duration of treatment was six weeks in the <LINK REF="STD-Clyne-1987" TYPE="STUDY">Clyne 1987</LINK> trial but at least 12 to 24 months in the other trials. The percentage of participants with critical leg ischaemia (CLI) ranged from 60% to 80%, with the exception of <LINK REF="STD-Donaldson-1985" TYPE="STUDY">Donaldson 1985</LINK> which only included participants with disabling intermittent claudication.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Aspirin (ASA) or aspirin and dipyridamole (ASA/DIP) versus pentoxifylline (PTX)</HEADING>
<P>Two studies were included, comparing 1000 mg or 1500 mg ASA to 1200 mg PTX daily (<LINK REF="STD-Lucas-1984" TYPE="STUDY">Lucas 1984</LINK>; <LINK REF="STD-Raithel-1987" TYPE="STUDY">Raithel 1987</LINK>). Participant characteristics and graft type were similar in both trials. While <LINK REF="STD-Raithel-1987" TYPE="STUDY">Raithel 1987</LINK>'s participants all received prosthetic grafts, <LINK REF="STD-Lucas-1984" TYPE="STUDY">Lucas 1984</LINK> also included participants with venous grafts. More than 90% of <LINK REF="STD-Raithel-1987" TYPE="STUDY">Raithel 1987</LINK>'s participants had CLI compared to only 55% in the <LINK REF="STD-Lucas-1984" TYPE="STUDY">Lucas 1984</LINK> trial.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Aspirin and dipyridamole (ASA/DIP) versus indobufen (IND)</HEADING>
<P>We found only one multicentre double-blind randomised clinical trial including participants operated on for a prosthetic polytetrafluoroethylene (PTFE) femoropopliteal graft for inclusion (<LINK REF="STD-D_x0027_Addato-1992" TYPE="STUDY">D'Addato 1992</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Aspirin and dipyridamole (ASA/DIP) versus vitamin K antagonists (VKA)</HEADING>
<P>We include two trials in this category (<LINK REF="STD-BOA-2000" TYPE="STUDY">BOA 2000</LINK>; <LINK REF="STD-Schneider-1979" TYPE="STUDY">Schneider 1979</LINK>), comparing ASA or ASA and DIP with VKA. The Dutch <LINK REF="STD-BOA-2000" TYPE="STUDY">BOA 2000</LINK> trial included a much higher number of participants than the <LINK REF="STD-Schneider-1979" TYPE="STUDY">Schneider 1979</LINK> trial; prosthetic grafts were included in the <LINK REF="STD-BOA-2000" TYPE="STUDY">BOA 2000</LINK> trial. It should be noted that participants receiving ASA in the <LINK REF="STD-BOA-2000" TYPE="STUDY">BOA 2000</LINK> trial were treated with a dose of only 80 mg, while all other trials included in this review compared doses of 600 mg to 1500 mg daily, sometimes with additional DIP.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Aspirin and dipyridamole (ASA/DIP) versus low molecular weight heparin (LMWH)</HEADING>
<P>We include one open, randomised clinical trial for comparison of LMWH (Fragmin) and ASA and DIP (<LINK REF="STD-Edmondson-1994" TYPE="STUDY">Edmondson 1994</LINK>). Participants were assessed for their clinical outcomes on the seventh postoperative day.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Ticlopidine (TIC) versus nothing</HEADING>
<P>Only one double-blind trial (<LINK REF="STD-Becquemin-1997" TYPE="STUDY">Becquemin 1997</LINK>) could be included for analysis, which randomised 243 participants after surgery. All participants received autologous saphenous vein grafts.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Aspirin versus prostaglandin E1 (PGE1)</HEADING>
<P>One open, randomised clinical trial compared ASA to PGE1 on a background of 15,000 IU of heparin for early graft occlusion, within three days postoperatively, in 100 participants who all received autologous saphenous vein grafts (<LINK REF="STD-Gruss-1991" TYPE="STUDY">Gruss 1991</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Aspirin versus naftidrofuryl</HEADING>
<P>We could consider only one trial in the analysis that compared ASA to naftidrofuryl (<LINK REF="STD-Noppeney-1988" TYPE="STUDY">Noppeney 1988</LINK>). This study, which commenced on postoperative day one, randomised 99 participants who all had prosthetic PTFE grafts.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Clopidogrel and ASA (Clopidogrel/ASA) versus ASA alone</HEADING>
<P>A single trial evaluated the comparison between clopidogrel with ASA versus ASA alone (<LINK REF="STD-CASPAR-2010" TYPE="STUDY">CASPAR 2010</LINK>), which was a large trial of 851 randomised, receiving a mixture of venous and prosthetic grafts.</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2015-01-27 14:04:05 +0000" MODIFIED_BY="[Empty name]">
<P>For this update we excluded an additional three studies (<LINK REF="STD-Burdess-2010" TYPE="STUDY">Burdess 2010</LINK>; <LINK REF="STD-EUCTR2007-2008" TYPE="STUDY">EUCTR2007 2008</LINK>; <LINK REF="STD-Monaco-2012" TYPE="STUDY">Monaco 2012</LINK>), making a total of 20 excluded studies (<LINK REF="STD-B_x00f6_hmig-1995" TYPE="STUDY">Böhmig 1995</LINK>; <LINK REF="STD-Burdess-2010" TYPE="STUDY">Burdess 2010</LINK>; <LINK REF="STD-DeWeese-1971" TYPE="STUDY">DeWeese 1971</LINK>; <LINK REF="STD-Ehersmann-1977" TYPE="STUDY">Ehersmann 1977</LINK>; <LINK REF="STD-EUCTR2007-2008" TYPE="STUDY">EUCTR2007 2008</LINK>; <LINK REF="STD-Gorter-2001" TYPE="STUDY">Gorter 2001</LINK>; <LINK REF="STD-Harjola-1981" TYPE="STUDY">Harjola 1981</LINK>; <LINK REF="STD-Jivegard-2005" TYPE="STUDY">Jivegard 2005</LINK>; <LINK REF="STD-Johnson-2002" TYPE="STUDY">Johnson 2002</LINK>; <LINK REF="STD-Johnson-2004" TYPE="STUDY">Johnson 2004</LINK>; <LINK REF="STD-Kibbe-2002" TYPE="STUDY">Kibbe 2002</LINK>; <LINK REF="STD-Lassila-1991" TYPE="STUDY">Lassila 1991</LINK>; <LINK REF="STD-Monaco-2012" TYPE="STUDY">Monaco 2012</LINK>; <LINK REF="STD-Nevelsteen-1991" TYPE="STUDY">Nevelsteen 1991</LINK>; <LINK REF="STD-Raithel-1987b" TYPE="STUDY">Raithel 1987b</LINK>; <LINK REF="STD-Reichle-1979" TYPE="STUDY">Reichle 1979</LINK>; <LINK REF="STD-Rosenthal-1987" TYPE="STUDY">Rosenthal 1987</LINK>; <LINK REF="STD-Satiani-1985" TYPE="STUDY">Satiani 1985</LINK>; <LINK REF="STD-Shionoya-1990" TYPE="STUDY">Shionoya 1990</LINK>; <LINK REF="STD-Smout-2004" TYPE="STUDY">Smout 2004</LINK>).The reasons for exclusion varied and include, among others: lack of a control group, not a randomised controlled trial, a heterogeneous cohort of participants, intervention not within the scope of the review, and too little information to determine inclusion.</P>
<P>See <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> for full descriptions of excluded studies.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2015-01-27 14:04:57 +0000" MODIFIED_BY="[Empty name]">
<P>See <LINK REF="FIG-02" TYPE="FIGURE">Figure 2 </LINK>and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK> for 'Risk of bias' evaluation.</P>
<ALLOCATION MODIFIED="2015-01-27 14:04:14 +0000" MODIFIED_BY="[Empty name]">
<P>Random sequence generation methods were adequately described in six studies (<LINK REF="STD-Becquemin-1997" TYPE="STUDY">Becquemin 1997</LINK>; <LINK REF="STD-BOA-2000" TYPE="STUDY">BOA 2000</LINK>; <LINK REF="STD-CASPAR-2010" TYPE="STUDY">CASPAR 2010</LINK>; <LINK REF="STD-Edmondson-1994" TYPE="STUDY">Edmondson 1994</LINK>; <LINK REF="STD-Kohler-1984" TYPE="STUDY">Kohler 1984</LINK>; <LINK REF="STD-Lucas-1984" TYPE="STUDY">Lucas 1984</LINK>). The remaining 10 studies did not sufficiently describe how they generated their random sequence, leading to a rating of 'unclear' (<LINK REF="STD-Clyne-1987" TYPE="STUDY">Clyne 1987</LINK>; <LINK REF="STD-D_x0027_Addato-1992" TYPE="STUDY">D'Addato 1992</LINK>; <LINK REF="STD-Donaldson-1985" TYPE="STUDY">Donaldson 1985</LINK>; <LINK REF="STD-Goldman-1984" TYPE="STUDY">Goldman 1984</LINK>; <LINK REF="STD-Green-1982" TYPE="STUDY">Green 1982</LINK>; <LINK REF="STD-Gruss-1991" TYPE="STUDY">Gruss 1991</LINK>; <LINK REF="STD-McCollum-1991" TYPE="STUDY">McCollum 1991</LINK>; <LINK REF="STD-Noppeney-1988" TYPE="STUDY">Noppeney 1988</LINK>; <LINK REF="STD-Raithel-1987" TYPE="STUDY">Raithel 1987</LINK>; <LINK REF="STD-Schneider-1979" TYPE="STUDY">Schneider 1979</LINK>).</P>
<P>Six studies described allocation concealment methods that were low-risk (<LINK REF="STD-BOA-2000" TYPE="STUDY">BOA 2000</LINK>; <LINK REF="STD-CASPAR-2010" TYPE="STUDY">CASPAR 2010</LINK>; <LINK REF="STD-Edmondson-1994" TYPE="STUDY">Edmondson 1994</LINK>; <LINK REF="STD-Green-1982" TYPE="STUDY">Green 1982</LINK>; <LINK REF="STD-Lucas-1984" TYPE="STUDY">Lucas 1984</LINK>; <LINK REF="STD-McCollum-1991" TYPE="STUDY">McCollum 1991</LINK>), while the remaining 10 studies did not describe their methods adequately (<LINK REF="STD-Becquemin-1997" TYPE="STUDY">Becquemin 1997</LINK>; <LINK REF="STD-Clyne-1987" TYPE="STUDY">Clyne 1987</LINK>; <LINK REF="STD-D_x0027_Addato-1992" TYPE="STUDY">D'Addato 1992</LINK>; <LINK REF="STD-Donaldson-1985" TYPE="STUDY">Donaldson 1985</LINK>; <LINK REF="STD-Goldman-1984" TYPE="STUDY">Goldman 1984</LINK>; <LINK REF="STD-Gruss-1991" TYPE="STUDY">Gruss 1991</LINK>; <LINK REF="STD-Kohler-1984" TYPE="STUDY">Kohler 1984</LINK>; <LINK REF="STD-Noppeney-1988" TYPE="STUDY">Noppeney 1988</LINK>; <LINK REF="STD-Raithel-1987" TYPE="STUDY">Raithel 1987</LINK>; <LINK REF="STD-Schneider-1979" TYPE="STUDY">Schneider 1979</LINK>).</P>
</ALLOCATION>
<BLINDING MODIFIED="2015-01-27 14:04:15 +0000" MODIFIED_BY="[Empty name]">
<P>Blinding of participants and personnel was adequate in seven studies (<LINK REF="STD-Becquemin-1997" TYPE="STUDY">Becquemin 1997</LINK>; <LINK REF="STD-CASPAR-2010" TYPE="STUDY">CASPAR 2010</LINK>; <LINK REF="STD-Donaldson-1985" TYPE="STUDY">Donaldson 1985</LINK>; <LINK REF="STD-Goldman-1984" TYPE="STUDY">Goldman 1984</LINK>; <LINK REF="STD-Green-1982" TYPE="STUDY">Green 1982</LINK>; <LINK REF="STD-Kohler-1984" TYPE="STUDY">Kohler 1984</LINK>; <LINK REF="STD-McCollum-1991" TYPE="STUDY">McCollum 1991</LINK>). Six studies were unblinded, leading to a high risk of performance bias (<LINK REF="STD-BOA-2000" TYPE="STUDY">BOA 2000</LINK>; <LINK REF="STD-Clyne-1987" TYPE="STUDY">Clyne 1987</LINK>; <LINK REF="STD-Edmondson-1994" TYPE="STUDY">Edmondson 1994</LINK>; <LINK REF="STD-Gruss-1991" TYPE="STUDY">Gruss 1991</LINK>; <LINK REF="STD-Noppeney-1988" TYPE="STUDY">Noppeney 1988</LINK>; <LINK REF="STD-Raithel-1987" TYPE="STUDY">Raithel 1987</LINK>). The remaining three studies mentioned blinding but did not adequately describe their methods (<LINK REF="STD-D_x0027_Addato-1992" TYPE="STUDY">D'Addato 1992</LINK>; <LINK REF="STD-Lucas-1984" TYPE="STUDY">Lucas 1984</LINK>; <LINK REF="STD-Schneider-1979" TYPE="STUDY">Schneider 1979</LINK>), and are rated at unclear risk.</P>
<P>Blinding of outcome assessors was only described in two studies (<LINK REF="STD-Becquemin-1997" TYPE="STUDY">Becquemin 1997</LINK>; <LINK REF="STD-CASPAR-2010" TYPE="STUDY">CASPAR 2010</LINK>), while the remaining were at unclear risk of detection bias, with no description of assessor blinding.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2015-01-27 14:04:29 +0000" MODIFIED_BY="[Empty name]">
<P>The majority of studies had no issues with attrition bias, but five studies were at unclear risk, with <LINK REF="STD-Donaldson-1985" TYPE="STUDY">Donaldson 1985</LINK> having a higher rate of drop-outs in the intervention arm, <LINK REF="STD-Gruss-1991" TYPE="STUDY">Gruss 1991</LINK> not reporting drop-outs or withdrawals, <LINK REF="STD-Kohler-1984" TYPE="STUDY">Kohler 1984</LINK> inconsistently reporting drop-outs between treatment groups, <LINK REF="STD-Raithel-1987" TYPE="STUDY">Raithel 1987</LINK> only reporting participants available for follow-up but not the number initially randomised, and <LINK REF="STD-Schneider-1979" TYPE="STUDY">Schneider 1979</LINK> not having enough information for us to adequately assess whether attrition bias was a problem.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2015-01-27 14:04:36 +0000" MODIFIED_BY="[Empty name]">
<P>Selective reporting was a concern in three studies, which we evaluated as 'unclear' (<LINK REF="STD-Green-1982" TYPE="STUDY">Green 1982</LINK>; <LINK REF="STD-Gruss-1991" TYPE="STUDY">Gruss 1991</LINK>; <LINK REF="STD-Schneider-1979" TYPE="STUDY">Schneider 1979</LINK>). For <LINK REF="STD-Green-1982" TYPE="STUDY">Green 1982</LINK> adverse events were not clearly reported, and for both <LINK REF="STD-Gruss-1991" TYPE="STUDY">Gruss 1991</LINK> and <LINK REF="STD-Schneider-1979" TYPE="STUDY">Schneider 1979</LINK> there was not enough information in the text to determine the risk of reporting bias. All remaining studies were at low risk of reporting bias.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2015-01-27 14:04:57 +0000" MODIFIED_BY="[Empty name]">
<P>Other bias was a concern in five studies (<LINK REF="STD-Clyne-1987" TYPE="STUDY">Clyne 1987</LINK>; <LINK REF="STD-Donaldson-1985" TYPE="STUDY">Donaldson 1985</LINK>; <LINK REF="STD-Goldman-1984" TYPE="STUDY">Goldman 1984</LINK>; <LINK REF="STD-McCollum-1991" TYPE="STUDY">McCollum 1991</LINK>; <LINK REF="STD-Raithel-1987" TYPE="STUDY">Raithel 1987</LINK>), with the rest at low risk of other bias. For <LINK REF="STD-Clyne-1987" TYPE="STUDY">Clyne 1987</LINK> and <LINK REF="STD-Donaldson-1985" TYPE="STUDY">Donaldson 1985</LINK> all the data were presented by number of bypasses and not by the number of participants. <LINK REF="STD-Goldman-1984" TYPE="STUDY">Goldman 1984</LINK>, <LINK REF="STD-McCollum-1991" TYPE="STUDY">McCollum 1991</LINK>, and <LINK REF="STD-Raithel-1987" TYPE="STUDY">Raithel 1987</LINK> had differences in the treatment groups at baseline, and <LINK REF="STD-McCollum-1991" TYPE="STUDY">McCollum 1991</LINK> may be at risk of being underpowered, as the study power calculation required a study population of 800 participants to detect a 10% reduction in occlusion rate, but only 549 participants were randomised.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2015-01-28 08:39:54 +0000" MODIFIED_BY="[Empty name]">
<P>For the outcome 'primary patency' the numbers recorded for analyses were actually the number of grafts that occluded during the specified time period as reported by the trialists. We used these numbers due to the properties of odds ratios (ORs), and we found this method more straightforward to interpret. Both patency and occlusion are used to describe the treatment outcomes within the included studies and within this review, which should be kept in mind when interpreting the presented data.</P>
<P>Analysis for secondary graft patency, side effects of treatment and complications, limb amputation, cardiovascular events and mortality are only described when sufficient data were available. Otherwise, these outcomes are not mentioned.</P>
<P>None of the included studies reported on assisted primary patency, objective assessment of lower limb blood flow or participant quality of life.</P>
<P>None of the meta-analyses included 10 or more studies, so we could not construct funnel plots to evaluate possible publication bias.</P>
<SUBSECTION>
<HEADING LEVEL="4">Aspirin (ASA) or aspirin and dipyridamole (ASA/DIP) versus nothing or placebo</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Primary graft patency</HEADING>
<P>The effect of ASA or ASA/DIP on infrainguinal bypass patency was assessed in six trials (<LINK REF="STD-Clyne-1987" TYPE="STUDY">Clyne 1987</LINK>; <LINK REF="STD-Donaldson-1985" TYPE="STUDY">Donaldson 1985</LINK>; <LINK REF="STD-Goldman-1984" TYPE="STUDY">Goldman 1984</LINK>; <LINK REF="STD-Green-1982" TYPE="STUDY">Green 1982</LINK>; <LINK REF="STD-Kohler-1984" TYPE="STUDY">Kohler 1984</LINK>; <LINK REF="STD-McCollum-1991" TYPE="STUDY">McCollum 1991</LINK>). The OR from the random-effects model for primary occlusion at 12 months for all grafts was 0.42 (95% confidence interval (CI) 0.22 to 0.83; P = 0.01, I² = 72%, participants = 952), showing a positive effect of ASA on infrainguinal grafts at one year (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>).<BR/>Three of these studies had unit of analysis issues, with multiple grafts or re-randomisation of participants (<LINK REF="STD-Clyne-1987" TYPE="STUDY">Clyne 1987</LINK>; <LINK REF="STD-Donaldson-1985" TYPE="STUDY">Donaldson 1985</LINK>; <LINK REF="STD-Kohler-1984" TYPE="STUDY">Kohler 1984</LINK>). The association becomes attenuated when these studies are excluded (OR 0.36, 95% CI 0.13 to 0.99; P = 0.05, participants = 651).</P>
<P>When we performed the analysis for venous grafts alone, there was no difference in primary graft patency between the treatment groups at one, three and six months (OR 0.76, 95% CI 0.26 to 2.25, P = 0.62; OR 0.85, 95% CI 0.54 to 1.35, P = 0.50; and OR 0.88, 95% CI 0.59 to 1.31; P = 0.53, respectively, participants = 642 for all) (all fixed-effect analyses) (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>; <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>; <LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>). At 12 months post-operation there was a possible increase in occlusion in the control group (OR 0.69, 95% CI 0.48 to 0.99; P = 0.05, participants = 642) (fixed-effect), but this was not seen at 24 months in the random-effects model analysis, (OR 1.03; 95% CI 0.32 to 3.28; P = 0.96, I² = 79%, participants = 620) (<LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>; <LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK>).</P>
<P>Analysis for prosthetic grafts, however, showed a much stronger positive effect of ASA on primary patency as calculated from four studies (<LINK REF="STD-Clyne-1987" TYPE="STUDY">Clyne 1987</LINK>; <LINK REF="STD-Donaldson-1985" TYPE="STUDY">Donaldson 1985</LINK>; <LINK REF="STD-Goldman-1984" TYPE="STUDY">Goldman 1984</LINK>; <LINK REF="STD-Green-1982" TYPE="STUDY">Green 1982</LINK>): ORs of 0.14 (95% CI 0.04 to 0.51; P = 0.003, participants = 157) at one month; 0.31 (95% CI 0.14 to 0.66; P = 0.003, participants = 222) at three months; 0.21 (95% CI 0.11 to 0.41; P &lt; 0.00001, participants = 222) at six months; and 0.19 (95% CI 0.10 to 0.36, participants = 222) at 12 months (<LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK>; <LINK REF="CMP-002.07" TYPE="ANALYSIS">Analysis 2.7</LINK>; <LINK REF="CMP-002.08" TYPE="ANALYSIS">Analysis 2.8</LINK>; <LINK REF="CMP-002.10" TYPE="ANALYSIS">Analysis 2.10</LINK>). Primary patency at nine months was only evaluated in a single study, with an OR of 0.17 (95% CI 0.04 to 0.67, participants = 65) (<LINK REF="CMP-002.09" TYPE="ANALYSIS">Analysis 2.9</LINK>).</P>
<P>Removal of the trials associated with unit of analysis issues meant that we could not conduct data analysis for venous grafts at one, three, six,12, and 24 months as only one study remained. For prosthetic grafts, the OR was 0.25 (95% CI 0.05 to 1.30; P = 0.10, participants = 102) at one month; 0.30 (95% CI 0.09 to 1.01; P = 0.05, participants = 102) at three months; 0.31 (95% CI 0.13 to 0.74; P = 0.008, participants = 102) at six months; and 0.23 (95% CI 0.10 to 0.54; P = 0.0008, participants = 102) at 12 months, all fixed-effect models. For all comparisons the overall effect was reduced, and for months one and three the association no longer favoured ASA or ASA/DIP<B>.</B>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Secondary graft patency</HEADING>
<P>
<LINK REF="STD-McCollum-1991" TYPE="STUDY">McCollum 1991</LINK> reported on secondary patency of the failed grafts, but the time frame of the reported cases is unclear. The study reported that of the 172 failed grafts (86 in each treatment group), eight in the ASA/DIP group and four in the placebo group were restored by re-operation but it is unclear if all failed grafts were re-operated. <LINK REF="STD-McCollum-1991" TYPE="STUDY">McCollum 1991</LINK> also reported that the cumulative secondary patency rate for the ASA/DIP group was 80% at one year, 73% at two years and 63% at three years, and 74%, 64% and 61% respectively for the placebo group. Because the number of participants that were included to derive these values was unclear, we cannot use them in meta-analysis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Side effects of treatment and complications</HEADING>
<P>Side effects were reported in five studies (<LINK REF="STD-Clyne-1987" TYPE="STUDY">Clyne 1987</LINK>; <LINK REF="STD-Donaldson-1985" TYPE="STUDY">Donaldson 1985</LINK>; <LINK REF="STD-Green-1982" TYPE="STUDY">Green 1982</LINK>; <LINK REF="STD-Kohler-1984" TYPE="STUDY">Kohler 1984</LINK>; <LINK REF="STD-McCollum-1991" TYPE="STUDY">McCollum 1991</LINK>) and the fixed-effect model found an OR of 1.55 (95% CI 1.00 to 2.41; P = 0.05, participants = 913) for general side effects (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>). However, when <LINK REF="STD-Clyne-1987" TYPE="STUDY">Clyne 1987</LINK>, <LINK REF="STD-Donaldson-1985" TYPE="STUDY">Donaldson 1985</LINK> and <LINK REF="STD-Kohler-1984" TYPE="STUDY">Kohler 1984</LINK> were removed due to unit of analysis issues the association was attenuated with an OR of 1.34 (95% CI 0.83 to 2.16; P = 0.23, participants = 598). Six studies evaluated side effects specific to the gastrointestinal tract (<LINK REF="STD-Clyne-1987" TYPE="STUDY">Clyne 1987</LINK>; <LINK REF="STD-Donaldson-1985" TYPE="STUDY">Donaldson 1985</LINK>; <LINK REF="STD-Goldman-1984" TYPE="STUDY">Goldman 1984</LINK>; <LINK REF="STD-Green-1982" TYPE="STUDY">Green 1982</LINK>; <LINK REF="STD-Kohler-1984" TYPE="STUDY">Kohler 1984</LINK>; <LINK REF="STD-McCollum-1991" TYPE="STUDY">McCollum 1991</LINK>), and found no differences between the two treatment groups (OR 1.44, 95% CI 0.92 to 2.24; P = 0.11, participants = 952) in the fixed-effect model. When <LINK REF="STD-Clyne-1987" TYPE="STUDY">Clyne 1987,</LINK> <LINK REF="STD-Donaldson-1985" TYPE="STUDY">Donaldson 1985</LINK> and <LINK REF="STD-Kohler-1984" TYPE="STUDY">Kohler 1984</LINK> were removed due to unit of analysis issues there was very little change in the outcome (OR 1.38, 95% CI 0.87 to 2.21; P = 0.17, participants = 651).</P>
<P>Major bleeding was similar between the treatment groups for two trials (<LINK REF="STD-Green-1982" TYPE="STUDY">Green 1982</LINK>; <LINK REF="STD-McCollum-1991" TYPE="STUDY">McCollum 1991</LINK>) (OR 1.88, 95% CI 0.85 to 4.16; P = 0.12, participants = 598) in the fixed-effect model. Minor bleeding was only evaluated in one study (<LINK REF="STD-Clyne-1987" TYPE="STUDY">Clyne 1987</LINK>), with an OR of 0.73 (95% CI 0.31 to 1.70, participants = 148). Wound or graft infection was only evaluated in <LINK REF="STD-McCollum-1991" TYPE="STUDY">McCollum 1991</LINK>, with similar events in both treatment groups (OR 1.07, 95% CI 0.67 to 1.71, participants = 549).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Limb amputation</HEADING>
<P>
<LINK REF="STD-Clyne-1987" TYPE="STUDY">Clyne 1987</LINK> reported amputations with an OR of 0.55 (95% CI 0.21 to 1.44, grafts = 148), but it should be noted this was one of the studies with multiple grafts in some of the participants (148 grafts in 140 participants) (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Cardiovascular events and mortality</HEADING>
<P>Analysis of cardiovascular events was performed in four trials (<LINK REF="STD-Clyne-1987" TYPE="STUDY">Clyne 1987</LINK>; <LINK REF="STD-Donaldson-1985" TYPE="STUDY">Donaldson 1985</LINK>; <LINK REF="STD-Green-1982" TYPE="STUDY">Green 1982</LINK>; <LINK REF="STD-McCollum-1991" TYPE="STUDY">McCollum 1991</LINK>) and the random-effects model found an OR of 1.27 (95% CI 0.43 to 3.80; P = 0.66, I² = 52%, participants = 811) (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>). When <LINK REF="STD-Clyne-1987" TYPE="STUDY">Clyne 1987</LINK> and <LINK REF="STD-Donaldson-1985" TYPE="STUDY">Donaldson 1985</LINK> were removed for unit of analysis issues, the association was statistically significant, in favour of ASA or ASA/DIP (OR 0.58, 95% CI 0.37 to 0.91; P = 0.02, participants = 598), although it should be noted that <LINK REF="STD-McCollum-1991" TYPE="STUDY">McCollum 1991</LINK> then comprises 96% of the analysis.</P>
<P>The OR for postoperative death for the fixed-effect model, as evaluated in four studies (<LINK REF="STD-Clyne-1987" TYPE="STUDY">Clyne 1987</LINK>; <LINK REF="STD-Goldman-1984" TYPE="STUDY">Goldman 1984</LINK>; <LINK REF="STD-Green-1982" TYPE="STUDY">Green 1982</LINK>; <LINK REF="STD-McCollum-1991" TYPE="STUDY">McCollum 1991</LINK>) was 0.84 (95% CI 0.56 to 1.26; P = 0.41, participants = 799) (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>). When <LINK REF="STD-Clyne-1987" TYPE="STUDY">Clyne 1987</LINK> was removed for sensitivity analysis due to unit of analysis issues the resulting OR was 0.77 (95% CI 0.49 to 1.21; P = 0.26, participants = 651). Again <LINK REF="STD-McCollum-1991" TYPE="STUDY">McCollum 1991</LINK> accounted for a large majority of the weight.<BR/>
</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Aspirin (ASA) or aspirin and dipyridamole (ASA/DIP) versus pentoxifylline (PTX)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Primary graft patency</HEADING>
<P>The effect of PTX on graft patency when compared to ASA or ASA/DIP treatment could only be evaluated in a formal analysis from two RCTs (<LINK REF="STD-Lucas-1984" TYPE="STUDY">Lucas 1984</LINK>; <LINK REF="STD-Raithel-1987" TYPE="STUDY">Raithel 1987</LINK>) at six months post-operation. The fixed-effect model had an OR of 1.32 (95% CI 0.56 to 3.11; P = 0.52, participants = 151) showing no difference between the treatment groups (<LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>). This analysis should be considered with caution as <LINK REF="STD-Lucas-1984" TYPE="STUDY">Lucas 1984</LINK> involved multiple grafts and there appeared to be substantial heterogeneity among the sample population. At other time points, only <LINK REF="STD-Raithel-1987" TYPE="STUDY">Raithel 1987</LINK> provided raw data and showed a similar effect of both drugs on graft patency: OR 2.04 (95% CI 0.18 to 23.07, participants = 118) at one month; OR 1.00 (95% CI 0.27 to 3.65, participants = 118) at three months; and OR 0.91 (95% CI 0.38 to 2.15, participants = 118) at 12 months (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>; <LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>; <LINK REF="CMP-003.04" TYPE="ANALYSIS">Analysis 3.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Side effects of treatment and complications</HEADING>
<P>
<LINK REF="STD-Raithel-1987" TYPE="STUDY">Raithel 1987</LINK> reported on side effects that included gastric intolerance, gastric haemorrhage and vertigo, with ORs of 18.04 (95% CI 5.07 to 64.17), 3.11 (95% CI 0.31 to 30.77) and 0.48 (95% CI 0.08 to 2.74) respectively, all with 118 participants (<LINK REF="CMP-003.05" TYPE="ANALYSIS">Analysis 3.5</LINK>). It should be noted that side effects were extrapolated from graphs and therefore may not be completely accurate.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Limb amputation</HEADING>
<P>Amputation was also only evaluated in the <LINK REF="STD-Raithel-1987" TYPE="STUDY">Raithel 1987</LINK> study, with an OR of 0.38 (95% CI 0.07 to 2.04, participants = 118) (<LINK REF="CMP-003.06" TYPE="ANALYSIS">Analysis 3.6</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Cardiovascular events and mortality</HEADING>
<P>Reported only in <LINK REF="STD-Raithel-1987" TYPE="STUDY">Raithel 1987</LINK>, there were six deaths in the ASA group and three in the PTX group, with an OR of 2.11 (95% CI 0.50 to 8.88, participants = 118) (<LINK REF="CMP-003.07" TYPE="ANALYSIS">Analysis 3.7</LINK>). The authors reported that eight of the deaths were from myocardial infarction and one from cardiac failure, but they did not detail which treatment groups they came from.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Aspirin and dipyridamole (ASA/DIP) versus indobufen (IND)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Primary graft patency</HEADING>
<P>The one eligible RCT (<LINK REF="STD-D_x0027_Addato-1992" TYPE="STUDY">D'Addato 1992</LINK>) compared ASA/DIP to IND in receiving infrainguinal prosthetic PTFE grafts. The study had an OR of 1.67 (95% CI 0.51 to 5.44, participants = 113) for primary patency at three months, OR 1.60 (95% CI 0.60 to 4.27, participants = 113) at six months, OR 1.26 (95% CI 0.56 to 2.85, participants = 113) at nine months and OR 1.34 (95% CI 0.61 to 2.93, participants = 113) at 12 months (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>; <LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>; <LINK REF="CMP-004.03" TYPE="ANALYSIS">Analysis 4.3</LINK>; <LINK REF="CMP-004.04" TYPE="ANALYSIS">Analysis 4.4</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Aspirin and dipyridamole (ASA/DIP) versus vitamin K antagonists (VKA)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Primary graft patency</HEADING>
<P>This was reported in two trials (<LINK REF="STD-BOA-2000" TYPE="STUDY">BOA 2000</LINK>; <LINK REF="STD-Schneider-1979" TYPE="STUDY">Schneider 1979</LINK>). Primary graft patency for all grafts showed no difference for coumarin versus aspirin, irrespective of time point: OR 0.88 (95% CI 0.68 to 1.14; P = 0.34, I² = 0%) at three months, OR 0.72 (95% CI 0.27 to 1.96; P = 0.52, I² = 61%) at six months, OR 0.68 (95% CI 0.27 to 1.69; P = 0.40, I² = 67%) at 12 months; and OR 0.64 (95% CI 0.25 to 1.63; P = 0.36, I² = 74%) at 24 months, with 2781 participants included in each outcome (<LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>; <LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK>; <LINK REF="CMP-005.03" TYPE="ANALYSIS">Analysis 5.3</LINK>; <LINK REF="CMP-005.04" TYPE="ANALYSIS">Analysis 5.4</LINK>). We used a fixed-effect model at three months, and random-effects models for months six, 12 and 24, due to high heterogeneity.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Side effects of treatment and complications</HEADING>
<P>In the <LINK REF="STD-BOA-2000" TYPE="STUDY">BOA 2000</LINK> trial, haemorrhage necessitating hospital admission was reported for 119 (9%) participants in the coumarin group and 59 (4.5%) in the aspirin group. A total of 16 (1.2%) participants died from fatal bleeding in the coumarin group and 12 (0.9%) participants in the aspirin group. In <LINK REF="STD-Schneider-1979" TYPE="STUDY">Schneider 1979</LINK> the adverse effects reported were: two participants (0.6%) who stopped coumarin treatment because of bleeding complications and 13 participants (21%) who stopped aspirin for differing reasons.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Limb amputation</HEADING>
<P>The two trials (<LINK REF="STD-BOA-2000" TYPE="STUDY">BOA 2000</LINK>; <LINK REF="STD-Schneider-1979" TYPE="STUDY">Schneider 1979</LINK>), did not report data on limb salvage or survival that was suitable for formal meta-analysis. However, in <LINK REF="STD-BOA-2000" TYPE="STUDY">BOA 2000</LINK> limb amputation had to be performed in a similar number of participants in each treatment group, with an OR of 0.99 (95% CI 0.75 to 1.30, participants = 2690) (<LINK REF="CMP-005.05" TYPE="ANALYSIS">Analysis 5.5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Cardiovascular events and mortality</HEADING>
<P>Only <LINK REF="STD-BOA-2000" TYPE="STUDY">BOA 2000</LINK> reported on cardiovascular events and mortality for this treatment comparison. Myocardial infarction and stroke were similar for both treatment groups, with slightly higher occurrences in the ASA/DIP group: OR 1.45 (95% CI 0.90 to 2.34) and OR 1.34 (95% CI 0.86 to 2.09) respectively; participants = 2690 (<LINK REF="CMP-005.06" TYPE="ANALYSIS">Analysis 5.6</LINK>). Death from all causes, after two years, was similar in both treatment groups, with an OR of 1.02 (95% CI 0.83 to 1.26, participants = 2690) (<LINK REF="CMP-005.07" TYPE="ANALYSIS">Analysis 5.7</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Aspirin and dipyridamole (ASA/DIP) versus low molecular weight heparin (LMWH)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Primary graft patency</HEADING>
<P>In <LINK REF="STD-Edmondson-1994" TYPE="STUDY">Edmondson 1994</LINK> primary patency was measured at six and 12 months with little difference between the treatment groups: OR 1.69 (95% CI 0.78 to 3.65, participants = 200), and OR 1.19 (95% CI 0.66 to 2.15, participants = 200), respectively (<LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>; <LINK REF="CMP-006.02" TYPE="ANALYSIS">Analysis 6.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Side effects of treatment and complications</HEADING>
<P>No major bleedings or adverse events occurred.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Cardiovascular events and mortality</HEADING>
<P>There were more deaths in the LMWH treatment group compared to the ASA/DIP group: OR 0.18 (95% CI 0.04 to 0.86, participants = 200) (<LINK REF="CMP-006.03" TYPE="ANALYSIS">Analysis 6.3</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Ticlopidine (TIC) versus nothing</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Primary graft patency</HEADING>
<P>Intention-to-treat analysis of one trial (<LINK REF="STD-Becquemin-1997" TYPE="STUDY">Becquemin 1997</LINK>) involving participants undergoing bypass with venous grafts showed no difference in primary patency at one month between the treatment groups: OR 3.00 (95% CI 0.12 to 74.37, participants = 243), with a wide confidence interval as only one event occurred by this time point (<LINK REF="CMP-007.01" TYPE="ANALYSIS">Analysis 7.1</LINK>). However, primary patency at six, 12 and 24 months showed increased patency in the TIC treatment group: OR 0.26 (95% CI 0.11 to 0.63, participants = 243) at six months; OR 0.38 (95% CI 0.19 to 0.75, participants = 243) at 12 months; and OR 0.37 (95% CI 0.21 to 0.67, participants = 243) at 24 months (<LINK REF="CMP-007.02" TYPE="ANALYSIS">Analysis 7.2</LINK>; <LINK REF="CMP-007.03" TYPE="ANALYSIS">Analysis 7.3</LINK>; <LINK REF="CMP-007.04" TYPE="ANALYSIS">Analysis 7.4</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Aspirin versus prostaglandin E1 (PGE1)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Primary graft patency</HEADING>
<P>One study (<LINK REF="STD-Gruss-1991" TYPE="STUDY">Gruss 1991</LINK>) reported on the drug comparison of aspirin to PGE1 in participants receiving autologous venous grafts. Early occlusion, within the first three postoperative days, had few events, with an OR of 3.91 (95% CI 0.77 to 19.83, participants = 100) (<LINK REF="CMP-008.01" TYPE="ANALYSIS">Analysis 8.1</LINK>). Longer-term patency was not reported.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Aspirin versus naftidrofuryl</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Primary graft patency</HEADING>
<P>One study (<LINK REF="STD-Noppeney-1988" TYPE="STUDY">Noppeney 1988</LINK>) reported graft occlusion in seven of the 50 participants administered naftidrofuryl compared to 10 of the 49 given ASA, with an OR of 1.58 (95% CI 0.55 to 4.54, participants = 99) (<LINK REF="CMP-009.01" TYPE="ANALYSIS">Analysis 9.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Side effects of treatment and complications</HEADING>
<P>More general side effects were experienced by the ASA group compared to naftidrofuryl: OR 13.86 (95% CI 3.80 to 50.60, participants = 99). Gastrointestinal side effects were also more common in the aspirin group: OR 28.45 (95% CI 3.61 to 223.97, participants = 99). Only two participants reported vertigo, both in the naftidrofuryl treatment group: OR 0.20 (95% CI 0.01 to 4.19, participants = 99). Stomach bleeding was reported in five participants, all in the aspirin treatment group: OR 12.48 (95% CI 0.67 to 232.14, participants = 99) (<LINK REF="CMP-009.02" TYPE="ANALYSIS">Analysis 9.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Cardiovascular events and mortality</HEADING>
<P>Deaths occurred in both treatment groups, with an OR of 2.73 (95% CI 0.50 to 14.78, participants = 99) (<LINK REF="CMP-009.03" TYPE="ANALYSIS">Analysis 9.3</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Clopidogrel and ASA (clopidogrel/ASA) versus ASA alone</HEADING>
<P>
<LINK REF="STD-CASPAR-2010" TYPE="STUDY">CASPAR 2010</LINK> was the only study to compare clopidogrel/ASA to ASA alone. Outcomes were reported at 24 months as a whole population and split by subgroups based on whether participants received venous or prosthetic grafts.</P>
<SUBSECTION>
<HEADING LEVEL="5">Primary graft patency</HEADING>
<P>Primary graft patency for all participants was similar between both treatment groups, OR 0.95 (95% CI 0.69 to 1.31, participants = 851) <LINK REF="CMP-010.01" TYPE="ANALYSIS">Analysis 10.1</LINK>. There were more cases of occlusion in the clopidogrel/ASA group, compared to ASA alone, when only venous grafts were included: OR 1.47 (95% CI 0.93 to 2.31, participants = 598), but higher occlusion rates in the ASA alone group for prosthetic grafts: OR 0.53 (95% CI 0.32 to 0.88, participants = 253) (<LINK REF="CMP-011.01" TYPE="ANALYSIS">Analysis 11.1</LINK>; <LINK REF="CMP-011.02" TYPE="ANALYSIS">Analysis 11.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Side effects of treatment and complications</HEADING>
<P>Total cases of bleeding were fewer in the ASA alone group: OR 2.65 (95% CI 1.69 to 4.15, participants = 851), as were mild bleeding: OR 2.34 (95% CI 1.37 to 4.00, participants = 851) and moderate bleeding: OR 4.13 (95% CI 1.37 to 12.45, participants = 851). Cases of severe bleeding and fatal bleeding were few, and similar between the treatment groups: OR 1.82 (95% CI 0.61 to 5.48, participants = 851) and OR 2.01 (95% CI 0.18 to 22.24, participants = 851), respectively (<LINK REF="CMP-010.02" TYPE="ANALYSIS">Analysis 10.2</LINK>).</P>
<P>When we evaluated graft subgroups, there was still less mild bleeding in the ASA alone group for venous grafts: OR 2.46 (95% CI 1.33 to 4.53, participants = 598), but the occurrence of mild bleeding events was more similar between the treatment groups for prosthetic grafts: OR 1.86 (95% CI 0.67 to 5.21, participants = 253). The same trend was seen for moderate bleeding: venous grafts: OR 5.75 (95% CI 1.26 to 26.17, participants = 598) and prosthetic grafts: OR 2.50 (95% CI 0.48 to 13.13, participants = 253). Severe bleeding was similar between treatment groups for both venous and prosthetic grafts: OR 2.75 (95% CI 0.72 to 10.47, participants = 598) and OR 0.48 (95% CI 0.04 to 5.41, participants = 253), respectively (<LINK REF="CMP-011.03" TYPE="ANALYSIS">Analysis 11.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Limb amputation</HEADING>
<P>For all grafts, amputations were similar between groups, with slightly higher occurrence in the ASA alone group: OR 0.67 (95% CI 0.41 to 1.08, participants = 851) (<LINK REF="CMP-010.03" TYPE="ANALYSIS">Analysis 10.3</LINK>). Amputation occurrence was also similar between treatment groups for venous grafts: OR 0.91 (95% CI 0.48 to 1.73, participants = 598), but more occurred in the ASA alone group for prosthetic grafts: OR 0.44 (95% CI 0.21 to 0.91, participants = 253) (<LINK REF="CMP-011.04" TYPE="ANALYSIS">Analysis 11.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Cardiovascular events and mortality</HEADING>
<P>For all graft types, death was similar between both treatment groups: OR 1.44 (95% CI 0.76 to 2.72, participants = 851), which was also the case for both venous and prosthetic grafts: OR 1.43 (95% CI 0.69 to 2.97, participants = 598), and OR 1.49 (95% CI 0.41 to 5.40, participants = 253), respectively (<LINK REF="CMP-010.04" TYPE="ANALYSIS">Analysis 10.4</LINK>; <LINK REF="CMP-011.05" TYPE="ANALYSIS">Analysis 11.5</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2015-01-27 14:13:38 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2015-01-27 14:12:04 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Antiplatelet therapy effect on bypass patency</HEADING>
<P>In the present meta-analysis we evaluated the effect of postoperatively administered antiplatelet treatment in people with peripheral arterial disease (PAD) receiving infrainguinal bypasses. It was shown that antiplatelet treatment with aspirin (ASA) or a combination of ASA and dipyridamole (ASA/DIP) has an overall positive effect on primary patency 12 months after the procedure. Interestingly, the size of the effect differed between participants receiving prosthetic grafts and those receiving venous grafts. When we limited the analysis to the subgroups receiving prosthetic (polytetrafluoroethylene (PTFE) or Dacron) grafts, the effect was statistically significant at all time points. In contrast, there was no evidence to support an effect of ASA or ASA/DIP in participants receiving venous graft bypasses. The evidence for secondary patency is too limited to draw any conclusions at this time. It should be noted that we did not perform a formal test for interaction to statistically demonstrate a differential effect of antiplatelet agents by graft type.</P>
<P>There was no difference in primary patency for the comparison between ASA/DIP versus pentoxifylline (PTX) at one, three, six and 12 months. However, for most of the time points we evaluated only a single study. For the comparisons between ASA and DIP versus indobufen (prosthetic grafts only), ASA or ASA/DIP versus vitamin K antagonists (VKA), as well as ASA/DIP versus low molecular weight heparin (LMWH), there were no differences between the treatment groups in primary patency at any time point. The analyses of indobufen and LMWH only had single study reporting and VKA included only two studies.</P>
<P>A single study evaluated ticlopidine versus placebo in participants receiving venous graphs only. Primary patency was significantly improved at six, 12 and 24 months after the procedure, but not in the first month post-procedure. Thus, ticlopidine seems to be the only antiplatelet agent achieving a favourable effect on venous graft patency. ASA versus prostaglandin E1, also only with venous grafts, was reported in a single study, with few outcome events and no difference between the treatment groups for early occlusions. Comparing ASA with naftidrofuryl in a single study, there was no difference in primary patency at 12 months.</P>
<P>Clopidogrel with ASA versus ASA alone was reported in a single study, with no difference in primary patency at 24 months for all participants, as well as no difference for venous grafts. Prosthetic grafts showed improvement in patency at 24 months for the clopidogrel with ASA group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Side effects and limb amputations</HEADING>
<P>For the comparison of ASA or ASA/DIP versus placebo or nothing, there were no differences between the treatment groups for any of the evaluated side effects, complications or amputations. Comparing ASA or ASA/DIP to PTX there was a possible increase in gastric intolerance, but no differences for gastric haemorrhage, vertigo or amputations. There were also no differences in amputation comparing ASA or ASA/DIP to VKA. Both general and gastrointestinal side effects were increased in the ASA group, compared with naftidrofuryl, but vertigo and stomach bleeding were similar between the two groups. Comparing clopidogrel/ASA with ASA alone, there were increased total, mild and moderate bleeding events in the one study that evaluated this treatment comparison, in all participants, but no difference for severe or fatal bleeding events. In venous grafts within this study, there was an increase in mild and moderate events, but no difference in severe bleeding events, and there was no difference in any of the bleeding categories for prosthetic grafts. Within this comparison, amputations were similar between treatment groups for all participants, including venous grafts, but there was a slight decrease in amputations in the clopidogrel/ASA group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Cardiovascular events and mortality</HEADING>
<P>For the comparisons of ASA or ASA/DIP versus placebo or nothing and ASA or ASA/DIP versus VKA there were no differences between the treatment groups for cardiovascular events or mortality. There was also no difference in mortality when comparing ASA or ASA/DIP versus PTX, ASA versus naftidrofuryl, or clopidogrel/ASA versus ASA alone; cardiovascular events were not evaluated within these comparisons.</P>
<P>Although very few events were reported in the single study, there appeared to be decreased mortality in the ASA/DIP treatment group, compared with LMWH.</P>
<P>In conclusion, the results of our meta-analysis suggest that the administration of platelet inhibitors such as ASA or ASA/DIP could result in improved venous and prosthetic graft patency compared to no treatment. However, subgroup analysis by graft type, i.e. venous versus PTFE or Dacron, shows that participants receiving a prosthetic graft are likely to benefit more from ASA or ASA and DIP administration than those treated with a venous graft. For most of the comparisons included in this review, there is currently not enough data to draw any conclusions.</P>
</SUBSECTION>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2015-01-27 14:12:26 +0000" MODIFIED_BY="[Empty name]">
<P>With 16 studies included in the review and meta-analysis, there was much relevant data available to provide evidence for the review question. However, we separately evaluated a total of nine different comparisons, with only one comparison having more than two studies providing data for meta-analysis. Therefore, while this review does bring many trials together touching on many antiplatelet treatments, the review does not reach a meaningful level of evidence for all of the predefined comparisons. Also, none of the included studies addressed the outcomes of assisted primary patency, objective assessment of blood flow or quality of life, and many studies did not report on any of the other outcomes. Assisted primary patency as an outcome is of specific importance, as even a highly stenotic graft may remain patent, and a graft at a highly stenotic stage would be more easily treated, both technically and for the patient, than a fully occluded graft. Therefore, knowing whether antiplatelet treatments help reduce full occlusion and allow treatment at a stenotic but not occluded stage would be of clinical importance.</P>
<P>Data presentation did not distinguish by graft type for the site of the distal anastomosis. Furthermore, the number of grafts frequently differed from the number of participants, without appropriate explanation. Insufficient information was available in the included studies to assess the effects of antiplatelet agents in different clinical settings such as diabetes and other co-morbidities. Another concern with the applicability of evidence is the fact that different dosages of the various treatments were used between the included studies. Further information on the dosages can be found in <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> tables.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2015-01-27 14:13:04 +0000" MODIFIED_BY="[Empty name]">
<P>This review included 16 studies with a total of 5683 randomised participants. Currently we can only draw a robust conclusion regarding antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery for the comparison between ASA or ASA/DIP versus placebo or nothing, showing a positive reduction in occlusion at 12 months in participants who received ASA or ASA/DIP. The comparisons of ASA or ASA/DIP versus vitamin K antagonists and of clopidogrel and ASA versus ASA alone only included one or two studies, but they encompassed a large number of participants. Neither comparison found any difference in primary graft patency at any of the time points. All other comparisons only included one or two smaller studies. Also limiting the quality of the evidence is the fact that several included studies provided their results by the number of bypasses and not by the number of participants, indicating bilaterally-treated patients. This could alter results, although currently only a few studies provided results in this manner, with few participants in their study population receiving multiple bypasses. Also of concern is the reporting of outcomes at varying time points, which vary between studies. This reduces our ability to combine outcome data in the most robust way possible.</P>
<P>Overall, study quality was moderate, with the largest problem being that the majority of studies did not adequately describe their methods of randomisation or outcome assessor blinding. The other main issue with study quality was not blinding participants or personnel to the treatment received. These concerns, along with the previously reported issues with paucity of data for many of the comparisons, unit of analysis issues, variation of treatment dosages and lack of data on our review's prespecified outcomes, leaves the quality of the evidence of the review moderate to low. We expect that with future updates and more high-quality studies, the quality of evidence will improve.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2015-01-27 14:13:31 +0000" MODIFIED_BY="[Empty name]">
<P>In order to reduce potential bias two review authors assessed studies for inclusion and performed data extraction and quality assessment. We made every attempt to include all relevant studies, but it is still possible that we did not identify all studies.</P>
<P>The majority of included studies randomised individuals as the unit for analysis, but four studies included participants with multiple or bilateral reconstructions or re-randomised participants, and used grafts as the unit of analysis. In order to include these data we performed analyses with the four studies with unit of analyses issues, but also performed sensitivity analyses by excluding them to see if the results were affected. Only the comparison between ASA or ASA/DIP versus nothing or placebo contained enough studies to evaluate the effects of the unit of analysis issues by sensitivity analysis, and within this comparison we could not evaluate all outcomes. Overall there was very little change in the results when the studies were removed, but when the odds ratios (ORs) did change, it was an expected attenuation and decreasing of power due to a reduction in the overall number of participants included in the calculation. Readers should keep in mind our methods of addressing these unit of analysis issues when evaluating the results of this review, as other reviews may take a different approach.</P>
<P>For the outcome 'primary patency', the numbers recorded for analyses were actually the number of grafts that occluded during the specified time period as reported by the trialists. Both patency and occlusion are used to describe the treatment outcomes within the included studies and within this review, which should be kept in mind when interpreting the presented data. As assisted primary patency was not reported by the trialists of the included studies, it is unclear if the reported occlusion is actual occlusion i.e. thrombosis of the graft, or if it also includes participants whose grafts were revised prior to occlusion/thrombosis.</P>
<P>We calculated data for graft failure from the survival curves if raw data were not reported or were unavailable after contacting the authors of the trials.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2015-01-27 14:13:38 +0000" MODIFIED_BY="[Empty name]">
<P>A systematic review and meta-analysis that was published in 1999 also set out to evaluate antiplatelet therapy (specifically aspirin) in the prevention of graft occlusion after infrainguinal bypass surgery (<LINK REF="REF-Tangelder-1999" TYPE="REFERENCE">Tangelder 1999</LINK>). This review differs from our own, as it was interested in oral anticoagulants, as well as antiplatelet agents, and they used risk ratios (RRs) and not odds ratios for their dichotomous outcomes. The <LINK REF="REF-Tangelder-1999" TYPE="REFERENCE">Tangelder 1999</LINK> review included five studies that we also included in our own review, and an additional two studies, one of which was specific to oral anticoagulants, while the other compared an anticoagulant with aspirin to aspirin alone. The findings in <LINK REF="REF-Tangelder-1999" TYPE="REFERENCE">Tangelder 1999</LINK> were similar to our own meta-analyses findings for the comparison between ASA or ASA/DIP versus nothing or placebo. They found a decrease in bypass occlusions in the aspirin group (RR 0.78, 95% CI 0.64 to 0.95), and no difference between the treatment groups for total mortality (RR 0.92, 95% CI 0.64 to 1.32).</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2015-01-27 14:13:52 +0000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2015-01-27 14:13:47 +0000" MODIFIED_BY="[Empty name]">
<P>There is evidence to suggest that the administration of platelet inhibitors such as ASA or ASA/DIP will result in improved venous and prosthetic graft patency compared to no treatment. However, patients with a prosthetic graft may benefit more from ASA or ASA/DIP administration than those with a venous graft, but this needs further investigation. The results of this review should be interpreted with caution, due to the unit of analysis issues described within the review, as well as the fact that many of the comparisons were only reported in a single study, and that the dosages often differed between studies.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2015-01-27 14:13:52 +0000" MODIFIED_BY="[Empty name]">
<P>Further high-quality randomised clinical trials, with adequate sample sizes, are required to evaluate the efficacy of antiplatelet medications for graft patency in infrainguinal venous and prosthetic grafts for all treatment comparisons. Presentation of data should be detailed and not only show survival curves for overall patency. Tables showing the raw data would improve the transparency of the trial performance and allow comparison of endpoints at consecutive time points. The reader would be able to identify the number of occlusions, or other endpoints, at different time points in each comparison group as well as in subgroups defined by bypass material, above- and below-knee anastomosis, and inflow and outflow conditions. Other concerns for research within this area would be determining the optimal dosage of antiplatelet medications and also outcome stratification by co-morbidities, such as diabetes. A more complete outcome profile should be evaluated, such as assisted primary patency. Uniformity of unit of analysis issues should be addressed in studies of peripheral vascular disease, as there needs to be clarity around single and multiple grafts and the time points at which these occurred.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2014-09-25 12:11:27 +0100" MODIFIED_BY="[Empty name]">
<P>A special thank you to Karen Welch for assistance with German translation for several of the included studies.</P>
<P>We would like to thank the authors of the previous versions of the this review: Julie Brown, Andrew Wawryzniak, Janine Dörffler Melly, Marianne Koopmann, Harry Büller and Donald Adam.</P>
<P>The authors would like to thank the Peripheral Vascular Diseases Review group for their support and guidance.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2015-02-18 14:53:32 +0000" MODIFIED_BY="[Empty name]">
<P>RB: none known<BR/>AL: none known<BR/>HM: none known<BR/>SA: none known<BR/>MP: Prof Prins' institution has received a grant from ZON-MW (not-for-profit organisation) for demonstrating cost-effectiveness on the topic of this review. Prof Prins' institution has received funding for his board membership of clinical studies and consultancy from Bayer, Boeringer Ingelheim, Daiichi Sankyo, Pfizer and ISIS Pharmaceuticals. These were not related to this review.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2015-01-27 14:14:50 +0000" MODIFIED_BY="[Empty name]">
<P>RB: performed study selection, data extraction and quality assessment and wrote the review update<BR/>AL: performed study selection, data extraction and quality assessment<BR/>HM: provided support in updating the manuscript<BR/>SA: provided support in updating the manuscript<BR/>MP: provided support in updating the manuscript<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2015-01-27 14:15:16 +0000" MODIFIED_BY="[Empty name]">
<P>We amended the outcome 'Limb salvage rate: survival rates with limb intact' to included 'or limb amputation', as most studies reported amputations, but not necessarily limb salvage rate.</P>
<P>We amended the outcome 'Side effects of treatment' to include 'and complications', as in several studies these two outcome types were grouped together.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2014-04-01 15:11:38 +0100" MODIFIED_BY="[Empty name]"/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2015-02-18 15:02:19 +0000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2015-02-18 15:02:19 +0000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2015-02-18 15:02:19 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Becquemin-1997" MODIFIED="2014-09-23 09:39:11 +0100" MODIFIED_BY="Karen Welch" NAME="Becquemin 1997" YEAR="1997">
<REFERENCE MODIFIED="2014-09-02 14:21:15 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Becquemin JP</AU>
<TI>Effect of ticlopidine on the long-term patency of saphenous-vein bypass grafts in the legs</TI>
<SO>New England Journal of Medicine</SO>
<YR>1997</YR>
<VL>337</VL>
<NO>24</NO>
<PG>1726-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-BOA-2000" MODIFIED="2015-02-18 15:02:19 +0000" MODIFIED_BY="[Empty name]" NAME="BOA 2000" YEAR="2000">
<REFERENCE MODIFIED="2015-02-18 15:02:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Algra A</AU>
<TI>A randomised trial of oral anticoagulants versus aspirin after infrainguinal bypass surgery</TI>
<SO>Tijdschrift voor Sociale Gezondheidszorg</SO>
<YR>1999</YR>
<VL>77</VL>
<NO>4</NO>
<PG>11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-24 14:05:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ariesen MJ, Tangelder MJD, Lawson JA, Eikelboom BC, Grobbee DE, Algra A</AU>
<TI>Risk of major haemorrhage in patients after infrainguinal venous bypass surgery: Therapeutic consequences? The Dutch BOA (Bypass Oral Anticoagulants or Aspirin) study</TI>
<SO>European Journal of Vascular and Endovascular Surgery</SO>
<YR>2005</YR>
<VL>30</VL>
<NO>2</NO>
<PG>154-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-05-02 10:46:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Dutch Bypass Oral anticoagulants of Aspirin (BOA) Study Group</AU>
<TI>Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral anticoagulants or Aspirin study): a randomised trial</TI>
<SO>Lancet</SO>
<YR>2000</YR>
<VL>355</VL>
<NO>9201</NO>
<PG>346-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-18 15:02:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eikelboom BC</AU>
<TI>Prevention of occlusions after infrainguinal bypass surgery with oral anticoagulants or acetylsalicylic acid: A randomised trial</TI>
<SO>Nederlands Tijdschrift voor Geneeskunde</SO>
<YR>2001</YR>
<VL>145</VL>
<NO>22</NO>
<PG>1060-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-27 14:32:05 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oostenbrink JB, Tangelder MJ, Busschbach JJ, Van Hout BA, Buskens E, Algra A, et al</AU>
<TI>Cost effectiveness of oral anticoagulants versus aspirin in patients after infrainguinal bypass grafting surgery</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>2001</YR>
<VL>34</VL>
<NO>2</NO>
<PG>254-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-27 14:32:13 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smeets L, Ho GH, Tangelder MJ, Algra A, Lawson JA, Eikelboom BC, et al; Dutch BOA Study Group</AU>
<TI>Outcome after occlusion of infrainguinal bypasses in the Dutch BOA Study: comparison of amputation rate in venous and prosthetic grafts</TI>
<SO>European Journal of Vascular and Endovascular Surgery</SO>
<YR>2005</YR>
<VL>30</VL>
<NO>6</NO>
<PG>604-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-09-01 15:44:44 +0100" MODIFIED_BY="Karen Welch" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tangelder MJ, Algra A, Lawson JA, Eikelboom BC</AU>
<TI>Risk factors for occlusion of infrainguinal bypass grafts</TI>
<SO>European Journal of Vascular and Endovascular Surgery</SO>
<YR>2000</YR>
<VL>20</VL>
<NO>2</NO>
<PG>118-24</PG>
<IDENTIFIERS MODIFIED="2014-09-01 15:44:44 +0100" MODIFIED_BY="Karen Welch"/>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-14 20:56:25 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tangelder MJ, Algra A, Lawson JA, Hennekes S, Eikelboom BC</AU>
<TI>Optimal oral anticoagulant intensity to prevent secondary ischemic and hemorrhagic events in patients after infrainguinal bypass graft surgery. Dutch BOA Study Group</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>2001</YR>
<VL>33</VL>
<NO>3</NO>
<PG>522-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-27 14:33:05 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tangelder MJ, Eikelboom BC, Lawson JA, Algra A</AU>
<TI>Prevention of occlusion following peripheral bypass surgery using oral anticoagulants or acetylsalicylic acid: a randomized comparison within the Dutch BOA study</TI>
<TO>Preventi van occlusies na perifere bypass-chirurgie met orale anticoagulantia of acetylsalicylzuur: een gerandomiseerde vergelijking in het Nederlands BOA-onderzoek</TO>
<SO>Nederlands Tijdschrift voor Geneeskunde</SO>
<YR>1995</YR>
<VL>139</VL>
<NO>29</NO>
<PG>1504-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-14 20:56:09 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tangelder MJ, McDonnel J, Van Busschbach JJ, Buskens E, Algra A, Lawson JA, Eikelboom BC</AU>
<TI>Quality of life after infrainguinal bypass grafting surgery. Dutch Bypass Oral Anticoagulants or Aspirin (BOA) Study Group</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>1999</YR>
<VL>29</VL>
<NO>5</NO>
<PG>913-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-18 15:02:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Hattum ES, Algra A, Lawson JA, Eikelboom BC, Moll FL, Tangelder MJD</AU>
<TI>Bleeding increases the risk of ischemic events in patients with peripheral arterial disease</TI>
<SO>Circulation</SO>
<YR>2009</YR>
<VL>120</VL>
<NO>16</NO>
<PG>1569-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-18 15:02:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Hattum ES, Tangelder MJD, Lawson JA, Moll FL, Algra A</AU>
<TI>The quality of life in patients after peripheral bypass surgery deteriorates at long-term follow-up</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>2011</YR>
<VL>53</VL>
<NO>3</NO>
<PG>643-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-CASPAR-2010" MODIFIED="2015-02-18 15:02:19 +0000" MODIFIED_BY="[Empty name]" NAME="CASPAR 2010" YEAR="2010">
<REFERENCE MODIFIED="2015-01-27 14:34:02 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Anonymous</AU>
<TI>Clopidogrel and acetyl salicylic acid in bypass surgery for peripheral arterial disease</TI>
<SO>clinicaltrials.gov/ct2/show/NCT00174759?term=CASPAR&amp;rank=2</SO>
<YR>(accessed 5 May 2014)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-27 14:37:08 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>Dual antiplatelet therapy benefits prosthetic but not venous grafts</TI>
<SO>Vascular News</SO>
<YR>2009</YR>
<VL>Feb</VL>
<PG>17</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-18 15:02:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Belch JJ, Dormandy J</AU>
<TI>Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>2010</YR>
<VL>52</VL>
<NO>4</NO>
<PG>825-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-24 14:14:30 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>The Caspar Investigators, Belch J</AU>
<TI>Effect of adding clopidogrel to aspirin on the success of below knee arterial bypass grafts. A randomised placebo controlled study</TI>
<SO>Vascular Annual Meeting; 2007 Jun; Baltimore, USA</SO>
<YR>2007</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Clyne-1987" MODIFIED="2015-01-27 14:35:11 +0000" MODIFIED_BY="[Empty name]" NAME="Clyne 1987" YEAR="1987">
<REFERENCE MODIFIED="2015-01-27 14:35:11 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clyne CA, Archer TJ, Atuhaire LK, Chant AD, Webster JH</AU>
<TI>Random control trial of a short course of aspirin and dipyridamole (Persantin) for femorodistal grafts</TI>
<SO>British Journal of Surgery</SO>
<YR>1987</YR>
<VL>74</VL>
<NO>4</NO>
<PG>246-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-D_x0027_Addato-1992" MODIFIED="2014-09-02 14:04:36 +0100" MODIFIED_BY="[Empty name]" NAME="D'Addato 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>D'Addato M, Curti T, Bertini D, Donini I, Ferrero R, Fiorani P, et al</AU>
<TI>Indobufen vs acetylsalicylic acid plus dipyridamole in long-term patency after femoropopliteal bypass</TI>
<SO>International Angiology</SO>
<YR>1992</YR>
<VL>11</VL>
<NO>2</NO>
<PG>106-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Donaldson-1985" MODIFIED="2015-01-27 14:35:24 +0000" MODIFIED_BY="[Empty name]" NAME="Donaldson 1985" YEAR="1985">
<REFERENCE MODIFIED="2015-01-27 14:35:24 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Donaldson DR, Salter MC, Kester RC, Rajah SM, Hall TJ, Sreeharan N, et al</AU>
<TI>The influence of platelet inhibition on the patency of femoro-popliteal Dacron bypass grafts</TI>
<SO>Vascular Surgery</SO>
<YR>1985</YR>
<VL>19</VL>
<NO>4</NO>
<PG>224-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Edmondson-1994" NAME="Edmondson 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Edmondson RA, Cohen AT, Das SK, Wagner BM, Kakkar VV</AU>
<TI>Low-molecular weight heparin versus aspirin and dipyridamole after femoropopliteal bypass grafting</TI>
<SO>Lancet</SO>
<YR>1994</YR>
<VL>344</VL>
<NO>8927</NO>
<PG>914-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goldman-1984" NAME="Goldman 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goldman M, McCollum C</AU>
<TI>A prospective randomized study to examine the effect of aspirin plus dipyridamole on the patency of prosthetic femoro-popliteal grafts</TI>
<SO>Vascular Surgery</SO>
<YR>1984</YR>
<VL>18</VL>
<NO>4</NO>
<PG>217-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Green-1982" MODIFIED="2014-09-22 14:33:14 +0100" MODIFIED_BY="[Empty name]" NAME="Green 1982" YEAR="1982">
<REFERENCE MODIFIED="2014-09-22 14:33:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Green RM, Roedersheimer RL, DeWeese JA</AU>
<TI>Effects of aspirin and dipyridamole on expanded polytetrafluoethylene graft patency</TI>
<SO>Surgery</SO>
<YR>1982</YR>
<VL>92</VL>
<NO>6</NO>
<PG>1016-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gruss-1991" MODIFIED="2014-09-02 14:26:45 +0100" MODIFIED_BY="[Empty name]" NAME="Gruss 1991" YEAR="1991">
<REFERENCE MODIFIED="2014-09-02 14:26:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gruss JD, Hiemer W, Kroiss A, Geissler C</AU>
<TI>Experiences with adjuvant prostaglandin therapy in vascular surgery interventions</TI>
<SO>Vasa-Supplementum</SO>
<YR>1991</YR>
<VL>33</VL>
<PG>353-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kohler-1984" NAME="Kohler 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kohler TR, Kaufman JL, Kacoyanis G, Clowes A, Donaldson MC, Kelly E, et al</AU>
<TI>Effect of aspirin and dipyridamole on the patency of lower extremity bypass grafts</TI>
<SO>Surgery</SO>
<YR>1984</YR>
<VL>96</VL>
<NO>3</NO>
<PG>462-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lucas-1984" NAME="Lucas 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lucas MA</AU>
<TI>Prevention of post-operative thrombosis in peripheral arteriopathies. Pentoxifylline vs conventional antiaggregants: a six-month randomized follow-up study</TI>
<SO>Angiology</SO>
<YR>1984</YR>
<VL>35</VL>
<NO>7</NO>
<PG>443-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McCollum-1991" MODIFIED="2015-01-27 14:36:11 +0000" MODIFIED_BY="[Empty name]" NAME="McCollum 1991" YEAR="1991">
<REFERENCE MODIFIED="2015-01-27 14:35:49 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Franks PJ, Sian M, Kenchington GF, Alexander CE, Powell JT</AU>
<TI>Aspirin usage and its influence on femoro-popliteal vein graft patency</TI>
<SO>European Journal of Vascular Surgery</SO>
<YR>1992</YR>
<VL>6</VL>
<NO>2</NO>
<PG>185-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-27 14:36:11 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Franks PJ, Sian M, Kenchington GF, Alexander CE, Powell JT</AU>
<TI>Aspirin usage and its influence on femoropopliteal vein graft patency</TI>
<SO>European Society for Vascular Surgery 5th Annual Meeting, 25-27 September 1991; Warsaw, Poland</SO>
<YR>1991</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-05-02 10:46:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>McCollum C, Alexander C, Kenchington G, Franks PJ, Greenhalgh R</AU>
<TI>Antiplatelet drugs in femoropopliteal vein bypasses: A multicenter trial</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>1991</YR>
<VL>13</VL>
<NO>1</NO>
<PG>150-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-05-02 10:44:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Powell JT, Greenhalgh RM</AU>
<TI>Smoking and factors influencing the outcome of arterial reconstruction</TI>
<SO>Annales Chirurgiae et Gynaecologiae</SO>
<YR>1992</YR>
<VL>81</VL>
<NO>2</NO>
<PG>236-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Noppeney-1988" MODIFIED="2014-09-02 14:25:43 +0100" MODIFIED_BY="[Empty name]" NAME="Noppeney 1988" YEAR="1988">
<REFERENCE MODIFIED="2014-09-02 14:25:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Noppeney T, Kasprzak P, Raithel D, Hirche H</AU>
<TI>Naftidrofuryl in postoperative treatment after femoropopliteal bypass</TI>
<SO>Die Medizinische Welt</SO>
<YR>1988</YR>
<VL>39</VL>
<PG>1545-50</PG>
<IDENTIFIERS MODIFIED="2008-05-08 10:18:48 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Raithel-1987" MODIFIED="2014-05-02 10:46:34 +0100" MODIFIED_BY="[Empty name]" NAME="Raithel 1987" YEAR="1987">
<REFERENCE MODIFIED="2014-04-24 14:54:29 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Raithel D, Kasprzak P, Noppeney Th</AU>
<TI>Relapse prophylaxis after femoropopliteal reconstruction with PTFE-prostheses</TI>
<SO>Die Medizinische Welt</SO>
<YR>1986</YR>
<VL>37</VL>
<PG>664-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-05-02 10:46:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Raithel D</AU>
<TI>Prevention of reocclusion after prosthetic bypass operations in the femoro-popliteal region: a comparative study of pentoxifylline versus acetylsalicylic acid</TI>
<SO>Vascular Surgery</SO>
<YR>1987</YR>
<VL>21</VL>
<NO>3</NO>
<PG>208-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schneider-1979" MODIFIED="2015-01-27 14:36:32 +0000" MODIFIED_BY="[Empty name]" NAME="Schneider 1979" YEAR="1979">
<REFERENCE MODIFIED="2015-01-27 14:36:32 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schneider E, Brunner U, Bollinger A</AU>
<TI>No English title available</TI>
<TO>Medikamentose Rezidivprophylaxe nach femoro-poplitealer Arterienrekonstruktion</TO>
<SO>Angio</SO>
<YR>1979</YR>
<VL>2</VL>
<NO>1</NO>
<PG>73-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2015-02-18 15:02:19 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-B_x00f6_hmig-1995" MODIFIED="2015-01-27 14:38:05 +0000" MODIFIED_BY="[Empty name]" NAME="Böhmig 1995" YEAR="1995">
<REFERENCE MODIFIED="2015-01-27 14:38:05 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Böhmig HJ, Zeidler G, Schwierz TH, Loy E</AU>
<TI>Orthograde vein bypass procedure for inguinal arterial reconstructions - 20 years experience</TI>
<TO>20 Jahre orthograder venen-bypass für infrainguinale arterielle rekonstruktion</TO>
<SO>Chirurg</SO>
<YR>1995</YR>
<VL>66</VL>
<NO>2</NO>
<PG>120-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Burdess-2010" MODIFIED="2015-02-18 15:02:19 +0000" MODIFIED_BY="[Empty name]" NAME="Burdess 2010" YEAR="2010">
<REFERENCE MODIFIED="2015-01-27 14:38:12 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Burdess A, Nimmo A, Garden OJ, Murie JA, Dawson AR, Fox KA, et al</AU>
<TI>Dual antiplatelet therapy in surgery for critical limb ischaemia</TI>
<SO>The Vascular Society of Great Britain &amp; Ireland Yearbook 2008</SO>
<YR>2008</YR>
<PG>47</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-18 15:02:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Burdess A, Nimmo AF, Garden OJ, Murie JA, Dawson AR, Fox KA, et al</AU>
<TI>Randomized controlled trial of dual antiplatelet therapy in patients undergoing surgery for critical limb ischemia</TI>
<SO>Annals of Surgery</SO>
<YR>2010</YR>
<VL>252</VL>
<NO>1</NO>
<PG>37-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-DeWeese-1971" NAME="DeWeese 1971" YEAR="1971">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>DeWeese JA, Rob CG</AU>
<TI>Autogenous venous bypass grafts five years later</TI>
<SO>Annals of Surgery</SO>
<YR>1971</YR>
<VL>174</VL>
<NO>3</NO>
<PG>346-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ehersmann-1977" MODIFIED="2015-01-27 14:38:36 +0000" MODIFIED_BY="[Empty name]" NAME="Ehersmann 1977" YEAR="1977">
<REFERENCE MODIFIED="2015-01-27 14:38:36 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ehresmann U, Alemany J, Loew D</AU>
<TI>Use of acetylsalicylic acid in the prevention of re-occlusion following revascularization interventions. Results of a double blind long term study</TI>
<TO>Prophylaxe von rezidivverschlüssen nach revaskularisationseingriffen mit acetylsalicylsäure</TO>
<SO>Medizinische Welt</SO>
<YR>1977</YR>
<VL>28</VL>
<NO>26</NO>
<PG>1157-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-EUCTR2007-2008" MODIFIED="2015-01-27 14:38:51 +0000" MODIFIED_BY="[Empty name]" NAME="EUCTR2007 2008" YEAR="2008">
<REFERENCE MODIFIED="2015-01-27 14:38:51 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>EUCTR2007-003746-15-DE</AU>
<TI>Prospective randomized open study on the comparison of fondaparinux with the low-molecular-weight heparin enoxaparin in patients undergoing femoro-distal venous bypass operation</TI>
<SO>www.clinicaltrialsregister.eu/ctr-search/trial/2007-003746-15/DE</SO>
<YR>2008</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gorter-2001" MODIFIED="2015-01-27 14:38:57 +0000" MODIFIED_BY="[Empty name]" NAME="Gorter 2001" YEAR="2001">
<REFERENCE MODIFIED="2015-01-27 14:38:57 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gorter JW, Oostenbrink JB, Tangelder MJ; Stroke Pi, Reversible Ischemia Trial (SPIRIT) Study Group, Dutch Bypass O, Anticoagulants or Aspirin Study (BOA)</AU>
<TI>Costs of outpatient anticoagulant treatment in patients with cerebral and peripheral arterial occlusive disease</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>2001</YR>
<VL>85</VL>
<NO>1</NO>
<PG>52-6</PG>
<IDENTIFIERS MODIFIED="2008-05-08 10:19:36 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harjola-1981" NAME="Harjola 1981" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harjola PT, Meurala H, Frick MH</AU>
<TI>Prevention of early reocclusion by dipyridamole and ASA in arterial reconstructive surgery</TI>
<SO>Journal of Cardiovascular Surgery</SO>
<YR>1981</YR>
<VL>22</VL>
<NO>2</NO>
<PG>141-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jivegard-2005" MODIFIED="2008-05-08 10:19:47 +0100" MODIFIED_BY="[Empty name]" NAME="Jivegard 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-05-08 10:19:47 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jivegard L, Drott C, Gelin J, Groth O, Hensater M, Jensen N, et al</AU>
<TI>Effects of three months of low molecular weight heparin (Dalteparin) treatment after bypass surgery for lower limb ischemia - A randomised placebo-controlled double blind multicentre trial</TI>
<SO>European Journal of Vascular and Endovascular Surgery</SO>
<YR>2005</YR>
<VL>29</VL>
<NO>2</NO>
<PG>190-8</PG>
<IDENTIFIERS MODIFIED="2008-05-08 10:19:47 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Johnson-2002" MODIFIED="2015-01-27 14:39:05 +0000" MODIFIED_BY="[Empty name]" NAME="Johnson 2002" YEAR="2002">
<REFERENCE MODIFIED="2015-01-27 14:39:05 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Johnson WC, Williford WO; Department of Veterans Affairs Cooperative Study # 362</AU>
<TI>Benefits, morbidity, and mortality associated with long-term administration of oral anticoagulant therapy to patients with peripheral arterial bypass procedures: a prospective randomized study</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>2002</YR>
<VL>35</VL>
<NO>3</NO>
<PG>413-21</PG>
<IDENTIFIERS MODIFIED="2008-05-08 10:19:56 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Johnson-2004" MODIFIED="2008-05-08 10:20:04 +0100" MODIFIED_BY="[Empty name]" NAME="Johnson 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-05-08 10:20:04 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Johnson WC, Williford WO, Corson JD, Padberg FT Jr</AU>
<TI>Hemorrhagic complications during long-term postoperative warfarin administration in patients undergoing lower extremity arterial bypass surgery</TI>
<SO>Vascular</SO>
<YR>2004</YR>
<VL>12</VL>
<NO>6</NO>
<PG>362-8</PG>
<IDENTIFIERS MODIFIED="2008-05-08 10:20:04 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kibbe-2002" MODIFIED="2008-05-08 10:20:12 +0100" MODIFIED_BY="[Empty name]" NAME="Kibbe 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-05-08 10:20:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kibbe MR, Hassett AL, McSherry F, Conner P, Bontempo FA, Williford W, et al</AU>
<TI>Can screening for genetic markers improve peripheral artery bypass patency?</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>2002</YR>
<VL>36</VL>
<NO>6</NO>
<PG>1198-206</PG>
<IDENTIFIERS MODIFIED="2008-05-08 10:20:12 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lassila-1991" NAME="Lassila 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lassila R, Lepäntalo M, Lindfors O</AU>
<TI>The effect of acetylicsalicylic acid on the outcome after lower limb arterial surgery with special reference to cigarette smoking</TI>
<SO>World Journal of Surgery</SO>
<YR>1991</YR>
<VL>15</VL>
<NO>3</NO>
<PG>378-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Monaco-2012" MODIFIED="2015-02-18 15:02:19 +0000" MODIFIED_BY="[Empty name]" NAME="Monaco 2012" YEAR="2012">
<REFERENCE MODIFIED="2015-02-18 15:02:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Monaco M, Di Tommaso L, Pinna GB, Lillo S, Schiavone V, Stassano P</AU>
<TI>Combination therapy with warfarin plus clopidogrel improves outcomes in femoropopliteal bypass surgery patients</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>2012</YR>
<VL>56</VL>
<NO>1</NO>
<PG>96-105</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nevelsteen-1991" MODIFIED="2015-01-27 14:39:19 +0000" MODIFIED_BY="[Empty name]" NAME="Nevelsteen 1991" YEAR="1991">
<REFERENCE MODIFIED="2015-01-27 14:39:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nevelsteen A, Mortelmans L, Van de Cruys A, Merckx E, Verhaeghe R</AU>
<TI>Effect of ticlopidine on blood loss, platelet turnover and platelet deposition on prosthetic surfaces in patients undergoing aorto-femoral bypass grafting</TI>
<SO>Thrombosis Research</SO>
<YR>1991</YR>
<VL>64</VL>
<NO>3</NO>
<PG>363-9</PG>
<IDENTIFIERS MODIFIED="2008-05-08 10:20:22 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Raithel-1987b" MODIFIED="2014-09-02 14:04:58 +0100" MODIFIED_BY="[Empty name]" NAME="Raithel 1987b" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Raithel D, Noppeney T, Kasprzak P</AU>
<TO>Medikamentöse Therapie nach femoro.poplitealem Kunststoffbypass - naftidrofuryl versus ASS</TO>
<SO>Vasa-Supplementum</SO>
<YR>1987</YR>
<VL>20</VL>
<PG>223-Abstract No 78</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reichle-1979" MODIFIED="2015-01-28 08:34:22 +0000" MODIFIED_BY="[Empty name]" NAME="Reichle 1979" YEAR="1979">
<REFERENCE MODIFIED="2015-01-28 08:34:22 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reichle FA, Rankin KP, Tyson RR, Finestone AJ, Shuman C</AU>
<TI>Long-term results of 474 arterial reconstructions for severely ischemic limbs: A fourteen year follow-up</TI>
<SO>Surgery</SO>
<YR>1979</YR>
<VL>85</VL>
<NO>1</NO>
<PG>93-100</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rosenthal-1987" MODIFIED="2014-09-02 14:24:48 +0100" MODIFIED_BY="[Empty name]" NAME="Rosenthal 1987" YEAR="1987">
<REFERENCE MODIFIED="2014-09-02 14:24:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rosenthal D, Mittenthal MH, Ruben DM, Jones DH, Estes JW, Stanton PE, et al</AU>
<TI>The effects of aspirin, dipyridamole and warfarin in femorodistal reconstruction: long-term results</TI>
<SO>American Surgeon</SO>
<YR>1987</YR>
<VL>53</VL>
<NO>9</NO>
<PG>477-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Satiani-1985" NAME="Satiani 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Satiani B</AU>
<TI>A prospective randomized trial of aspirin in femoral popliteal and tibial bypass grafts</TI>
<SO>Angiology</SO>
<YR>1985</YR>
<VL>36</VL>
<NO>9</NO>
<PG>608-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shionoya-1990" MODIFIED="2008-04-27 10:54:21 +0100" MODIFIED_BY="[Empty name]" NAME="Shionoya 1990" YEAR="1990">
<REFERENCE MODIFIED="2008-04-27 10:54:21 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shionoya S, Sakurai T, Ueyama T, Kusakawa M, Sakaguchi S, Tsuchioka H, et al</AU>
<TI>Effect of ticlopidine on graft patency following arterial reconstructive surgery in the lower extremity: a multicenter three-year prospective study</TI>
<SO>Vascular Surgery</SO>
<YR>1990</YR>
<VL>24</VL>
<NO>8</NO>
<PG>541-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smout-2004" MODIFIED="2014-09-01 15:45:58 +0100" MODIFIED_BY="Karen Welch" NAME="Smout 2004" YEAR="2004">
<REFERENCE MODIFIED="2014-09-01 15:45:58 +0100" MODIFIED_BY="Karen Welch" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smout JD, Mikhailidis DP, Shenton BK, Stansby G</AU>
<TI>Combination antiplatelet therapy in patients with peripheral vascular bypass grafts</TI>
<SO>Clinical and Applied Thrombosis/Hemostasis</SO>
<YR>2004</YR>
<VL>10</VL>
<NO>1</NO>
<PG>9-18</PG>
<IDENTIFIERS MODIFIED="2014-09-01 15:45:58 +0100" MODIFIED_BY="Karen Welch"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES MODIFIED="2014-09-28 16:42:14 +0100" MODIFIED_BY="[Empty name]"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2015-01-27 14:41:21 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2015-01-27 14:40:52 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Abbott-1997" MODIFIED="2008-05-05 22:31:34 +0100" MODIFIED_BY="Julie A Brown" NAME="Abbott 1997" TYPE="JOURNAL_ARTICLE">
<AU>Abbott WM, Green RM, Matsumoto T, Wheeler JR, Miller N, Veith FJ, et al</AU>
<TI>Prosthetic above-knee femoropopliteal bypass grafting: results of a multicenter randomized prospective trial. Above-Knee Femoropopliteal Study Group</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>1997</YR>
<VL>25</VL>
<NO>1</NO>
<PG>19-28</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Baril-2013" MODIFIED="2015-01-27 14:39:57 +0000" MODIFIED_BY="[Empty name]" NAME="Baril 2013" TYPE="JOURNAL_ARTICLE">
<AU>Baril D, Patel V, Judelson D, Goodney P, McPhee J, Hevelone N, et al</AU>
<TI>Outcomes of lower extremity bypass performed for acute limb ischemia</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>2013</YR>
<VL>58</VL>
<NO>4</NO>
<PG>949-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Becker-2011" MODIFIED="2015-01-27 14:40:03 +0000" MODIFIED_BY="[Empty name]" NAME="Becker 2011" TYPE="JOURNAL_ARTICLE">
<AU>Becker F, Robert-Ebadi H, Ricco JB, Setacci C, Cao P, De Donato G</AU>
<TI>Guidelines for critical limb ischaemia and diabetic foot, Chapter I: Definitions, Epidemiology, Clinical presentation and Prognosis</TI>
<SO>European Journal of Vascular and Endovascular Surgery</SO>
<YR>2011</YR>
<VL>42</VL>
<PG>4-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Consensus-1991" MODIFIED="2008-05-05 22:31:34 +0100" MODIFIED_BY="Julie A Brown" NAME="Consensus 1991" TYPE="JOURNAL_ARTICLE">
<AU>European Working Group on Critical Limb Ischemia. Second European Consensus Document on Chronic Critical Leg Ischemia</AU>
<TI>Second European Consensus Document on Chronic Critical Leg Ischemia</TI>
<SO>Circulation</SO>
<YR>1991</YR>
<VL>84 Suppl 4</VL>
<PG>1-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cooper-1990" MODIFIED="2008-05-05 22:31:34 +0100" MODIFIED_BY="Julie A Brown" NAME="Cooper 1990" TYPE="JOURNAL_ARTICLE">
<AU>Cooper GG, Austin C, Fitzsimmons E, Brannigan PD, Hood JM, D'Sa AA</AU>
<TI>Outflow resistance and early occlusion of infrainguinal bypass grafts</TI>
<SO>European Journal of Vascular Surgery</SO>
<YR>1990</YR>
<VL>4</VL>
<NO>3</NO>
<PG>279-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fujitani-1988" MODIFIED="2008-05-05 22:31:34 +0100" MODIFIED_BY="Julie A Brown" NAME="Fujitani 1988" TYPE="JOURNAL_ARTICLE">
<AU>Fujitani RM, Nordestgaard AG, Marcus CS, Wilson SE</AU>
<TI>Perioperative suppression of platelet adherence to small-diameter polytetrafluoroethylene (PTFE) grafts</TI>
<SO>Journal of Surgical Research</SO>
<YR>1988</YR>
<VL>44</VL>
<NO>4</NO>
<PG>455-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Geraghty-2011" MODIFIED="2014-09-02 14:11:34 +0100" MODIFIED_BY="[Empty name]" NAME="Geraghty 2011" TYPE="COCHRANE_REVIEW">
<AU>Geraghty AJ, Welch K</AU>
<TI>Antithrombotic agents for preventing thrombosis after infrainguinal arterial bypass surgery</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2011</YR>
<NO>6</NO>
<IDENTIFIERS MODIFIED="2014-09-02 14:11:32 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-09-02 14:11:32 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000536.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2015-01-27 14:40:17 +0000" MODIFIED_BY="[Empty name]" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2015-01-27 14:40:35 +0000" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NICE-2013" MODIFIED="2015-01-27 14:40:41 +0000" MODIFIED_BY="[Empty name]" NAME="NICE 2013" TYPE="OTHER">
<AU>Anon</AU>
<TI>Antiplatelet treatment- summary</TI>
<SO>National Institue for Health and Care Excellence (NICE)</SO>
<YR>2013</YR>
<VL>cks.nice.org.uk/antiplatelet-treatment#!topicsummary</VL>
<NO>(Accessed July 1 2014)</NO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rutherford-1988" MODIFIED="2008-05-05 22:31:34 +0100" MODIFIED_BY="Julie A Brown" NAME="Rutherford 1988" TYPE="JOURNAL_ARTICLE">
<AU>Rutherford RB, Jones DN, Bergentz SE, Bergqvist D, Comerota AJ, Dardik H, et al</AU>
<TI>Factors affecting the patency of infrainguinal bypass</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>1988</YR>
<VL>8</VL>
<NO>3</NO>
<PG>236-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tangelder-1999" MODIFIED="2015-01-27 14:40:52 +0000" MODIFIED_BY="[Empty name]" NAME="Tangelder 1999" TYPE="JOURNAL_ARTICLE">
<AU>Tangelder MJ, Lawson JA, Algra A, Eikelboom BC</AU>
<TI>Systematic review of randomized controlled trials of aspiring and oral anticoagulants in the prevention of graft occlusion and ischemic events after infrainguinal bypass surgery</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>1999</YR>
<VL>30</VL>
<NO>4</NO>
<PG>701-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tangelder-2000" MODIFIED="2008-05-05 22:31:34 +0100" MODIFIED_BY="Julie A Brown" NAME="Tangelder 2000" TYPE="JOURNAL_ARTICLE">
<AU>Tangelder MJ, Algra A, Lawson JA, Eikelboom, BC</AU>
<TI>Risk factors for occlusion of infrainguinal bypass grafts</TI>
<SO>European Journal of Vascular and Endovascular Surgery</SO>
<YR>2000</YR>
<VL>20</VL>
<NO>2</NO>
<PG>118-24</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2015-01-27 14:41:21 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Adams-1997" MODIFIED="2015-01-27 14:41:21 +0000" MODIFIED_BY="[Empty name]" NAME="Adams 1997" TYPE="COCHRANE_PROTOCOL">
<AU>Adams D, Stonebridge PA</AU>
<TI>Antiplatelet therapy after peripheral arterial bypass surgery</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>1997</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2015-01-27 10:48:26 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-01-27 10:48:26 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000535"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Brown-2008" MODIFIED="2014-04-01 15:09:13 +0100" MODIFIED_BY="[Empty name]" NAME="Brown 2008" TYPE="COCHRANE_REVIEW">
<AU>Brown J, Lethaby A, Maxwell H, Wawrzyniak AJ, Prins MH</AU>
<TI>Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2014-04-01 15:09:08 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-04-01 15:09:08 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000535.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-D_x00f6_rffler_x002d_Melly-2003" MODIFIED="2014-04-01 15:11:10 +0100" MODIFIED_BY="[Empty name]" NAME="Dörffler-Melly 2003" TYPE="COCHRANE_REVIEW">
<AU>Dörffler-Melly J, Büller HR, Koopman MM, Prins MH</AU>
<TI>Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2014-04-01 15:11:10 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-04-01 15:11:10 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000535"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2014-05-05 10:07:56 +0100" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2015-01-27 14:33:27 +0000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2015-01-27 14:29:04 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2015-01-27 14:17:13 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Becquemin-1997">
<CHAR_METHODS MODIFIED="2015-01-27 14:15:19 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>
<B>Study type:</B>
</I> Multicentre, double-blind, randomised controlled trial</P>
<P>
<I>
<B>Study aim:</B>
</I> To determine whether ticlopidine (TIC) could reduce the rate of late occlusion of saphenous-vein grafts below the knee</P>
<P>
<I>
<B>Country:</B>
</I> France</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-27 14:16:49 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>
<B>Number randomised:</B>
</I> Total n = 243 (TIC n = 122; placebo n = 121)</P>
<P>
<I>
<B>Age- mean years:</B>
</I> TIC 67.1; placebo 67.7</P>
<P>
<I>
<B>Gender n (M/F): </B>
</I>TIC 96/26; placebo 92/29</P>
<P>
<I>
<B>Inclusion criteria:</B>
</I> All patients 18 to 80 years old who required femoropopliteal or femorotibial bypass graft for atheromatous occlusive disease; had a saphenous vein suitable for grafting</P>
<P>
<I>
<B>Exclusion criteria:</B>
</I> Acute ischaemia or aneurysm; marked stenosis in the ipsilateral iliac artery; previous arterial surgery on the same limb; reduced life expectancy; pregnancy; inability to comply with the protocol; associated conditions requiring treatment with platelet-inhibiting drugs or anticoagulants; abnormalities of haemostasis</P>
<P>
<I>
<B>Co-morbidity:</B>
</I> current angina or previous MI (TIC 20.5%; placebo 24.8%), impaired left ventricular function (TIC 10.7%; placebo 7.4%), arrhythmia (TIC 9.0%; placebo 15.7%), carotid stenosis (TIC 22.1%; placebo 21.5%), hypertension (TIC 48.4%; placebo 53.7%), current smoker (TIC 25.4%; placebo 19.0%), diabetes (TIC 27.0%; placebo 21.5%), hyperlipidaemia (TIC 23.8%; placebo 25.6%), previous vascular surgery (TIC 32.8%; placebo 30.6%)</P>
<P>
<I>
<B>Severity of occlusive disease: </B>
</I>Leriche-Fontaine stage of disease- stage IIb (TIC 27.0; placebo 22.3), stage III (TIC 30.3; placebo 41.3), stage IV (TIC 42.6; placebo 36.4)</P>
<P>
<I>
<B>Site of distal anastomosis: </B>
</I>popliteal (TIC n = 66; placebo n = 82), tibial (TIC n = 56; placebo n = 39)</P>
<P>
<I>
<B>Type of graft: </B>
</I>autologous saphenous-vein grafts</P>
<P>More than 70% of the participants in both groups suffered from critical limb ischaemia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-27 14:17:05 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>
<B>Treatment: </B>
</I>250 mg ticlopidine in bottles with a 1-month supply; given in boxes containing 6-month supply dispensed on day 0 and at 6, 12 and 18 months; participants instructed to take 1 tablet twice a day for the 24 months of the study</P>
<P>
<I>
<B>Control:</B>
</I> placebo identically matched to treatment in bottles with a 1-month supply; given in boxes containing 6-month supply dispensed on day 0 and at 6, 12 and 18 months; participants instructed to take 1 tablet twice a day for the 24 months of the study</P>
<P>
<I>
<B>Duration:</B>
</I> 24 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-27 14:17:10 +0000" MODIFIED_BY="[Empty name]">
<P>Primary endpoint was primary patency at 2 years postoperatively; Secondary endpoints were secondary graft patency, death from any cause, nonfatal MI, nonfatal stroke, limb ischaemia, mesenteric infarct, amputation of leg or thigh</P>
<P>Evaluated at 1, 3, 6, 12, 18 and 24 months</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-01-27 14:17:13 +0000" MODIFIED_BY="[Empty name]">
<P>Randomisation took place between the 3rd and 14th postoperative day and follow-up continued for 2 years</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-27 14:17:36 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-BOA-2000">
<CHAR_METHODS MODIFIED="2014-06-05 12:01:30 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Study type: </I>
</B>An open, randomised, multicentre clinical trial</P>
<P>
<B>
<I>Study aim: </I>
</B>To compared the effectiveness of oral anticoagulants with that of aspirin in the prevention of infrainguinal bypass-graft occlusion and other clinical events</P>
<P>
<B>
<I>Country:</I>
</B> the Netherlands<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-27 14:17:30 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>
<B>Number randomised:</B>
</I> Total n = 2690 (ASA n = 1351; coumarin n = 1339)</P>
<P>
<I>
<B>Age- mean years (SD):</B>
</I> ASA 69 (10); coumarin 69 (10)</P>
<P>
<I>
<B>Gender- M%:</B>
</I> ASA 63%; coumarin 65%</P>
<P>
<I>
<B>Inclusion criteria:</B>
</I> All patients who required an infrainguinal bypass graft for obstructive arterial disease</P>
<P>
<I>
<B>Exclusion criteria: </B>
</I>Contraindication or absolute indication for one of the trial medications; substantially shortened life expectancy; MI or stroke within 1 month before surgery; abnormalities of blood platelets or erythrocytes; anaemia; inability to adhere to the protocol; inability to give informed consent</P>
<P>
<I>
<B>Co-morbidity:</B>
</I> All participants: 54% smokers, 39% with hypertension, 26% with diabetes mellitus, and 16% with hyperlipidaemia</P>
<P>
<I>
<B>Severity of occlusive disease:</B>
</I> Claudicants (ASA 52%; coumarin 50%), Pain at rest (ASA 21%; coumarin 21%), Ischaemic ulceration (ASA 25%; coumarin 27%), gangrene (ASA 2%; coumarin 1%)</P>
<P>
<I>
<B>Site of distal anastomosis:</B>
</I> popliteal above knee (ASA 48%; coumarin 45%), popliteal below knee (ASA 32%; coumarin 36%), crural (ASA 19%; coumarin 18%), pedal (ASA 1%; coumarin 2%)</P>
<P>
<I>
<B>Type of graft:</B>
</I> vein (ASA 58%; coumarin 59%), biograft (ASA 6%; coumarin 6%), prosthetic (ASA 34%; coumarin 31%), composite (ASA 2%; coumarin 3%)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-27 14:17:33 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>
<B>Treatment:</B>
</I> Aspirin, 100 mg daily pulverised carbasalate calcium (equivalent to 80 mg daily), started within 5 days after surgery</P>
<P>
<I>
<B>Control: </B>
</I>coumarin derivatives (phenprocoumon or acenocoumarol) with intended International Normalised Ratio (INR) range was 3.0 - 4.5 (achieved in 50% of the observed patient years), started within 5 days after surgery</P>
<P>
<I>
<B>Duration: </B>
</I>unclear, but mean observation time was 21 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-27 14:17:36 +0000" MODIFIED_BY="[Empty name]">
<P>Primary endpoint was graft patency assessed clinically by Doppler flow measurement or duplex sonography, or by arteriography if indicated. Secondary endpoints were vascular death, MI, stroke, amputation, vascular intervention, and major haemorrhage. Follow-up was at 3, 6, 12, 18, and 24 months, with 6 monthly visits thereafter. Mean observation time was 21 months</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-06-05 10:45:04 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-27 14:18:09 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-CASPAR-2010">
<CHAR_METHODS MODIFIED="2014-06-05 12:02:58 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Study type:</I>
</B> Multicentre, prospective, randomised, placebo-controlled trial</P>
<P>
<B>
<I>Study aim:</I>
</B> To determine whether clopidogrel plus ASA had better limb outcomes compared to ASA alone, in patients undergoing below-knee bypass grafting</P>
<P>
<B>
<I>Country: </I>
</B>UK</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-27 14:18:05 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>
<B>Number randomised: </B>
</I>Total n = 851 (Clopidogrel + ASA n = 425; ASA + placebo n = 426)</P>
<P>
<I>
<B>Age- mean years (SD): </B>
</I>Clopidogrel + ASA 66.5 (8.7); ASA + placebo 65.6 (8.5)</P>
<P>
<I>
<B>Gender- M%:</B>
</I> Clopidogrel + ASA 75.5%; ASA + placebo 75.8%</P>
<P>
<I>
<B>Inclusion criteria:</B>
</I> &#8805; 40 and &#8804; 80 years; informed consent obtained before conducting any study-related procedure; chronic background treatment with daily ASA of any done, started at least 4 weeks before surgery; a post-randomisation dose of ASA between 75 and 100 mg/day; unilateral below-knee bypass graft for atherosclerotic PAD; patent index graft demonstrated during bypass surgery or between surgery and time of randomisation; no clinical evidence of graft occlusion at randomisation</P>
<P>
<I>
<B>Exclusion criteria:</B>
</I> Onset of PAD symptoms before age of 40; nonatherosclerotic vascular disease; patients receiving aortobifemoral, iliac-femoral or cross-over (femoral-femoral) grafts or undergoing peripheral transcutaneous angioplasty during the same surgery; significant bleeding risk such as current active bleeding at the surgical site; withdrawal of an epidural catheter less than 12 hours before randomisation; peptic ulceration within 12 months of randomisation; previous or current intracranial haemorrhage or haemorrhagic stroke; any history of severe spontaneous bleeding; current warfarin therapy or anticipated need for warfarin; concomitant additional antiplatelet agents or thrombolytic agents</P>
<P>
<I>
<B>Co-morbidity:</B>
</I> Hypertension (Clopidogrel + ASA 70.1%, ASA + placebo 70.0%); Hyperlipidemia (Clopidogrel + ASA 50.4%, ASA + placebo 48.8%); CAD and/or CRVD (Clopidogrel + ASA 38.4%, ASA + placebo 31.0%); Diabetes (Clopidogrel + ASA 37.4%, ASA + placebo 38.0%), claudication only (Clopidogrel + ASA 34.1%, ASA + placebo 32.6%), rest pain (Clopidogrel + ASA 26.1%, ASA + placebo 26.5%), ulcers/gangrene (Clopidogrel + ASA 39.3%, ASA + placebo 39.9%)</P>
<P>
<I>
<B>Severity of occlusive disease (determined by ABPI): </B>
</I>ABPI (SD) - Clopidogrel + ASA 0.44 (0.25), ASA + placebo 0.46 (0.26)</P>
<P>
<I>
<B>Site of distal anastomosis: </B>
</I>Below-knee popliteal (Clopidogrel + ASA 75.5%, ASA + placebo 74.8%); below-knee popliteal crural (Clopidogrel + ASA 20.7%, ASA + placebo 22.1%); beyond popliteal pedal (Clopidogrel + ASA 3.8%, ASA + placebo 3.1%)</P>
<P>
<I>
<B>Type of graft:</B>
</I> venous and prosthetic grafts (Clopidogrel + ASA venous = 297 prosthetic = 128; ASA + placebo venous = 301 prosthetic = 125)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-27 14:18:09 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>
<B>Treatment: </B>
</I>Clopidogrel + ASA: ASA 75 - 100 mg/day plus clopidogrel 75 mg/day</P>
<P>
<I>
<B>Control: </B>
</I>ASA + placebo: ASA 75 - 100 mg/day plus placebo 1 tablet/day</P>
<P>
<I>
<B>Duration: </B>
</I>Beginning 2- 4 days after bypass surgery; follow-up from 6 to 24 months after surgery; Follow-up evaluations at 1 month and then every 6 months thereafter</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-05 09:52:37 +0100" MODIFIED_BY="[Empty name]">
<P>Primary efficacy: composite of index-graft occlusion or revascularisation, above-ankle amputation of affect limb or death</P>
<P>Primary safety: severe bleeding (GUSTO classification), moderate and mild bleeding</P>
<P>ABPI</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-06-05 09:51:40 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-27 14:18:39 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Clyne-1987">
<CHAR_METHODS MODIFIED="2014-06-05 12:04:46 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Study type:</I>
</B> Prospective randomised single-centre trial</P>
<P>
<B>
<I>Study aim: </I>
</B>To discover whether improved patency could be achieved by a short course of maximum thrombogenicity</P>
<P>
<B>
<I>Country: </I>
</B>UK</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-27 14:18:27 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>
<B>Number randomised: </B>
</I>Total n = 140 (148 bypasses) (ASA/DIP = 78 bypasses; control = 70 bypasses)</P>
<P>
<I>
<B>Age:</B>
</I> not indicated</P>
<P>
<I>
<B>Gender n (M/F):</B>
</I> Total 107/41</P>
<P>
<I>
<B>Inclusion criteria:</B>
</I> patients undergoing femorodistal bypasses for rest pain or very short distance claudication</P>
<P>
<I>
<B>Exclusion criteria: </B>
</I>not indicated</P>
<P>
<I>
<B>Co-morbidity:</B>
</I> smoker (ASA/DIP 62%; control 61%), diabetes (ASA/DIP 13%; control 13%), duration of claudication- months (SD) (ASA/DIP 15.6 (24.9); control 24.7 (35)), rest pain (ASA/DIP = 42; control = 46)</P>
<P>
<I>
<B>Severity of occlusive disease (determined by ABPI):</B>
</I> ABPI (SD) - ASA/DIP 0.39 (0.25); control 0.35 (0.27)</P>
<P>
<I>
<B>Site of distal anastomosis:</B>
</I> below knee 119 (ASA/DIP = 64; control = 55)</P>
<P>
<I>
<B>Type of graft:</B>
</I> autogenous vein bypasses - 93 (63 %) (ASA/DIP = 49; control = 44), prosthetic including PTFE, Dacron and umbilical vein - 55 (ASA/DIP = 29; control = 26), 28 participants received secondary reconstructions</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-27 14:18:32 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>
<B>Treatment:</B>
</I> ASA/DIP - 200 mg twice daily DIP started 48 hours before surgery, continued on day of surgery and postoperatively 10 mg iv DIP; followed by 300 mg ASA and 200 mg DIP twice daily for 6 weeks after surgery. All participants received heparin perioperatively</P>
<P>
<I>
<B>Control:</B>
</I> no specific anti-thrombotic treatment or placebo</P>
<P>
<I>
<B>Duration:</B>
</I> 6 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-27 14:18:33 +0000" MODIFIED_BY="[Empty name]">
<P>Primary endpoints were graft failure, limb loss, death at 12 months follow-up. Graft patency was assessed clinically and by Doppler ankle blood pressure before discharge, at 1, 3, 6, and 12 months postoperatively. Arteriography was performed when further operative treatment was considered</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-01-27 14:18:39 +0000" MODIFIED_BY="[Empty name]">
<P>All data were related to the numbers of bypasses instead of numbers of participants (8 of 140 participants received 2 grafts)</P>
<P>98 participants underwent operation for rest pain, 42 for claudication</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-27 14:19:25 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-D_x0027_Addato-1992">
<CHAR_METHODS MODIFIED="2015-01-27 14:18:48 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>
<B>Study type: </B>
</I>Multicentre, double-blind, randomised clinical trial</P>
<P>
<I>
<B>Study aim: </B>
</I>To compare the efficacy of indobufen (IND) and the combination of ASA/DIP in improving long-term patency of the femoropopliteal prosthetic bypass</P>
<P>
<I>
<B>Country: </B>
</I>Italy</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-27 14:19:19 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>
<B>Number randomised: </B>
</I>Total n = 113 (ASA/DIP n = 57; IND n = 56)</P>
<P>
<I>
<B>Age- mean years (SD): </B>
</I>ASA/DIP
 
65.6 (8.4); IND 66.6 (8.4)</P>
<P>
<I>
<B>Gender n (M/F): </B>
</I>ASA/DIP 47/10; IND 49/7</P>
<P>
<I>
<B>Inclusion criteria: </B>
</I>Patients with vascular disease complaining of rest pain or trophic lesions or both; occlusion of the femoropoplitea-tibial tract; candidates for revascularising with PTFE bypass graft</P>
<P>
<I>
<B>Exclusion criteria: </B>
</I>Patients with severe obesity; severe or unstable diabetes; life expectancy &lt; 12 months; hypertensive patients with mean arterial pressure &gt; 115 mmHg not controllable by suitable therapy; patients with severe hepatic or renal insufficiency; chronic anaemia; haemorrhagic diathesis; present or previous peptic ulcer; need for treatment with drugs that could affect platelet aggregation or clotting or both</P>
<P>
<I>
<B>Co-morbidity: </B>
</I>Diabetes mellitus (ASA/DIP 15.8%; IND 14.3%), hypercholesterolaemia (ASA/DIP 14.0%; IND 7.2%), smoking (ASA/DIP 68.4%; IND 71.4%), hypertension (ASA/DIP 22.8%; IND 19.6%), critical ischaemia (ASA/DIP 75.4%; IND 66.1%)</P>
<P>
<I>
<B>Severity of occlusive disease (determined by ABPI): </B>
</I>not indicated</P>
<P>
<I>
<B>Site of distal anastomosis: </B>
</I>Above-knee anastomosis (ASA/DIP 29%; IND 35%), below-knee anastomosis (ASA/DIP 28%; IND 21%)</P>
<P>
<I>
<B>Type of graft: </B>
</I>PTFE</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-27 14:19:22 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>
<B>Treatment: </B>
</I>900 mg ASA combined with 225 mg DIP, started 2 days before surgery</P>
<P>
<I>
<B>Control: </B>
</I>400 mg IND daily, started 2 days before surgery</P>
<P>7-day washout period during which no anticoagulants or inhibitors of prostaglandin synthesis were used</P>
<P>
<I>
<B>Duration: </B>
</I>12 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-27 14:19:25 +0000" MODIFIED_BY="[Empty name]">
<P>Graft patency was assessed by angiography 6 days and 12 months postoperatively, and clinically every 3 months by physical examination, Doppler ultrasound measurements on the graft, and by angiography if indicated<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-27 14:19:41 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Donaldson-1985">
<CHAR_METHODS MODIFIED="2014-06-05 14:06:55 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Study type: </I>
</B>A randomised, double-blind clinical trial performed between 1979 and 1981</P>
<P>
<B>
<I>Study aim: </I>
</B>To evaluate the effect of a combination of ASA and DIP on the early patency of femoro-popliteal Dacron bypass grafts implanted to relieve disabling claudication</P>
<P>
<B>
<I>Country: </I>
</B>UK<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-27 14:19:33 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>
<B>Number randomised: </B>
</I>Total n = 65 (73 grafts) (ASA/DIP n = 33 (35 grafts); placebo n = 32 (38 grafts))</P>
<P>
<I>
<B>Age- mean years:</B>
</I> ASA/DIP = 59.3; placebo 60.0</P>
<P>
<I>
<B>Gender n (M/F): </B>
</I>ASA/DIP 27/6; placebo 25/7</P>
<P>
<I>
<B>Inclusion criteria: </B>
</I>Patients with disabling intermittent claudication suitable for femoro-popliteal bypass</P>
<P>
<I>
<B>Exclusion criteria: </B>
</I>a history of dyspepsia, peptic ulceration or hypersensitivity to ASA or DIP</P>
<P>
<I>
<B>Co-morbidity: </B>
</I>diabetic (ASA/DIP n = 3; placebo n = 2), mean MWD- m (ASA/DIP 61.2; placebo 54.7)</P>
<P>
<I>
<B>Severity of occlusive disease (determined by ABPI): </B>
</I>ASA/DIP 0.63; placebo 0.61</P>
<P>
<I>
<B>Site of distal anastomosis: </B>
</I>below the knee (ASA/DIP 11; placebo 10)</P>
<P>
<I>
<B>Type of graft: </B>
</I>Dacron bypass grafts</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-27 14:19:37 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>
<B>Treatment: </B>
</I>3 times daily 330 mg ASA and 75 mg DIP</P>
<P>
<I>
<B>Control: </B>
</I>placebo</P>
<P>
<I>
<B>Duration: </B>
</I>Therapy was started preoperatively. 1 trial capsule given on the evening prior to surgery then resumed as soon as oral intake was permitted postoperatively) and continued for 12 months postoperatively</P>
<P>All participants received heparin intraoperatively<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-05 14:35:21 +0100" MODIFIED_BY="[Empty name]">
<P>Assessment of graft patency was performed by a standardised treadmill test, ankle/brachial systolic pressure index (ABPI), Doppler ultrasound and by palpation at 3, 6, 9, and 12 months postoperatively. Plasma drug levels were measured for ASA and DIP. Graft patency by clinical examination, ABPI, Doppler on graft, maximum walking distance, platelet adhesion/aggregation, bleeding time</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-01-27 14:19:41 +0000" MODIFIED_BY="[Empty name]">
<P>2 bilateral participants in the ASA/DIP group and 6 in the placebo group</P>
<P>All concomitant antithrombotic therapy had been stopped at least 3 weeks prior to surgery</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-27 14:20:31 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Edmondson-1994">
<CHAR_METHODS MODIFIED="2015-01-27 14:19:48 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>
<B>Study type: </B>
</I>An open, multicentre, randomised controlled trial</P>
<P>
<I>
<B>Study aim: </B>
</I>To determine if low molecular weight heparin (LMWH) would be more effective than ASA and DIP in maintaining graft patency in patients undergoing femoropopliteal bypass grafting</P>
<P>
<I>
<B>Country: </B>
</I>UK</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-27 14:20:19 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>
<B>Number randomised: </B>
</I>Total n = 200 (ASA/DIP n = 106; LMWH n = 94)</P>
<P>
<I>
<B>Age- mean years (SD): </B>
</I>ASA/DIP 68.4 (9.6); LMWH 66.8 (9.2)</P>
<P>
<I>
<B>Gender n (M/F): </B>
</I>ASA/DIP 74/32; LMWH
 
61/33</P>
<P>
<I>
<B>Inclusion criteria: </B>
</I>&gt; 40 years old; angiographically-proven arterial occlusive disease; scheduled to undergo femoropopliteal bypass surgery</P>
<P>
<I>
<B>Exclusion criteria: </B>
</I>currently taking oral anticoagulants; there was a known allergy to heparin, ASA or DIP; limb for operation had undergone previous femoropopliteal bypass grafting; the indication for bypass surgery was aneurysmal disease or trauma; there was a serious concomitant disease</P>
<P>
<I>
<B>Co-morbidity: </B>
</I>smoking (ASA/DIP 31.1%; LMWH 28.7%), diabetes (ASA/DIP 19.8%; LMWH 14.9%), hyperlipidaemia (ASA/DIP 6.6%; LMWH 5.3%)</P>
<P>
<I>
<B>Severity of occlusive disease (determined by ABPI): </B>
</I>not indicated</P>
<P>
<I>
<B>Site of distal anastomosis: </B>
</I>above-knee (ASA/DIP 69.8%; LMWH 68.1%), below-knee (ASA/DIP 27.4%; LMWH 27.7%), tibial vessels (ASA/DIP 2.8%; LMWH 4.3%)</P>
<P>
<I>
<B>Type of graft: </B>
</I>autologous vein (ASA/DIP 24.5%; LMWH 28.7%), prosthetic (PTFE and Dacron (ASA/DIP 46.2%; LMWH 30.9%))</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-27 14:20:25 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>
<B>Treatment: </B>
</I>ASA/DIP- 300 mg ASA and 100 mg DIP, both 3 times per day
 

</P>
<P>
<I>
<B>Control: </B>
</I>2500 IU LMWH (Fragmin) subcutaneously once daily</P>
<P>
<I>
<B>Duration:</B>
</I> 3 months</P>
<P>All the participants received LMWH subcutaneously 2 hours preoperatively, continuing for 1 week postoperatively, and at 1 week participants were randomised to continue LMWH or receive ASA/DIP</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-27 14:20:29 +0000" MODIFIED_BY="[Empty name]">
<P>On the 7th postoperative day participants were assessed for primary graft occlusion, wound infection, thrombectomy, bleeding, and death. Total follow-up was 1 year with visits at 1, 3, 6, and 12 months. Graft patency was evaluated clinically and by ABPI, and, if indicated, supplemented by arteriography or duplex sonography</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-01-27 14:20:31 +0000" MODIFIED_BY="[Empty name]">
<P>Indication for surgery was disabling claudication in 107 participants and salvage in 93 participants<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-27 14:20:49 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Goldman-1984">
<CHAR_METHODS MODIFIED="2014-06-05 15:39:15 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Study type: </I>
</B>Double-blind, randomised controlled trial</P>
<P>
<B>
<I>Study aim: </I>
</B>To assess the effect of ASA and DIP on the patency of prosthetic femoropopliteal bypass grafts</P>
<P>
<B>
<I>Country: </I>
</B>UK<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-27 14:20:47 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>
<B>Number randomised: </B>
</I>Total n = 53 (ASA/DIP n = 22; placebo n = 31)</P>
<P>
<I>
<B>Age- mean years: </B>
</I>ASA/DIP 64.3; placebo 63.2</P>
<P>
<I>
<B>Gender n (M/F): </B>
</I>ASA/DIP 16/6; placebo 27/4 </P>
<P>
<I>
<B>Inclusion criteria: </B>
</I>patients awaiting femoropopliteal bypass for occlusive disease</P>
<P>
<I>
<B>Exclusion criteria: </B>
</I>patients already receiving platelet inhibitory drugs; with a significant history of dyspepsia</P>
<P>
<I>
<B>Co-morbidity: </B>
</I>Claudicants (ASA/DIP 3; placebo 8), rest pain/gangrene (ASA/DIP 19; placebo 23), smokers (ASA/DIP 19; placebo 24), diabetes mellitus (ASA/DIP 2; placebo 3) hypertension (ASA/DIP 4; placebo 6), ischaemic heart disease (ASA/DIP 7; placebo 11)</P>
<P>
<I>
<B>Severity of occlusive disease (determined by ABPI): </B>
</I>not indicated</P>
<P>
<I>
<B>Site of distal anastomosis: </B>
</I>above-knee anastomoses (ASA/DIP 10; placebo 19), below-knee anastomoses (ASA/DIP 12; placebo 12)</P>
<P>
<I>
<B>Type of graft: </B>
</I>prosthetic (Dacron or PTFE)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-25 12:17:40 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Treatment: </I>
</B>ASA/DIP- combination of
 
300 mg ASA and 75 mg DIP 3 times daily</P>
<P>
<I>
<B>Control: </B>
</I>placebo- identical to treatment drug</P>
<P>
<I>
<B>Duration: </B>
</I>started 48 h before surgery and continued for 12 months<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-27 14:20:49 +0000" MODIFIED_BY="[Empty name]">
<P>Graft patency was assessed in monthly follow-up visits up to 1 year based on reported symptoms, palpation, directional Doppler, and isotope angiography</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-27 14:21:04 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Green-1982">
<CHAR_METHODS MODIFIED="2014-06-06 09:35:06 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Study type: </I>
</B>Double-blind, randomised controlled trial</P>
<P>
<B>
<I>Study aim: </I>
</B>To asses the effect of aspirin alone or in combination with DIP on the patency rates of expanded PTFE grafts placed in the infrainguinal position</P>
<P>
<B>
<I>Country: </I>
</B>US<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-27 14:20:54 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>
<B>Number randomised: </B>
</I>Total n = 49 (ASA alone n = 16; ASA/DIP n = 16; placebo n = 17)</P>
<P>
<I>
<B>Age: </B>
</I>not indicated</P>
<P>
<I>
<B>Gender: </B>
</I>not indicated</P>
<P>
<I>
<B>Inclusion criteria: </B>
</I>All private patients of study authors RMG and JAD seen in the Peripheral Vaular Surgical Service of the University of Rochester Medical Center, Strong Memorial Hospital, beginning May 1979 2 required an infrainguinal bypass</P>
<P>
<I>
<B>Exclusion criteria: </B>
</I>Patients with known sensitivity to ASA or DIP; platelet or clotting abnormalities; gastrointestinal disturbances with a tendency to bleeding; require ASA for other medical conditions; infrainguinal autogenous saphenous vein bypass available; concomitant inflow disease</P>
<P>
<I>
<B>Co-morbidity: </B>
</I>smoking (ASA 56%; ASA/DIP 56%; placebo 53%), diabetes (ASA 37%; ASA/DIP 50%; placebo 48%), previous
 
femoropopliteal bypass (ASA 6%; ASA/DIP 19%; placebo 41%),</P>
<P>
<I>
<B>Severity of occlusive disease: </B>
</I>procedure performed for limb salvage (ASA 75%; ASA/DIP 87%; placebo 88%)</P>
<P>
<I>
<B>Site of distal anastomosis: </B>
</I>below-knee (ASA 38%; ASA/DIP 56%; placebo 47%)</P>
<P>
<I>
<B>Type of graft: </B>
</I>prosthetic PTFE grafts</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-27 14:21:04 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>
<B>Treatment: </B>
</I>
</P>
<P>1) ASA alone- 325 mg ASA plus a red placebo tablet 3 times daily</P>
<P>2) ASA/DIP- 325 mg ASA and 75 mg DIP 3 times daily</P>
<P>
<I>
<B>Control: </B>
</I>Placebo- received red and white placebo tablets 3 times daily</P>
<P>
<I>
<B>Duration: </B>
</I>Started preoperatively: DIP or matching placebo started 48 hours prior to operation and ASA or matching placebo started 24 hours prior to surgery, and then
 
for 1 year</P>
<P>Patients were randomised to either treatment with 325 mg ASA once daily plus a placebo 3 times daily or 325 mg ASA once daily combined with 75 mg DIP 3 times per day for 1 year. Medication was started 48 hours preoperatively and continued for 1 year</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-27 14:21:04 +0000" MODIFIED_BY="[Empty name]">
<P>Primary graft occlusion, withdrawal, and death were considered as treatment failures. Graft patency was assessed by clinical examination and ABPI change of 0.4 to 1.0. Follow-up visits were every 3 months, or when problems arose, until death or withdrawal or for at least 1 year</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-02 14:45:42 +0100" MODIFIED_BY="[Empty name]">
<P>PTFE grafts when prosthetic graft was obligatory; all patients with available autologous saphenous veins for grafting were excluded<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-27 14:21:10 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gruss-1991">
<CHAR_METHODS MODIFIED="2015-01-27 14:21:08 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>
<B>Study type: </B>
</I>Prospective, randomised controlled trial</P>
<P>
<I>
<B>Study aim: </B>
</I>Can a permanent intra-arterial PGE1 therapy reduce the number of postoperative immediate and early closures in femoro-crural great saphenous vein in situ bypasses</P>
<P>
<I>
<B>Country: </B>
</I>Germany</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-06 11:38:25 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Number randomised: </I>
</B>Total n = 100 (ASA n = 50; PGE1 n = 50)</P>
<P>
<B>
<I>Age: </I>
</B>not indicated</P>
<P>
<B>
<I>Gender (M/F): </I>
</B>not indicated</P>
<P>
<B>
<I>Inclusion criteria: </I>
</B> patients with femorotibial greater saphenous vein in situ bypasses</P>
<P>
<B>
<I>Exclusion criteria: </I>
</B>not indicated</P>
<P>
<B>
<I>Co-morbidity: </I>
</B>not indicated</P>
<P>
<B>
<I>Severity of occlusive disease (determined by ABPI): </I>
</B>not indicated</P>
<P>
<B>
<I>Site of distal anastomosis: </I>
</B>not indicated</P>
<P>
<B>
<I>Type of graft: </I>
</B>autologous saphenous vein grafts</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-27 14:21:10 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>
<B>Treatment: </B>
</I>ASA, 0.5 g 3 times daily and 15,000 IU heparin continuously</P>
<P>
<I>
<B>Control: </B>
</I>Intra-arterial PGE1, 0.2 ng per kg body weight/min and 15,000 IU heparin continuously</P>
<P>
<I>
<B>Duration: </B>
</I>24 hours for the first 10 postoperative days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-06 11:39:33 +0100" MODIFIED_BY="[Empty name]">
<P>Early graft occlusion was the primary outcome of this study</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-06-06 11:39:58 +0100" MODIFIED_BY="[Empty name]">
<P>Study information came from a single abstract, with the majority of information in German</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-27 14:21:26 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kohler-1984">
<CHAR_METHODS MODIFIED="2014-06-06 12:41:25 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Study type: </I>
</B>Double-blind,
 
randomised controlled trial performed from 1978 to 1982</P>
<P>
<B>
<I>Study aim: </I>
</B>To determine whether ASA and DIP administered postoperatively to patients with PTFE or autologous vein infrainguinal bypasses would improve graft patency during the first 24 months after operation</P>
<P>
<B>
<I>Country: </I>
</B>US</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-27 14:21:23 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>
<B>Number randomised: </B>
</I>Total n = 100 (grafts = 102) (ASA/DIP n = 44 (grafts = 51); placebo n = 44 (grafts = 51) 12 patients were not included in the study post-randomisation</P>
<P>
<I>
<B>Age- mean years (SD): </B>
</I>ASA/DIP 66 (12); placebo 66 (10)</P>
<P>
<I>
<B>Gender n (M/F): </B>
</I>ASA/DIP 34/10; placebo 34/10</P>
<P>
<I>
<B>Inclusion criteria: </B>
</I>Private patients at the Beth Israel or Brigham and Women's Hospital who were scheduled for infrainguinal bypass procedures with either autologous saphenous vein or expanded PTFE grafts</P>
<P>
<I>
<B>Exclusion criteria: </B>
</I>Concomitant inflow disease; hypersensitivity to ASA or DIP; gastrointestinal bleeding; recently taken platelet-activating drugs or anticoagulants for any reason; or if geographical inaccessibility prevented follow-up</P>
<P>
<I>
<B>Co-morbidity: </B>
</I>Diabetic (ASA/DIP n = 15; placebo n = 15), history of smoking (ASA/DIP n = 32; placebo n = 33), claudication indication for operation (ASA/DIP n = 16; placebo n = 19), threatened limb indication for operation (ASA/DIP n = 35; placebo n = 32)</P>
<P>
<I>
<B>Severity of occlusive disease (determined by ABPI): </B>
</I>not indicated</P>
<P>
<I>
<B>Site of distal anastomosis: </B>
</I>Tibial (ASA/DIP n = 8; placebo n = 10), proximal popliteal (ASA/DIP n = 21; placebo n = 22), distal popliteal (ASA/DIP n = 22; placebo n = 24)</P>
<P>
<I>
<B>Type of graft: </B>
</I>vein grafts
 
(ASA/DIP n = 36; placebo n = 35), PTFE grafts (ASA/DIP n = 15; placebo n = 16)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-27 14:21:25 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>
<B>Treatment: </B>
</I>ASA/DIP- ASA 325 mg and DIP 75 mg 3 times daily, oral route</P>
<P>
<I>
<B>Control: </B>
</I>placebo- identical placebo tablets 3 time daily, oral route</P>
<P>
<I>
<B>Duration: </B>
</I>Starting on first day postoperatively, continuing 24 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-27 14:21:26 +0000" MODIFIED_BY="[Empty name]">
<P>Graft patency, the primary endpoint, was assessed at 3 and 6 weeks, further at 3, 6, 12, 18, 24 months postoperatively by evaluation of clinical symptoms, palpation of the graft, ABPI assessment, and if indicated by angiography</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-06-09 09:43:11 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-27 14:24:05 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lucas-1984">
<CHAR_METHODS MODIFIED="2015-01-27 14:21:33 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>
<B>Study type: </B>
</I>Randomised controlled trial</P>
<P>
<I>
<B>Study aim: </B>
</I>To compare post-operative course over 6 months of 2 parallel cohorts of peripheral arteriopathy patients, 1 treated with pentoxifylline (PTX) and the other with conventional anti-aggregant medication, ASA and DIP, with regard to the incidence of rethrombosis</P>
<P>
<I>
<B>Country: </B>
</I>Argentina<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-25 12:19:49 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Number randomised: </I>
</B>Total n = 100 (ASA/DIP n = 49; PTX n = 48), three patients were excluded post-randomisation</P>
<P>
<I>
<B>Age- mean years (SD): </B>
</I>ASA/DIP 66.1 (9.9); PTX 68.5 (8.2)</P>
<P>
<I>
<B>Gender: </B>
</I>ASA/DIP 71.4% males; PTX 80% males</P>
<P>
<I>
<B>Inclusion criteria: </B>
</I>not indicated</P>
<P>
<I>
<B>Exclusion criteria: </B>
</I>not indicated</P>
<P>
<I>
<B>Co-morbidity:</B>
</I> Claudicants (ASA/DIP 28.6%; PTX 50%), ischaemia (ASA/DIP 71.4%; PTX 50%)</P>
<P>
<I>
<B>Severity of occlusive disease (determined by ABPI): </B>
</I>ASA/DIP 0.33 ± 0.33; PTX 0.46 ± 0.27</P>
<P>
<I>
<B>Site of distal anastomosis: </B>
</I>not indicated</P>
<P>
<I>
<B>Type of graft: </B>
</I>autologous vein (ASA/DIP 12; PTX 12), synthetic prosthetic- Dacron and Foretex (ASA/DIP 34; PTX 30)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-27 14:23:43 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>
<B>Treatment: </B>
</I>ASA/DIP- 1050 mg/day ASA (divided into 3 doses) plus 150 mg/day DIP</P>
<P>
<I>
<B>Control: </B>
</I>PTX- 1200 mg/day (divided into 3 doses of 400 mg)</P>
<P>
<I>
<B>Duration: </B>
</I>6 months<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-27 14:23:45 +0000" MODIFIED_BY="[Empty name]">
<P>Graft occlusion within 6 months was the primary endpoint, evaluated by clinical examination, ABPI, treadmill assessment of walking distance, and angiography. Follow-up controls were at 1, 3, 4, and 6 months</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-01-27 14:24:05 +0000" MODIFIED_BY="[Empty name]">
<P>The study included patients with aortoiliac or femoropopliteal bypass or both; for the purposes of this review, only participants receiving femoropopliteal bypass were included and analysed; 14 participants were included in our analysis randomised to ASA/DIP and 19 to PTX<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-27 14:24:28 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McCollum-1991">
<CHAR_METHODS MODIFIED="2014-06-09 10:59:53 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>
<B>Study type: </B>
</I>Multicentre, double-blind, randomised controlled trial, performed between 1984 and 1989</P>
<P>
<B>
<I>Study aim: </I>
</B>To investigate whether ASA/DIP therapy improved graft patency in autologous saphenous vein femoropopliteal bypasses</P>
<P>
<B>
<I>Country: </I>
</B>UK<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-27 14:24:09 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>
<B>Number randomised: </B>
</I>Total n = 549 (ASA/DIP n = 286; placebo n = 263</P>
<P>
<I>
<B>Age- mean years (SEM): </B>
</I>ASA/DIP 66.8 (0.5); placebo 66.6 (0.6)</P>
<P>
<I>
<B>Gender: </B>
</I>ASA/DIP 75.5% men; placebo 74.9% men</P>
<P>
<I>
<B>Inclusion criteria: </B>
</I>All patients undergoing femoropopliteal bypass; informed consent given</P>
<P>
<I>
<B>Exclusion criteria: </B>
</I>Contraindication to ASA or DIP; patient taking drugs with platelet-inhibitory or anticoagulant effects that could not be stopped; adequate follow-up could not be achieved</P>
<P>
<I>
<B>Co-morbidity: </B>
</I>smoking (current) (ASA/DIP 42.2%; placebo 40.5%), hypertension (ASA/DIP 36.0%; placebo 35.0%), diabetes (ASA/DIP 18.2%; placebo 18.3%), IHD (ASA/DIP 26.2%; placebo 22.4%), claudication only (ASA/DIP 40.6%; placebo 39.6%), rest pain/gangrene (ASA/DIP 59.4%; placebo 60.4%)</P>
<P>
<I>
<B>Severity of occlusive disease (determined by ABPI): </B>
</I>not indicated</P>
<P>
<I>
<B>Site of distal anastomosis: </B>
</I>Above-knee (ASA/DIP 36%; placebo 46%)</P>
<P>
<I>
<B>Type of graft: </B>
</I>autologous saphenous vein<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-27 14:24:25 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>
<B>Treatment: </B>
</I>ASA/DIP-
 
300 mg ASA plus 150 mg DIP, twice daily orally</P>
<P>
<I>
<B>Control:</B>
</I> Identical
 
placebo, twice daily orally</P>
<P>
<I>
<B>Duration: </B>
</I>Starting 48 h before surgery, taken indefinitely (mean follow-up was 35 months)<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-27 14:24:28 +0000" MODIFIED_BY="[Empty name]">
<P>Primary endpoints were graft occlusion, MI and stroke. Patency assessment was performed by pulse palpation, Doppler signal or duplex sonography, DSA, isotope angiography at 3-monthly intervals of follow-ups during the first year, and 6-monthly for 5 years</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-06-09 10:51:02 +0100" MODIFIED_BY="[Empty name]">
<P>Participants that required a prosthetic implant were given ASA/DIP and randomised to HUV or PTFE grafts; results of these participants are not currently reported</P>
<P>Also known as the Femoropopliteal Bypass Trial</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-27 14:24:40 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Noppeney-1988">
<CHAR_METHODS MODIFIED="2014-09-25 12:20:00 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Study type: </I>
</B>Randomised controlled trial</P>
<P>
<I>
<B>Study aim: </B>
</I>To evaluate the antithrombotic efficacy of naftidrofuryl in comparison to ASA</P>
<P>
<I>
<B>Country: </B>
</I>Germany</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-25 12:20:12 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Number randomised: </I>
</B>Total n = 99 (ASA n = 49; naftidrofuryl n = 50)</P>
<P>
<I>
<B>Age- years: </B>
</I>0 - 39 (ASA 2%; naftidrofuryl 0%), 40 - 49 (ASA 2%; naftidrofuryl 0%), 50 - 59 (ASA 27%; naftidrofuryl 12%), 60 - 69 (ASA 33%; naftidrofuryl 38%), 70 - 79 (ASA 33%; naftidrofuryl 48%), 80 - 89 (ASA 4%; naftidrofuryl 2%)</P>
<P>
<I>
<B>Gender (M/F): </B>
</I>not indicated</P>
<P>
<I>
<B>Inclusion criteria: </B>
</I>not indicated</P>
<P>
<I>
<B>Exclusion criteria: </B>
</I>not indicated</P>
<P>
<I>
<B>Co-morbidity: </B>
</I>Hypertension (ASA/DIP n = 25; naftidrofuryl n = 23), hyperlipidaemia (ASA/DIP n = 36; naftidrofuryl n = 34), hyperuricaemia (ASA/DIP n = 14; naftidrofuryl n = 12), diabetes mellitus (ASA/DIP n = 32; naftidrofuryl n = 28), obesity (ASA/DIP n = 10; naftidrofuryl n = 11), smoker (ASA/DIP n = 34; naftidrofuryl n = 38)</P>
<P>
<I>
<B>Severity of occlusive disease (determined by ABPI): </B>
</I>not indicated</P>
<P>
<I>
<B>Site of distal anastomosis: </B>
</I>not indicated</P>
<P>
<I>
<B>Type of graft: </B>
</I>PTFE grafts<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-27 14:24:40 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>
<B>Treatment: </B>
</I>ASA 1500mg daily orally</P>
<P>
<I>
<B>Control: </B>
</I>naftidrofuryl 600 mg daily orally</P>
<P>
<I>
<B>Duration: </B>
</I>commenced on day 1 postoperatively for 12 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-25 12:20:15 +0100" MODIFIED_BY="[Empty name]">
<P>Graft occlusion within 12 months was the primary endpoint, also reported side effects and treatment withdrawal</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-27 14:24:58 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Raithel-1987">
<CHAR_METHODS MODIFIED="2015-01-27 14:24:43 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>
<B>Study type: </B>
</I>Open, randomised controlled trial</P>
<P>
<I>
<B>Study aim: </B>
</I>To examine whether a protective effect associated with a low risk of side effects could be achieved with pentoxifylline (PTX), compared with ASA</P>
<P>
<I>
<B>Country: </B>
</I>Germany<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-27 14:24:54 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>
<B>Number randomised: </B>
</I>Total n = 118 (ASA n = 59; PTX n = 59)</P>
<P>
<I>
<B>Age- mean years (range): </B>
</I>Total study population 67.2 (42 to 87)</P>
<P>
<I>
<B>Gender n (M/F): </B>
</I>Total study population 88/30</P>
<P>
<I>
<B>Inclusion criteria: </B>
</I>Patients who had undergone a prosthetic bypass operation in the femoropopliteal region</P>
<P>
<I>
<B>Exclusion criteria: </B>
</I>not indicated</P>
<P>
<I>
<B>Co-morbidity: </B>
</I>Angina pectoris (ASA 15; PTX 21), myocardial infarction (ASA 39; PTX 42), coronary insufficiency (ASA 11; PTX 14), arrhythmias (ASA 5; PTX 8), hypertension (ASA 31; PTX 22), hyperlipidaemia (ASA 38; PTX 41), hyperuraemia (ASA 20; PTX 17), obesity (ASA 3; PTX 6), diabetes mellitus (ASA 45; PTX 32), smoking (ASA 42; PTX 46), operated on for critical ischemias (ASA 94.9 %; PTX 96.6%)</P>
<P>
<I>
<B>Severity of occlusive disease (determined by ABPI): </B>
</I>not indicated</P>
<P>
<I>
<B>Site of distal anastomosis: </B>
</I>not indicated</P>
<P>
<I>
<B>Type of graft: </B>
</I>prosthetic grafts<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-27 14:24:58 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>
<B>Treatment: </B>
</I>ASA- 500 mg 3 times daily</P>
<P>
<I>
<B>Control: </B>
</I>PTX - 400 mg daily</P>
<P>
<I>
<B>Duration: </B>
</I>Starting 2 days before operation and continuing until 12 months postoperatively.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Graft patency was assessed by clinical examination, pulses, Doppler pressure, and arteriography when indicated, before and 3, 6, 9, 12 months postoperatively.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-27 14:29:04 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schneider-1979">
<CHAR_METHODS MODIFIED="2015-01-27 14:25:08 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>
<B>Study type: </B>
</I>Single-centre, double-blind, randomised controlled trial, performed between 1974 and 1978</P>
<P>
<I>
<B>Study aim: </B>
</I>To evaluate the prophylactic value of long-term oral anticoagulation and inhibition of platelet aggregation</P>
<P>
<I>
<B>Country: </B>
</I>Switzerland</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-27 14:25:10 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>
<B>Number randomised: </B>
</I>Total n = 213 randomised to femoropopliteal bypass or thromboendarterectomy (TEA); n = 91 randomised to femoropopliteal bypass (ASA or ASA/DIP n = 61; coumarin n = 30)</P>
<P>
<I>
<B>Age- mean years (SD): </B>
</I>All participants receiving femoropopliteal bypass 63.9 (8.8)</P>
<P>
<I>
<B>Gender (M:F ratio): </B>
</I>All participants receiving femoropopliteal bypass 3.3:1</P>
<P>
<I>
<B>Inclusion criteria: </B>
</I>Patients with atherosclerosis obliterans undergoing femoropopliteal reconstruction</P>
<P>
<I>
<B>Exclusion criteria: </B>
</I>not indicated</P>
<P>
<I>
<B>Co-morbidity: </B>
</I>not indicated</P>
<P>
<I>
<B>Severity of occlusive disease (determined by ABPI): </B>
</I>not indicated</P>
<P>
<I>
<B>Site of distal anastomosis: </B>
</I>not indicated</P>
<P>
<I>
<B>Type of graft: </B>
</I>not indicated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-27 14:26:14 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>
<B>Treatment: </B>
</I>ASA or ASA/DIP- 1 g/day ASA or 1 g ASA and 225 mg DIP per day</P>
<P>
<I>
<B>Control: </B>
</I>coumarin - (Quick, aim 25 - 30%)</P>
<P>
<I>
<B>Duration: </B>
</I>2 years</P>
<P>All participants were treated with therapeutic doses of heparin and coumarins in the first 1 to 2 postoperative weeks and were then randomly allocated to either coumarins (Quick, aim 25 - 30%) or aspirin, or aspirin/dipyridamole</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-27 14:28:10 +0000" MODIFIED_BY="[Empty name]">
<P>Graft patency was assessed angiographically before dismissal, further by evaluation of segmental oscillography and a fall of the systolic pressure of at least 20 mm Hg; Signs of occlusions were measured angiographically; Follow-up period was 2 years with visits every 3 months during the first year and every 6 months in the second year; Drug assessment was performed by measurement of prothrombin time for coumarins and ASA levels in urine; Death and bleeding complications were recorded; Side effects like gastrointestinal bleeding or ulceration or pain or other bleeding complications could not be disclosed, as results were only presented for all participants, including those undergoing TEA</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-01-27 14:29:04 +0000" MODIFIED_BY="[Empty name]">
<P>This study randomised patients to receive either femoropopliteal bypass or TEA; only patients receiving femoropopliteal bypass are considered in this review</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>ABPI: ankle brachial pressure index<BR/>ASA: aspirin<BR/>CAD: coronary artery disease<BR/>CRVD: cerebrovascular disease<BR/>DIP: dipyridamole<BR/>DPM: dipyridamole (equivalent to DIP)<BR/>DSA: digital subtraction angiography<BR/>h: hour<BR/>HUV: human umbilical vein<BR/>IND: indobufen<BR/>IU: international units<BR/>iv: intravenous<BR/>kg: kilograms<BR/>LMWH: low molecular weight heparin<BR/>m: metre<BR/>mg: milligram<BR/>MI: myocardial infarction<BR/>min: minute<BR/>MWD: maximum walking distance<BR/>ng: nanograms<BR/>PAD: peripheral arterial disease<BR/>PGE1: prostaglandin E1<BR/>PTFE: polytetrafluoroethylene<BR/>PTX: pentoxifylline<BR/>SD: standard deviation<BR/>TEA: thromboendarterectomy<BR/>TIC: ticlopidine</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2015-01-27 14:33:27 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2014-05-22 14:07:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Burdess-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-22 14:07:02 +0100" MODIFIED_BY="[Empty name]">
<P>Heterogeneous study population: bypass, femoral endartectomy and lower limb amputation without stratification</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-01-27 14:33:27 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-B_x00f6_hmig-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-27 14:33:27 +0000" MODIFIED_BY="[Empty name]">
<P>Not a controlled trial. 20-year follow-up study of infrainguinal venous bypass grafts. All participants received 100 IU/kg heparin iv intraoperatively, followed by 5000 IU 4 times daily sc in the first postoperative days, then dicoumarol lifelong. No control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-01-27 14:30:50 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-DeWeese-1971">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-27 14:30:50 +0000" MODIFIED_BY="[Empty name]">
<P>Non-randomised, non-controlled study on femoropopliteal venous bypass patency</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-25 12:21:03 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ehersmann-1977">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-25 12:21:03 +0100" MODIFIED_BY="[Empty name]">
<P>Heterogeneous cohort of patients. Results not separated for infrainguinal bypass surgery</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-10-02 14:44:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-EUCTR2007-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-10-02 14:44:59 +0100" MODIFIED_BY="[Empty name]">
<P>Intervention is anticoagulant (fondaparinux) versus anticoagulant (enoxaparin) with no antiplatelet treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-01-27 14:30:55 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gorter-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-27 14:30:55 +0000" MODIFIED_BY="[Empty name]">
<P>Comparison of 2 studies, one of which is the <LINK REF="STD-BOA-2000" TYPE="STUDY">BOA 2000</LINK> trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-01-27 14:30:57 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Harjola-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-27 14:30:57 +0000" MODIFIED_BY="[Empty name]">
<P>No clear distinction between bypass operations and other reconstructive therapies. No definition of 'major' and 'minor' injury. No details on claudicants, ischaemic participants, on distal insertion of the grafts, other risk factors like diabetes<BR/>No description of randomisation procedure<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-01-27 14:30:58 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jivegard-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-27 14:30:58 +0000" MODIFIED_BY="[Empty name]">
<P>Intervention is anticoagulant (LMWH) versus placebo. All participants received 75 mg of ASA daily</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-25 12:21:06 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Johnson-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-25 12:21:06 +0100" MODIFIED_BY="[Empty name]">
<P>Intervention is anticoagulant (warfarin) + ASA versus ASA alone i.e. both groups received ASA</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-25 12:21:07 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Johnson-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-25 12:21:07 +0100" MODIFIED_BY="[Empty name]">
<P>Intervention is anticoagulant (warfarin) + ASA versus ASA alone i.e. both groups received ASA</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-25 12:21:07 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kibbe-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-25 12:21:07 +0100" MODIFIED_BY="[Empty name]">
<P>Intervention is anticoagulant (warfarin) + ASA versus ASA alone i.e. both groups received ASA</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-01-27 14:30:59 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lassila-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-27 14:30:59 +0000" MODIFIED_BY="[Empty name]">
<P>144 participants, randomised controlled trial. Mainly endarterectomy involved, ASA vs nothing. Results not presented separately</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-01-27 14:31:00 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Monaco-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-27 14:31:00 +0000" MODIFIED_BY="[Empty name]">
<P>Intervention is anticoagulant + clopidogrel versus clopidogrel + ASA. Only 1 treatment group received the anticoagulant, so there could be a drug interaction between the clopidogrel and anticoagulant that would make it impossible to directly compare with ASA</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-25 12:21:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nevelsteen-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-25 12:21:57 +0100" MODIFIED_BY="[Empty name]">
<P>No relevant outcomes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-01-27 14:31:04 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Raithel-1987b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-27 14:31:04 +0000" MODIFIED_BY="[Empty name]">
<P>99 participants assigned to treatment by ASA or naftidrofuryl in a randomised trial. Time point and method of randomisation are unclear. Data are only presented in an abstract mentioning cumulative patency rate 12 months postoperatively, which was 80% in both groups without any significant differences. The authors state that side effects occurred in 23 participants of the ASA group versus 3 participants in the naftidrofuryl group, without describing the type of side effect. Too little information is available for inclusion in the present meta-analysis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-01-27 14:31:14 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Reichle-1979">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-27 14:31:14 +0000" MODIFIED_BY="[Empty name]">
<P>Retrospective non-controlled, non-randomised study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-25 12:22:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rosenthal-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-25 12:22:17 +0100" MODIFIED_BY="[Empty name]">
<P>Retrospective study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-25 12:22:18 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Satiani-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-25 12:22:18 +0100" MODIFIED_BY="[Empty name]">
<P>Excluded because of pseudo-randomisation (odd ages receiving ASA)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-01-27 14:31:24 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shionoya-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-27 14:31:24 +0000" MODIFIED_BY="[Empty name]">
<P>Intention-to-treat analysis is not possible as the results are only analysed for operated arterial segments and not for number of participants. In addition, bias has been introduced by exclusion of prosthetic grafts when final data were analysed</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-10-02 14:45:10 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Smout-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-10-02 14:45:10 +0100" MODIFIED_BY="[Empty name]">
<P>All patients received aspirin</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>ASA: aspirin<BR/>iv: intravenous<BR/>LMWH: low molecular weight heparin<BR/>sc: subcutaneous<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2014-09-28 16:42:14 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2015-01-27 14:25:05 +0000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2015-01-27 14:20:33 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-10 10:40:41 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-BOA-2000">
<DESCRIPTION>
<P>Randomisation was performed by telephone through a central trial office, using computer-generated sequences of numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-25 12:11:41 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Becquemin-1997">
<DESCRIPTION>
<P>"&#8230;according to a predetermined randomization list of numbers balanced in blocks of four"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-10 10:44:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-CASPAR-2010">
<DESCRIPTION>
<P>Used an interactive voice-response system with a pre-established randomisation scheme, stratified by graft type (venous or prosthetic)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-10 10:59:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Clyne-1987">
<DESCRIPTION>
<P>Insufficient description of randomisation sequence generation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-10 11:01:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-D_x0027_Addato-1992">
<DESCRIPTION>
<P>Insufficient description of randomisation sequence generation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-10 11:08:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Donaldson-1985">
<DESCRIPTION>
<P>"The patient sample was divided into two groups depending on whether the distal anastomosis was to be above or below the knee. Each group was then randomised to receive either placebo or active capsules&#8230;". Insufficient information to determine adequate sequence generation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-27 14:20:33 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Edmondson-1994">
<DESCRIPTION>
<P>Central telephone randomisation using computer-generated random numbers was used 1 week after operation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-10 11:20:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Goldman-1984">
<DESCRIPTION>
<P>Insufficient description of randomisation sequence generation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-25 12:19:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Green-1982">
<DESCRIPTION>
<P>Although authors state "key to the randomization was kept in a sealed envelope and was opened only on emergency basis by an independent observer", the sequence generation was not adequately described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-10 11:27:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gruss-1991">
<DESCRIPTION>
<P>Insufficient description of randomisation sequence generation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-10 11:35:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kohler-1984">
<DESCRIPTION>
<P>"&#8230;the research pharmacist randomized the patients to receive treatment or placebo according to a table of random numbers"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-25 12:19:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lucas-1984">
<DESCRIPTION>
<P>"Patients were assigned to one of the treatments using a random number table"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-10 11:51:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McCollum-1991">
<DESCRIPTION>
<P>"Randomization was in batches of 10 to ensure that each hospital recruited similar numbers of patients on ASA + DPM or placebo"; Insufficient description of sequence generation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-10 11:53:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Noppeney-1988">
<DESCRIPTION>
<P>Insufficient description of randomisation sequence generation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-10 11:55:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Raithel-1987">
<DESCRIPTION>
<P>Insufficient description of randomisation sequence generation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-10 11:57:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schneider-1979">
<DESCRIPTION>
<P>Insufficient description of randomisation sequence generation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2014-07-31 12:06:22 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-10 10:41:03 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-BOA-2000">
<DESCRIPTION>
<P>Performed by telephone through central trial office</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-10 10:38:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Becquemin-1997">
<DESCRIPTION>
<P>Allocation concealment methods not adequately described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-10 10:44:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-CASPAR-2010">
<DESCRIPTION>
<P>Interactive voice-response system</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-10 10:59:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Clyne-1987">
<DESCRIPTION>
<P>Allocation concealment methods not adequately described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-10 11:02:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-D_x0027_Addato-1992">
<DESCRIPTION>
<P>Allocation concealment methods not adequately described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-10 11:07:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Donaldson-1985">
<DESCRIPTION>
<P>Allocation concealment methods not adequately described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-10 11:16:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Edmondson-1994">
<DESCRIPTION>
<P>Used central telephone service</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-10 11:21:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Goldman-1984">
<DESCRIPTION>
<P>Allocation concealment methods not adequately described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-31 12:06:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Green-1982">
<DESCRIPTION>
<P>"The key to the randomization was kept in a sealed envelope and was opened only on emergency basis by an independent observer"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-10 11:28:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gruss-1991">
<DESCRIPTION>
<P>Allocation concealment methods not adequately described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-10 11:35:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kohler-1984">
<DESCRIPTION>
<P>Allocation concealment methods not adequately described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-10 11:49:43 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lucas-1984">
<DESCRIPTION>
<P>"Once patients had been assigned, the individual envelope containing the treatment to be followed in each case was opened"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-31 11:12:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McCollum-1991">
<DESCRIPTION>
<P>Allocation centrally controlled by pharmacy</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-10 11:53:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Noppeney-1988">
<DESCRIPTION>
<P>Allocation concealment methods not adequately described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-10 11:55:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Raithel-1987">
<DESCRIPTION>
<P>Allocation concealment methods not adequately described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-10 11:57:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schneider-1979">
<DESCRIPTION>
<P>Allocation concealment methods not adequately described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2015-01-27 14:18:11 +0000" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-06-10 10:41:19 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-BOA-2000">
<DESCRIPTION>
<P>Open trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-09-25 12:11:41 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Becquemin-1997">
<DESCRIPTION>
<P>"Treatment bottles containing a one-month supply of ticlopidine (250-mg tablets) or matching placebo were prepared by Sanofi and labelled according to a predetermined randomization list of number balanced in block of four"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-01-27 14:18:11 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-CASPAR-2010">
<DESCRIPTION>
<P>Described as "double-blind" and used placebo tablets in ASA-only group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-07-31 11:17:11 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Clyne-1987">
<DESCRIPTION>
<P>Open trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-06-10 11:02:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-D_x0027_Addato-1992">
<DESCRIPTION>
<P>"...blindly assigned to treatment"; insufficient description of blinding methods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-06-10 11:08:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Donaldson-1985">
<DESCRIPTION>
<P>"&#8230; randomised to receive either placebo or active capsules&#8230;"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-07-31 11:18:35 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Edmondson-1994">
<DESCRIPTION>
<P>Described as open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-06-10 11:21:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Goldman-1984">
<DESCRIPTION>
<P>"&#8230; double blind to receive identical capsules containing either placebo or a combination of aspirin 300mg plus dipyridamole 75mg&#8230;"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-06-10 11:25:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Green-1982">
<DESCRIPTION>
<P>"The placebo group received red and white placebo tablets three times daily, the ASA group received 325 mg ASA and a red placebo tablet three times daily and the ASA/DIP group received 325 mg ASA and 75 mg DIP three times daily"; Use of coded bottles</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-06-10 11:28:25 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gruss-1991">
<DESCRIPTION>
<P>No indication of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-06-10 11:35:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kohler-1984">
<DESCRIPTION>
<P>Used identical placebo with same schedule as active treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-07-31 11:10:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lucas-1984">
<DESCRIPTION>
<P>No indication of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-06-10 11:52:33 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McCollum-1991">
<DESCRIPTION>
<P>Used identical placebo with same schedule as active treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-07-31 11:20:39 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Noppeney-1988">
<DESCRIPTION>
<P>No indication of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-06-10 11:55:22 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Raithel-1987">
<DESCRIPTION>
<P>Described as an open study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-06-10 11:57:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schneider-1979">
<DESCRIPTION>
<P>Authors mention double-blinding but the methods are unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2014-09-25 12:17:11 +0100" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-06-10 10:41:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-BOA-2000">
<DESCRIPTION>
<P>Blinding of outcome assessors not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-09-25 12:11:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Becquemin-1997">
<DESCRIPTION>
<P>"All records concerning graft patency were reviewed by a validation committee that was unaware of the patients' treatment assignments. The clinical events were reviewed and adjudicated blindly by an independent panel&#8230;"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-09-25 12:17:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-CASPAR-2010">
<DESCRIPTION>
<P>"All occurrences of the primary endpoint were adjudicated on a blinded basis by the Clinical Enpoints Committee"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-06-10 10:59:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Clyne-1987">
<DESCRIPTION>
<P>Blinding of outcome assessors not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-06-10 11:02:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-D_x0027_Addato-1992">
<DESCRIPTION>
<P>Blinding of outcome assessors not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-06-10 11:08:07 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Donaldson-1985">
<DESCRIPTION>
<P>Blinding of outcome assessors not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-06-10 11:19:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Edmondson-1994">
<DESCRIPTION>
<P>Blinding of outcome assessors not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-06-10 11:22:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Goldman-1984">
<DESCRIPTION>
<P>Blinding of outcome assessors not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-06-10 11:25:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Green-1982">
<DESCRIPTION>
<P>Blinding of outcome assessors not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-06-10 11:28:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gruss-1991">
<DESCRIPTION>
<P>Blinding of outcome assessors not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-06-10 11:35:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kohler-1984">
<DESCRIPTION>
<P>Blinding of outcome assessors not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-06-10 11:50:07 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lucas-1984">
<DESCRIPTION>
<P>Blinding of outcome assessors not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-06-10 11:52:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McCollum-1991">
<DESCRIPTION>
<P>Blinding of outcome assessors not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-06-10 11:54:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Noppeney-1988">
<DESCRIPTION>
<P>Blinding of outcome assessors not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-06-10 11:55:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Raithel-1987">
<DESCRIPTION>
<P>Blinding of outcome assessors not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-06-10 11:58:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schneider-1979">
<DESCRIPTION>
<P>Blinding of outcome assessors not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2015-01-27 14:25:05 +0000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-27 14:17:37 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-BOA-2000">
<DESCRIPTION>
<P>Reasons given for drop-outs, and final numbers for each treatment group are similar</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-25 12:11:43 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Becquemin-1997">
<DESCRIPTION>
<P>No evidence of incomplete outcome data; used intention-to-treat analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-27 14:18:12 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-CASPAR-2010">
<DESCRIPTION>
<P>Drop-outs and losses to follow up were clearly described and similar between groups; efficacy analysis performed on an intention-to-treat basis, with all randomised participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-27 14:18:42 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Clyne-1987">
<DESCRIPTION>
<P>No evidence of incomplete outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-27 14:19:26 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-D_x0027_Addato-1992">
<DESCRIPTION>
<P>Reasons given for drop-outs, and final numbers for each treatment group are similar</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-27 14:19:41 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Donaldson-1985">
<DESCRIPTION>
<P>Although drop-out reasons given, withdrawals were much greater in the intervention treatment group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-27 14:20:34 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Edmondson-1994">
<DESCRIPTION>
<P>All participants accounted for; analysis on an intention-to-treat basis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-27 14:20:50 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Goldman-1984">
<DESCRIPTION>
<P>Reasons given for drop-outs and all participants accounted for</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-27 14:21:07 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Green-1982">
<DESCRIPTION>
<P>Reasons given for drop-outs and all participants accounted for</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-27 14:21:11 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gruss-1991">
<DESCRIPTION>
<P>There is no discussion of drop-outs or withdrawals</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-27 14:21:27 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kohler-1984">
<DESCRIPTION>
<P>Discussed drop-outs, but not consistently by which treatment group, drop-outs &gt; 10%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-25 12:19:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lucas-1984">
<DESCRIPTION>
<P>Analysis is performed with all randomised participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-27 14:24:31 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McCollum-1991">
<DESCRIPTION>
<P>Reasons given for drop-outs and all participants accounted for. Analysis on an intention-to-treat basis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-27 14:24:41 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Noppeney-1988">
<DESCRIPTION>
<P>All participants accounted for; analysis on an intention-to-treat basis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-27 14:25:05 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Raithel-1987">
<DESCRIPTION>
<P>Authors state: "One hundred eighteen patients&#8230; were available for the final assessment"; unclear how many were initially randomised, and whether the data are incomplete</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-06-10 11:58:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schneider-1979">
<DESCRIPTION>
<P>Not enough descriptive information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2014-07-31 11:10:13 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-10 10:41:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-BOA-2000">
<DESCRIPTION>
<P>All outcomes reported on</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-10 10:43:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Becquemin-1997">
<DESCRIPTION>
<P>All outcomes reported on</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-10 10:45:56 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-CASPAR-2010">
<DESCRIPTION>
<P>All outcomes reported on</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-10 11:00:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Clyne-1987">
<DESCRIPTION>
<P>All outcomes reported on</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-10 11:03:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-D_x0027_Addato-1992">
<DESCRIPTION>
<P>All outcomes reported on</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-31 11:10:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Donaldson-1985">
<DESCRIPTION>
<P>All outcomes reported on; it should be noted that adverse events were only reported for those that withdrew from treatment and not the whole randomised group, but as adverse events were not a specified outcome, this would not increase reporting bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-10 11:20:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Edmondson-1994">
<DESCRIPTION>
<P>All outcomes reported on</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-10 11:22:41 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Goldman-1984">
<DESCRIPTION>
<P>All outcomes reported on</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-21 10:29:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Green-1982">
<DESCRIPTION>
<P>Adverse events not clearly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-10 11:29:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gruss-1991">
<DESCRIPTION>
<P>Not enough information in text to determine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-10 11:36:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kohler-1984">
<DESCRIPTION>
<P>All outcomes reported on</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-10 11:50:33 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lucas-1984">
<DESCRIPTION>
<P>All outcomes reported on</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-10 11:53:01 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McCollum-1991">
<DESCRIPTION>
<P>All outcomes reported on</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-10 11:54:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Noppeney-1988">
<DESCRIPTION>
<P>All outcomes reported on</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-10 11:56:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Raithel-1987">
<DESCRIPTION>
<P>All outcomes reported on</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-10 11:58:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schneider-1979">
<DESCRIPTION>
<P>Not enough information in text to determine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2015-01-27 14:24:36 +0000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-10 10:44:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-BOA-2000">
<DESCRIPTION>
<P>No indication of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-10 10:40:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Becquemin-1997">
<DESCRIPTION>
<P>No indication of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-10 10:46:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-CASPAR-2010">
<DESCRIPTION>
<P>No indication of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-27 14:18:47 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Clyne-1987">
<DESCRIPTION>
<P>All data were related to the numbers of bypasses instead of numbers of participants (8 of 140 participants received bilateral grafts)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-10 11:03:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-D_x0027_Addato-1992">
<DESCRIPTION>
<P>No indication of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-27 14:19:45 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Donaldson-1985">
<DESCRIPTION>
<P>All data were related to the numbers of bypasses instead of numbers of participants (2 participants received bilateral grafts)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-10 11:20:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Edmondson-1994">
<DESCRIPTION>
<P>No indication of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-27 14:20:52 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Goldman-1984">
<DESCRIPTION>
<P>Groups did not appear comparable at baseline (differences in gender and above-/below-knee proportions)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-10 11:27:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Green-1982">
<DESCRIPTION>
<P>No indication of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-10 11:29:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gruss-1991">
<DESCRIPTION>
<P>No indication of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-10 11:36:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kohler-1984">
<DESCRIPTION>
<P>No indication of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-10 11:50:40 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lucas-1984">
<DESCRIPTION>
<P>No indication of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-27 14:24:36 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McCollum-1991">
<DESCRIPTION>
<P>Power calculation reported a study population of 800 participants to detect a 10% reduction in occlusion rate, but only 549 patients were randomised; groups not comparable at baseline (proportions with above-knee grafts, which is a prognostic factor that can influence the outcomes)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-10 11:54:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Noppeney-1988">
<DESCRIPTION>
<P>No indication of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-21 10:39:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Raithel-1987">
<DESCRIPTION>
<P>Groups do not appear to be comparable at baseline with respect to risk factors</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-10 12:04:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schneider-1979">
<DESCRIPTION>
<P>No indication of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2015-01-27 14:31:28 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2015-01-27 14:31:28 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2008-04-23 15:38:43 +0100" MODIFIED_BY="[Empty name]">Patient characteristics</TITLE>
<TABLE COLS="10" ROWS="17">
<TR>
<TH>
<P>Study ID</P>
</TH>
<TH>
<P>% CLI</P>
</TH>
<TH>
<P>% below knee</P>
</TH>
<TH>
<P>% vein</P>
</TH>
<TH>
<P>% 1-vessel run-off</P>
</TH>
<TH>
<P>dose</P>
</TH>
<TH>
<P>preoperative start of treatment</P>
</TH>
<TH>
<P>treatment duration</P>
</TH>
<TH>
<P>randomisation</P>
</TH>
<TH>
<P>ABI pre-op to postop</P>
</TH>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Becquemin-1997" TYPE="STUDY">Becquemin 1997</LINK>
</P>
</TD>
<TD>
<P>&gt; 70</P>
</TD>
<TD>
<P>nd</P>
</TD>
<TD>
<P>100</P>
</TD>
<TD>
<P>nd</P>
</TD>
<TD>
<P>TIC 250 mg vs placebo</P>
</TD>
<TD>
<P>between the 3rd and 14th post-op day</P>
</TD>
<TD>
<P>24 months</P>
</TD>
<TD>
<P>post-op</P>
</TD>
<TD>
<P>nd</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-BOA-2000" TYPE="STUDY">BOA 2000</LINK>
</P>
</TD>
<TD>
<P>50</P>
</TD>
<TD>
<P>52</P>
</TD>
<TD>
<P>58.5</P>
</TD>
<TD>
<P>nd</P>
</TD>
<TD>
<P>ASA 80 mg vs coumarin INR 3.0 - 4.5 reached in 50%</P>
</TD>
<TD>
<P>within 5 days until 1 month post-op</P>
</TD>
<TD>
<P>21 months</P>
</TD>
<TD>
<P>before surgery</P>
</TD>
<TD>
<P>nd</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-CASPAR-2010" TYPE="STUDY">CASPAR 2010</LINK>
</P>
</TD>
<TD>
<P>66</P>
</TD>
<TD>
<P>100</P>
</TD>
<TD>
<P>70</P>
</TD>
<TD>
<P>nd</P>
</TD>
<TD>
<P>ASA 75 - 100 mg plus clopidogrel 75 mg vs ASA 75 - 100 mg plus placebo</P>
</TD>
<TD>
<P>2 to 4 days post-op</P>
</TD>
<TD>
<P>24 months</P>
</TD>
<TD>
<P>post-op</P>
</TD>
<TD>
<P>nd</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Clyne-1987" TYPE="STUDY">Clyne 1987</LINK>
</P>
</TD>
<TD>
<P>70</P>
</TD>
<TD>
<P>85</P>
</TD>
<TD>
<P>63</P>
</TD>
<TD>
<P>24</P>
</TD>
<TD>
<P>ASA 2 x 300 mg, DIP 2 x 200 mg</P>
</TD>
<TD>
<P>48 hours pre-op</P>
</TD>
<TD>
<P>6 weeks</P>
</TD>
<TD>
<P>before surgery</P>
</TD>
<TD>
<P>0.38 to 0.78</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-D_x0027_Addato-1992" TYPE="STUDY">D'Addato 1992</LINK>
</P>
</TD>
<TD>
<P>70</P>
</TD>
<TD>
<P>25</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>56</P>
</TD>
<TD>
<P>ASA 900 mg plus DIP 225 mg vs 400 mg IND</P>
</TD>
<TD>
<P>48 h</P>
</TD>
<TD>
<P>12 months</P>
</TD>
<TD>
<P>before surgery</P>
</TD>
<TD>
<P>nd</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Donaldson-1985" TYPE="STUDY">Donaldson 1985</LINK>
</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>32</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>37</P>
</TD>
<TD>
<P>ASA 3 x 330 mg plus DIP 75 mg</P>
</TD>
<TD>
<P>Evening prior to surgery</P>
</TD>
<TD>
<P>12 months</P>
</TD>
<TD>
<P>before surgery</P>
</TD>
<TD>
<P>0.62 to nd</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Edmondson-1994" TYPE="STUDY">Edmondson 1994</LINK>
</P>
</TD>
<TD>
<P>46</P>
</TD>
<TD>
<P>31</P>
</TD>
<TD>
<P>27</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>3 x 300 mg ASA plus 3 x 100 mg DIP versus 2500 IU LMWH</P>
</TD>
<TD>
<P>LMWH 2 hours pre-op; ASA/DIP 1 week post-op</P>
</TD>
<TD>
<P>3 months</P>
</TD>
<TD>
<P>post-op</P>
</TD>
<TD>
<P>nd</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Goldman-1984" TYPE="STUDY">Goldman 1984</LINK>
</P>
</TD>
<TD>
<P>80</P>
</TD>
<TD>
<P>47</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>nd</P>
</TD>
<TD>
<P>ASA 3 x 300 mg plus DIP 3 x 75 mg</P>
</TD>
<TD>
<P>2 days ASA/DIP</P>
</TD>
<TD>
<P>12 months</P>
</TD>
<TD>
<P>before surgery</P>
</TD>
<TD>
<P>nd</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Green-1982" TYPE="STUDY">Green 1982</LINK>
</P>
</TD>
<TD>
<P>82</P>
</TD>
<TD>
<P>47</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>nd</P>
</TD>
<TD>
<P>ASA 3 x 325 mg, or ASA 3 x 325 mg plus DIP 3 x 75 mg</P>
</TD>
<TD>
<P>2 days ASA/DIP</P>
</TD>
<TD>
<P>12 months</P>
</TD>
<TD>
<P>before surgery</P>
</TD>
<TD>
<P>0.42 to 1.01</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Gruss-1991" TYPE="STUDY">Gruss 1991</LINK>
</P>
</TD>
<TD>
<P>nd</P>
</TD>
<TD>
<P>nd</P>
</TD>
<TD>
<P>100</P>
</TD>
<TD>
<P>nd</P>
</TD>
<TD>
<P>3 x 0.5 g ASA plus 15,000 IU heparin versus PGE1, 0.2 ng per kg body weight/min plus 15,000 IU heparin</P>
</TD>
<TD>
<P>post-op</P>
</TD>
<TD>
<P>10 days</P>
</TD>
<TD>
<P>nd</P>
</TD>
<TD>
<P>nd</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Kohler-1984" TYPE="STUDY">Kohler 1984</LINK>
</P>
</TD>
<TD>
<P>76</P>
</TD>
<TD>
<P>52</P>
</TD>
<TD>
<P>69</P>
</TD>
<TD>
<P>nd</P>
</TD>
<TD>
<P>ASA 3 x 325 mg plus DIP 3 x 75 mg</P>
</TD>
<TD>
<P>first post-op day</P>
</TD>
<TD>
<P>24 months</P>
</TD>
<TD>
<P>before surgery</P>
</TD>
<TD>
<P>nd</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Lucas-1984" TYPE="STUDY">Lucas 1984</LINK>
</P>
</TD>
<TD>
<P>55</P>
</TD>
<TD>
<P>nd</P>
</TD>
<TD>
<P>27</P>
</TD>
<TD>
<P>nd</P>
</TD>
<TD>
<P>ASA 1050 mg, DIP 150 mg or 1200 mg PTX</P>
</TD>
<TD>
<P>pre-op</P>
</TD>
<TD>
<P>6 months</P>
</TD>
<TD>
<P>before surgery</P>
</TD>
<TD>
<P>0.4</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-McCollum-1991" TYPE="STUDY">McCollum 1991</LINK>
</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>59</P>
</TD>
<TD>
<P>100</P>
</TD>
<TD>
<P>nd; vein &lt; 4 mm:38</P>
</TD>
<TD>
<P>ASA 2 x 300 mg plus DIP 2 x 150 mg</P>
</TD>
<TD>
<P>2 days ASA/DIP</P>
</TD>
<TD>
<P>continuing indefinitely</P>
</TD>
<TD>
<P>before surgery</P>
</TD>
<TD>
<P>0.47 to nd</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Noppeney-1988" TYPE="STUDY">Noppeney 1988</LINK>
</P>
</TD>
<TD>
<P>nd</P>
</TD>
<TD>
<P>nd</P>
</TD>
<TD>
<P>nd</P>
</TD>
<TD>
<P>nd</P>
</TD>
<TD>
<P>ASA 1500 mg vs naftidrofuryl 600 mg daily orally</P>
</TD>
<TD>
<P>day 1 post-op</P>
</TD>
<TD>
<P>12 months</P>
</TD>
<TD>
<P>before surgery</P>
</TD>
<TD>
<P>nd</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Raithel-1987" TYPE="STUDY">Raithel 1987</LINK>
</P>
</TD>
<TD>
<P>95</P>
</TD>
<TD>
<P>nd</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>56</P>
</TD>
<TD>
<P>ASA 1500 mg vs PTX 1200 mg</P>
</TD>
<TD>
<P>48 h</P>
</TD>
<TD>
<P>12 months</P>
</TD>
<TD>
<P>before surgery</P>
</TD>
<TD>
<P>nd</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Schneider-1979" TYPE="STUDY">Schneider 1979</LINK>
</P>
</TD>
<TD>
<P>nd</P>
</TD>
<TD>
<P>nd</P>
</TD>
<TD>
<P>100</P>
</TD>
<TD>
<P>nd</P>
</TD>
<TD>
<P>ASA 1000 mg, or ASA 1000 mg plus DIP 225 mg vs coumarin</P>
</TD>
<TD>
<P>post-op</P>
</TD>
<TD>
<P>24 months</P>
</TD>
<TD>
<P>post-op</P>
</TD>
<TD>
<P>nd</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>ASA: Aspirin<BR/>CLI: critical limb ischaemia<BR/>DIP: dipyridamole<BR/>h: hour<BR/>IU: international unit<BR/>LMWH: low molecular weight heparin<BR/>mg: milligram<BR/>nd: no data<BR/>ng: nanogram<BR/>PGE1: prostaglandin E1<BR/>PTX: pentoxifylline<BR/>TIC: ticlopidine<BR/>vs: versus</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2015-01-23 10:23:43 +0000" MODIFIED_BY="Kate Cahill">
<COMPARISON ID="CMP-001" MODIFIED="2015-01-23 10:23:43 +0000" MODIFIED_BY="Kate Cahill" NO="1">
<NAME>ASA or ASA/DIP vs placebo or nothing, all grafts</NAME>
<DICH_OUTCOME CHI2="18.06763127376516" CI_END="0.8312031442374891" CI_START="0.2160860313646886" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="OR" EFFECT_SIZE="0.42380583844035213" ESTIMABLE="YES" EVENTS_1="115" EVENTS_2="159" I2="72.32620079390165" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.0802928226183374" LOG_CI_START="-0.6653733066813688" LOG_EFFECT_SIZE="-0.3728330646498531" METHOD="MH" MODIFIED="2015-01-23 09:37:34 +0000" MODIFIED_BY="Kate Cahill" NO="1" P_CHI2="0.002862831829740786" P_Q="1.0" P_Z="0.012492768597810913" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.4721751917450144" TOTALS="YES" TOTAL_1="495" TOTAL_2="457" WEIGHT="100.0" Z="2.497910625508686">
<NAME>Primary graft patency at 12 months</NAME>
<GROUP_LABEL_1>Favours ASA or ASA/DIP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo or nothing</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ASA or ASA/DIP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo/nothing</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8077552405378711" CI_START="0.1588521487240889" EFFECT_SIZE="0.3582089552238806" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="22" LOG_CI_END="-0.09272021569435215" LOG_CI_START="-0.7990069062840887" LOG_EFFECT_SIZE="-0.4458635609892204" MODIFIED="2015-01-23 09:37:31 +0000" MODIFIED_BY="Kate Cahill" ORDER="4450" O_E="0.0" SE="0.4148762982279152" STUDY_ID="STD-Clyne-1987" TOTAL_1="78" TOTAL_2="70" VAR="0.17212234283129807" WEIGHT="18.332426758569174"/>
<DICH_DATA CI_END="0.5483231756050849" CI_START="0.04456590284831751" EFFECT_SIZE="0.15632183908045977" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="15" LOG_CI_END="-0.26096339769723387" LOG_CI_START="-1.3509972907995682" LOG_EFFECT_SIZE="-0.805980344248401" MODIFIED="2015-01-23 09:37:32 +0000" MODIFIED_BY="Kate Cahill" ORDER="4451" O_E="0.0" SE="0.6402913045631036" STUDY_ID="STD-Donaldson-1985" TOTAL_1="33" TOTAL_2="32" VAR="0.40997295469912104" WEIGHT="13.389516727953515"/>
<DICH_DATA CI_END="0.9327303881689337" CI_START="0.09313495860761983" EFFECT_SIZE="0.29473684210526313" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="19" LOG_CI_END="-0.030243873779553624" LOG_CI_START="-1.0308872741137034" LOG_EFFECT_SIZE="-0.5305655739466286" MODIFIED="2014-05-01 11:08:09 +0100" MODIFIED_BY="[Empty name]" ORDER="4452" O_E="0.0" SE="0.5877828866209965" STUDY_ID="STD-Goldman-1984" TOTAL_1="22" TOTAL_2="31" VAR="0.34548872180451123" WEIGHT="14.445467346201426"/>
<DICH_DATA CI_END="0.5172146974436254" CI_START="0.037296162603524405" EFFECT_SIZE="0.1388888888888889" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" LOG_CI_END="-0.28632914247692565" LOG_CI_START="-1.4283358503856112" LOG_EFFECT_SIZE="-0.8573324964312684" MODIFIED="2014-05-01 13:43:59 +0100" MODIFIED_BY="[Empty name]" ORDER="4453" O_E="0.0" SE="0.6708203932499369" STUDY_ID="STD-Green-1982" TOTAL_1="32" TOTAL_2="17" VAR="0.45" WEIGHT="12.808344302774175"/>
<DICH_DATA CI_END="3.7049075999953573" CI_START="0.6808513522669578" EFFECT_SIZE="1.588235294117647" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="17" LOG_CI_END="0.5687773811918533" LOG_CI_START="-0.1669476956304266" LOG_EFFECT_SIZE="0.20091484278071337" MODIFIED="2015-01-23 09:37:34 +0000" MODIFIED_BY="Kate Cahill" ORDER="4454" O_E="0.0" SE="0.43216855202327326" STUDY_ID="STD-Kohler-1984" TOTAL_1="44" TOTAL_2="44" VAR="0.18676965735789264" WEIGHT="17.924925552460515"/>
<DICH_DATA CI_END="1.0634400895582903" CI_START="0.48957418924496543" EFFECT_SIZE="0.7215489031632529" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="74" LOG_CI_END="0.026713028317608273" LOG_CI_START="-0.3101814866222303" LOG_EFFECT_SIZE="-0.14173422915231101" ORDER="4455" O_E="0.0" SE="0.19789350573040568" STUDY_ID="STD-McCollum-1991" TOTAL_1="286" TOTAL_2="263" VAR="0.0391618396102701" WEIGHT="23.099319312041196"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.462129281139394" CI_END="1.67802635749802" CI_START="1.0476781329574985" CI_STUDY="95" CI_TOTAL="95" DF="14" EFFECT_MEASURE="OR" EFFECT_SIZE="1.3259078102481323" ESTIMABLE="YES" EVENTS_1="188" EVENTS_2="134" I2="0.0" I2_Q="1.6483764273500119" ID="CMP-001.02" LOG_CI_END="0.22479877820069433" LOG_CI_START="0.020227879450560596" LOG_EFFECT_SIZE="0.12251332882562742" METHOD="MH" MODIFIED="2015-01-23 10:11:44 +0000" MODIFIED_BY="Kate Cahill" NO="2" P_CHI2="0.8003571098596026" P_Q="0.39700922815809714" P_Z="0.01889659003351013" Q="4.067040130807089" RANDOM="NO" SCALE="355.2" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1655" TOTAL_2="1505" WEIGHT="500.0" Z="2.3475647180651165">
<NAME>Side effects and complications</NAME>
<GROUP_LABEL_1>ASA or ASA/DIP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo or nothing</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ASA or ASA/DIP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo/nothing</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.674366086785274" CI_END="2.4106519189211744" CI_START="0.995796083543056" DF="4" EFFECT_SIZE="1.5493604292246714" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="36" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="0.3821345058543593" LOG_CI_START="-0.0018295861334496058" LOG_EFFECT_SIZE="0.19015245986045484" MODIFIED="2015-01-23 10:09:45 +0000" MODIFIED_BY="Kate Cahill" NO="1" P_CHI2="0.6137077923519996" P_Z="0.052223650531787534" STUDIES="5" TAU2="0.0" TOTAL_1="479" TOTAL_2="434" WEIGHT="100.00000000000001" Z="1.9412855559942466">
<NAME>Side effects- general</NAME>
<DICH_DATA CI_END="48.99893092173818" CI_START="0.6747596198130916" EFFECT_SIZE="5.75" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.6901866045212712" LOG_CI_START="-0.17085091514201034" LOG_EFFECT_SIZE="0.7596678446896304" MODIFIED="2015-01-23 10:09:43 +0000" MODIFIED_BY="Kate Cahill" ORDER="4470" O_E="0.0" SE="1.0931826513345078" STUDY_ID="STD-Clyne-1987" TOTAL_1="78" TOTAL_2="70" VAR="1.195048309178744" WEIGHT="3.010576477067264"/>
<DICH_DATA CI_END="17.239796525357505" CI_START="0.06180796334755396" EFFECT_SIZE="1.032258064516129" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.236532135709348" LOG_CI_START="-1.2089555667380814" LOG_EFFECT_SIZE="0.013788284485633285" MODIFIED="2015-01-23 10:09:44 +0000" MODIFIED_BY="Kate Cahill" ORDER="4471" O_E="0.0" SE="1.4364915817769797" STUDY_ID="STD-Donaldson-1985" TOTAL_1="32" TOTAL_2="33" VAR="2.063508064516129" WEIGHT="2.951394204441155"/>
<DICH_DATA CI_END="43.13520996718894" CI_START="0.06439699215306272" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.6348319163734264" LOG_CI_START="-1.1911344171407134" LOG_EFFECT_SIZE="0.2218487496163564" ORDER="4473" O_E="0.0" SE="1.6599866130651644" STUDY_ID="STD-Green-1982" TOTAL_1="32" TOTAL_2="17" VAR="2.7555555555555555" WEIGHT="1.911125753824562"/>
<DICH_DATA CI_END="39.46294531618338" CI_START="0.45885427238693804" EFFECT_SIZE="4.25531914893617" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.5961894956863352" LOG_CI_START="-0.33832522022980777" LOG_EFFECT_SIZE="0.6289321377282637" MODIFIED="2015-01-23 10:09:45 +0000" MODIFIED_BY="Kate Cahill" ORDER="4474" O_E="0.0" SE="1.136343520131426" STUDY_ID="STD-Kohler-1984" TOTAL_1="51" TOTAL_2="51" VAR="1.2912765957446808" WEIGHT="2.8515209660239496"/>
<DICH_DATA CI_END="2.163846193938533" CI_START="0.8246973220236152" EFFECT_SIZE="1.3358585858585859" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="33" LOG_CI_END="0.3352263879051003" LOG_CI_START="-0.08370541568575339" LOG_EFFECT_SIZE="0.12576048610967344" ORDER="4475" O_E="0.0" SE="0.24608261517514013" STUDY_ID="STD-McCollum-1991" TOTAL_1="286" TOTAL_2="263" VAR="0.0605566534914361" WEIGHT="89.27538259864308"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.0614319360244133" CI_END="2.2382050032480283" CI_START="0.9236771599001801" DF="5" EFFECT_SIZE="1.4378382526120634" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="36" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="0.34989986222000585" LOG_CI_START="-0.03447979520138579" LOG_EFFECT_SIZE="0.15771003350931" MODIFIED="2015-01-23 10:11:44 +0000" MODIFIED_BY="Kate Cahill" NO="2" P_CHI2="0.6905152516739282" P_Z="0.10776142192126112" STUDIES="6" TAU2="0.0" TOTAL_1="494" TOTAL_2="458" WEIGHT="100.0" Z="1.608336860241191">
<NAME>Gastrointestinal side effects</NAME>
<DICH_DATA CI_END="7.362959278595109" CI_START="0.011828655613390828" EFFECT_SIZE="0.2951167728237792" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.867052398584763" LOG_CI_START="-1.927064612334365" LOG_EFFECT_SIZE="-0.5300061068748011" MODIFIED="2015-01-23 10:11:42 +0000" MODIFIED_BY="Kate Cahill" ORDER="124" O_E="0.0" SE="1.641278163316165" STUDY_ID="STD-Clyne-1987" TOTAL_1="78" TOTAL_2="70" VAR="2.6937940093784842" WEIGHT="4.7291052242475375"/>
<DICH_DATA CI_END="17.239796525357505" CI_START="0.06180796334755396" EFFECT_SIZE="1.032258064516129" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.236532135709348" LOG_CI_START="-1.2089555667380814" LOG_EFFECT_SIZE="0.013788284485633285" MODIFIED="2015-01-23 10:11:43 +0000" MODIFIED_BY="Kate Cahill" ORDER="130" O_E="0.0" SE="1.4364915817769797" STUDY_ID="STD-Donaldson-1985" TOTAL_1="32" TOTAL_2="33" VAR="2.063508064516129" WEIGHT="2.873145751135202"/>
<DICH_DATA CI_END="35.33401928787418" CI_START="0.2547120362015707" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.5481930417728498" LOG_CI_START="-0.5939505323335247" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2014-06-20 14:56:38 +0100" MODIFIED_BY="[Empty name]" ORDER="126" O_E="0.0" SE="1.2583057392117918" STUDY_ID="STD-Goldman-1984" TOTAL_1="22" TOTAL_2="31" VAR="1.5833333333333335" WEIGHT="2.273335043503203"/>
<DICH_DATA CI_END="43.13520996718894" CI_START="0.06439699215306272" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.6348319163734264" LOG_CI_START="-1.1911344171407134" LOG_EFFECT_SIZE="0.2218487496163564" MODIFIED="2014-06-20 14:56:47 +0100" MODIFIED_BY="[Empty name]" ORDER="127" O_E="0.0" SE="1.6599866130651644" STUDY_ID="STD-Green-1982" TOTAL_1="32" TOTAL_2="17" VAR="2.7555555555555555" WEIGHT="1.860457281925783"/>
<DICH_DATA CI_END="189.42545329295353" CI_START="0.5162459519394896" EFFECT_SIZE="9.88888888888889" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.277438335184461" LOG_CI_START="-0.28714334077328546" LOG_EFFECT_SIZE="0.9951474972055879" MODIFIED="2015-01-23 10:11:44 +0000" MODIFIED_BY="Kate Cahill" ORDER="128" O_E="0.0" SE="1.506447971341617" STUDY_ID="STD-Kohler-1984" TOTAL_1="44" TOTAL_2="44" VAR="2.2693854903592734" WEIGHT="1.3554760196887847"/>
<DICH_DATA CI_END="2.163846193938533" CI_START="0.8246973220236152" EFFECT_SIZE="1.3358585858585859" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="33" LOG_CI_END="0.3352263879051003" LOG_CI_START="-0.08370541568575339" LOG_EFFECT_SIZE="0.12576048610967344" MODIFIED="2014-06-20 14:57:12 +0100" MODIFIED_BY="[Empty name]" ORDER="129" O_E="0.0" SE="0.24608261517514013" STUDY_ID="STD-McCollum-1991" TOTAL_1="286" TOTAL_2="263" VAR="0.0605566534914361" WEIGHT="86.90848067949949"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.005651177546557138" CI_END="4.159815873846672" CI_START="0.8500979254599106" DF="1" EFFECT_SIZE="1.8804921814919255" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="9" I2="0.0" ID="CMP-001.02.03" LOG_CI_END="0.6190741078522031" LOG_CI_START="-0.07053104365360408" LOG_EFFECT_SIZE="0.2742715320992995" MODIFIED="2014-06-20 15:03:09 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.9400760207510707" P_Z="0.11898600900865312" STUDIES="2" TAU2="0.0" TOTAL_1="318" TOTAL_2="280" WEIGHT="100.0" Z="1.5590438201496575">
<NAME>Major bleeding</NAME>
<DICH_DATA CI_END="43.13520996718894" CI_START="0.06439699215306272" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.6348319163734264" LOG_CI_START="-1.1911344171407134" LOG_EFFECT_SIZE="0.2218487496163564" MODIFIED="2014-06-20 15:02:56 +0100" MODIFIED_BY="[Empty name]" ORDER="131" O_E="0.0" SE="1.6599866130651644" STUDY_ID="STD-Green-1982" TOTAL_1="32" TOTAL_2="17" VAR="2.7555555555555555" WEIGHT="6.567546782876185"/>
<DICH_DATA CI_END="4.296698570275483" CI_START="0.8362246187088678" EFFECT_SIZE="1.8955223880597014" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="9" LOG_CI_END="0.6331348873451033" LOG_CI_START="-0.07767705083484251" LOG_EFFECT_SIZE="0.2777289182551304" MODIFIED="2014-06-20 15:03:09 +0100" MODIFIED_BY="[Empty name]" ORDER="132" O_E="0.0" SE="0.417534451062741" STUDY_ID="STD-McCollum-1991" TOTAL_1="286" TOTAL_2="263" VAR="0.17433501782426447" WEIGHT="93.43245321712381"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7003730678153448" CI_START="0.31106445394026344" DF="0" EFFECT_SIZE="0.7272727272727273" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="14" I2="0.0" ID="CMP-001.02.04" LOG_CI_END="0.2305442175654856" LOG_CI_START="-0.5071496138980485" LOG_EFFECT_SIZE="-0.13830269816628143" MODIFIED="2014-06-20 15:03:24 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.4623959307773464" STUDIES="1" TAU2="0.0" TOTAL_1="78" TOTAL_2="70" WEIGHT="99.99999999999999" Z="0.734907344508614">
<NAME>Minor bleeding</NAME>
<DICH_DATA CI_END="1.7003730678153446" CI_START="0.31106445394026344" EFFECT_SIZE="0.7272727272727273" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="14" LOG_CI_END="0.23054421756548554" LOG_CI_START="-0.5071496138980485" LOG_EFFECT_SIZE="-0.13830269816628143" MODIFIED="2014-06-20 15:03:24 +0100" MODIFIED_BY="[Empty name]" ORDER="133" O_E="0.0" SE="0.43332500824503856" STUDY_ID="STD-Clyne-1987" TOTAL_1="78" TOTAL_2="70" VAR="0.18777056277056275" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.708700059041819" CI_START="0.6731191257013593" DF="0" EFFECT_SIZE="1.072454516437919" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="39" I2="0.0" ID="CMP-001.02.05" LOG_CI_END="0.23266583443790403" LOG_CI_START="-0.17190806942162629" LOG_EFFECT_SIZE="0.03037888250813888" MODIFIED="2014-06-20 15:04:00 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.7684966971720366" STUDIES="1" TAU2="0.0" TOTAL_1="286" TOTAL_2="263" WEIGHT="99.99999999999999" Z="0.29434184972641775">
<NAME>Wound or graft infection</NAME>
<DICH_DATA CI_END="1.708700059041819" CI_START="0.6731191257013593" EFFECT_SIZE="1.072454516437919" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="39" LOG_CI_END="0.23266583443790403" LOG_CI_START="-0.17190806942162629" LOG_EFFECT_SIZE="0.03037888250813888" MODIFIED="2014-06-20 15:04:00 +0100" MODIFIED_BY="[Empty name]" ORDER="134" O_E="0.0" SE="0.23764871380021094" STUDY_ID="STD-McCollum-1991" TOTAL_1="286" TOTAL_2="263" VAR="0.05647691117089457" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-10-02 15:43:33 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="78" TOTAL_2="70" WEIGHT="0.0" Z="0.0">
<NAME>Limb amputation</NAME>
<GROUP_LABEL_1>ASA or ASA/DIP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo or nothing</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ASA or ASA/DIP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo/nothing</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4425115926913314" CI_START="0.2115232335734709" EFFECT_SIZE="0.5523809523809524" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" LOG_CI_END="0.15911931203341564" LOG_CI_START="-0.6746419230474172" LOG_EFFECT_SIZE="-0.25776130550700077" MODIFIED="2014-04-30 12:23:22 +0100" MODIFIED_BY="[Empty name]" ORDER="4456" O_E="0.0" SE="0.4897554766711572" STUDY_ID="STD-Clyne-1987" TOTAL_1="78" TOTAL_2="70" VAR="0.23986042692939244" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.191194667328443" CI_END="3.800267898067764" CI_START="0.4274085178009635" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="OR" EFFECT_SIZE="1.274467288540481" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="57" I2="51.544085411636274" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.5798142130777432" LOG_CI_START="-0.3691568270547401" LOG_EFFECT_SIZE="0.10532869301150147" METHOD="MH" MODIFIED="2015-01-23 10:22:04 +0000" MODIFIED_BY="Kate Cahill" NO="4" P_CHI2="0.10266987361824664" P_Q="1.0" P_Z="0.6635023958840596" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.6219356442530715" TOTALS="YES" TOTAL_1="428" TOTAL_2="383" WEIGHT="100.0" Z="0.43508270771339463">
<NAME>Cardiovascular events</NAME>
<GROUP_LABEL_1>ASA or ASA/DIP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo or nothing</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ASA or ASA/DIP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo/nothinh</GRAPH_LABEL_2>
<DICH_DATA CI_END="12.405029083483253" CI_START="0.43717401047662424" EFFECT_SIZE="2.328767123287671" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.0935977868090732" LOG_CI_START="-0.35934566429343706" LOG_EFFECT_SIZE="0.36712606125781805" MODIFIED="2015-01-23 10:22:04 +0000" MODIFIED_BY="Kate Cahill" ORDER="4457" O_E="0.0" SE="0.8534661753636915" STUDY_ID="STD-Clyne-1987" TOTAL_1="78" TOTAL_2="70" VAR="0.7284045124899274" WEIGHT="23.01112965551929"/>
<DICH_DATA CI_END="43.33939707803645" CI_START="0.482193122023475" EFFECT_SIZE="4.571428571428571" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.6368828652786047" LOG_CI_START="-0.31677898866730647" LOG_EFFECT_SIZE="0.6600519383056491" MODIFIED="2015-01-23 10:22:04 +0000" MODIFIED_BY="Kate Cahill" ORDER="4458" O_E="0.0" SE="1.1475906437899734" STUDY_ID="STD-Donaldson-1985" TOTAL_1="32" TOTAL_2="33" VAR="1.3169642857142856" WEIGHT="16.026021738208286"/>
<DICH_DATA CI_END="17.25220984197789" CI_START="0.15879680020560233" EFFECT_SIZE="1.6551724137931034" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.2368447319141431" LOG_CI_START="-0.7991582529608807" LOG_EFFECT_SIZE="0.21884323947663112" MODIFIED="2015-01-23 10:20:43 +0000" MODIFIED_BY="Kate Cahill" ORDER="4459" O_E="0.0" SE="1.195958231692906" STUDY_ID="STD-Green-1982" TOTAL_1="32" TOTAL_2="17" VAR="1.430316091954023" WEIGHT="15.140858149934001"/>
<DICH_DATA CI_END="0.8792286305568099" CI_START="0.34719516955709373" EFFECT_SIZE="0.5525069533188003" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="53" LOG_CI_END="-0.055898178307055825" LOG_CI_START="-0.45942632568820874" LOG_EFFECT_SIZE="-0.25766225199763226" MODIFIED="2014-12-10 12:00:08 +0000" MODIFIED_BY="[Empty name]" ORDER="4460" O_E="0.0" SE="0.23703443126823398" STUDY_ID="STD-McCollum-1991" TOTAL_1="286" TOTAL_2="263" VAR="0.05618532160665514" WEIGHT="45.821990456338426"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.999746021363563" CI_END="1.2632514482576618" CI_START="0.5626339925873579" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8430588389756497" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="56" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.10148980480850704" LOG_CI_START="-0.2497740326629166" LOG_EFFECT_SIZE="-0.07414211392720477" METHOD="MH" MODIFIED="2015-01-23 10:23:43 +0000" MODIFIED_BY="Kate Cahill" NO="5" P_CHI2="0.5724594541574979" P_Q="1.0" P_Z="0.40801676504930307" Q="0.0" RANDOM="NO" SCALE="213.7" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="418" TOTAL_2="381" WEIGHT="100.0" Z="0.8273887461974153">
<NAME>Mortality</NAME>
<GROUP_LABEL_1>ASA or ASA/DIP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo or nothing</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ASA or ASA/DIP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo/nothing</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.369983570070878" CI_START="0.48040927820810664" EFFECT_SIZE="1.2723880597014925" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" LOG_CI_END="0.5276277835286236" LOG_CI_START="-0.31838861360120585" LOG_EFFECT_SIZE="0.10461958496370888" MODIFIED="2015-01-23 10:23:43 +0000" MODIFIED_BY="Kate Cahill" ORDER="4467" O_E="0.0" SE="0.4969542195227683" STUDY_ID="STD-Clyne-1987" TOTAL_1="78" TOTAL_2="70" VAR="0.2469634963014838" WEIGHT="14.171654475190136"/>
<DICH_DATA CI_END="5.737134959326502" CI_START="0.011985162335318754" EFFECT_SIZE="0.26222222222222225" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.7586950662675527" LOG_CI_START="-1.9213560792059894" LOG_EFFECT_SIZE="-0.5813305064692182" MODIFIED="2015-01-12 13:11:15 +0000" MODIFIED_BY="[Empty name]" ORDER="4468" O_E="0.0" SE="1.5742753093182875" STUDY_ID="STD-Goldman-1984" TOTAL_1="22" TOTAL_2="31" VAR="2.47834274952919" WEIGHT="4.0020021542048125"/>
<DICH_DATA CI_END="63.221186701505154" CI_START="0.1301828526323511" EFFECT_SIZE="2.8688524590163933" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.8008626435611115" LOG_CI_START="-0.8854462162100569" LOG_EFFECT_SIZE="0.4577082136755274" MODIFIED="2014-05-01 13:54:24 +0100" MODIFIED_BY="[Empty name]" ORDER="93" O_E="0.0" SE="1.5779511216728985" STUDY_ID="STD-Green-1982" TOTAL_1="32" TOTAL_2="17" VAR="2.4899297423887585" WEIGHT="1.1700842899657644"/>
<DICH_DATA CI_END="1.2167416511321971" CI_START="0.4835653767429558" EFFECT_SIZE="0.767055496641923" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="46" LOG_CI_END="0.08519837494459137" LOG_CI_START="-0.31554480216151404" LOG_EFFECT_SIZE="-0.11517321360846129" ORDER="4469" O_E="0.0" SE="0.23539852594284588" STUDY_ID="STD-McCollum-1991" TOTAL_1="286" TOTAL_2="263" VAR="0.05541246601606469" WEIGHT="80.65625908063927"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2015-01-23 10:05:31 +0000" MODIFIED_BY="Kate Cahill" NO="2">
<NAME>ASA or ASA/DIP vs placebo or nothing, subgroups</NAME>
<DICH_OUTCOME CHI2="0.020500289188404856" CI_END="2.2503976268268926" CI_START="0.2584687181208309" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="0.7626646641008792" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.35225926116899636" LOG_CI_START="-0.5875920110597387" LOG_EFFECT_SIZE="-0.11766637494537116" METHOD="MH" MODIFIED="2014-09-22 15:17:48 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8861486496484468" P_Q="1.0" P_Z="0.6235944720573766" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="335" TOTAL_2="307" WEIGHT="100.0" Z="0.49076245124917256">
<NAME>Primary graft patency, venous grafts, 1 month</NAME>
<GROUP_LABEL_1>ASA or ASA/DIP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo or nothing</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ASA or ASA/DIP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo/nothing</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.389847764518136" CI_START="0.2276159653153047" EFFECT_SIZE="0.7375415282392026" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.3783702368747182" LOG_CI_START="-0.6427972791611277" LOG_EFFECT_SIZE="-0.13221352114320475" ORDER="4480" O_E="0.0" SE="0.599838853780184" STUDY_ID="STD-Clyne-1987" TOTAL_1="49" TOTAL_2="44" VAR="0.3598066505043249" WEIGHT="86.17760255327138"/>
<DICH_DATA CI_END="14.77201625254264" CI_START="0.05721014991731936" EFFECT_SIZE="0.9192982456140351" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1694397768008815" LOG_CI_START="-1.242526914178411" LOG_EFFECT_SIZE="-0.03654356868876476" ORDER="4481" O_E="0.0" SE="1.4168011737089135" STUDY_ID="STD-McCollum-1991" TOTAL_1="286" TOTAL_2="263" VAR="2.0073255658229545" WEIGHT="13.822397446728623"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.180542345465177" CI_END="1.3469350308167245" CI_START="0.5412579893138066" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8538380095288511" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="44" I2="15.293169801040607" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.12934664810734306" LOG_CI_START="-0.2665956801271829" LOG_EFFECT_SIZE="-0.06862451600991991" METHOD="MH" MODIFIED="2014-09-22 15:18:07 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.2772456685231258" P_Q="1.0" P_Z="0.4968845474131537" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="335" TOTAL_2="307" WEIGHT="100.0" Z="0.6793998531840068">
<NAME>Primary graft patency, venous grafts, 3 months</NAME>
<GROUP_LABEL_1>ASA or ASA/DIP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo or nothing</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ASA or ASA/DIP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo/nothing</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4243222122063286" CI_START="0.19008221231057343" EFFECT_SIZE="0.5203252032520326" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" LOG_CI_END="0.15360824713361196" LOG_CI_START="-0.7210585220446335" LOG_EFFECT_SIZE="-0.2837251374555107" ORDER="4482" O_E="0.0" SE="0.5137835898856369" STUDY_ID="STD-Clyne-1987" TOTAL_1="49" TOTAL_2="44" VAR="0.26397357723577236" WEIGHT="26.479618845950235"/>
<DICH_DATA CI_END="1.6295448922957005" CI_START="0.5821225543121217" EFFECT_SIZE="0.9739583333333334" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="32" LOG_CI_END="0.21206632933491337" LOG_CI_START="-0.23498557366901468" LOG_EFFECT_SIZE="-0.011459622167050623" ORDER="4483" O_E="0.0" SE="0.26260050076711705" STUDY_ID="STD-McCollum-1991" TOTAL_1="286" TOTAL_2="263" VAR="0.06895902300314065" WEIGHT="73.52038115404976"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.7015993942969253" CI_END="1.3128686858367908" CI_START="0.5887300517158784" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="0.879161674158315" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="59" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.11822128978450902" LOG_CI_START="-0.23008379506727636" LOG_EFFECT_SIZE="-0.05593125264138366" METHOD="MH" MODIFIED="2014-09-22 15:18:30 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.402247231516491" P_Q="1.0" P_Z="0.5290435115978354" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="335" TOTAL_2="307" WEIGHT="100.0" Z="0.6294667838913168">
<NAME>Primary graft patency, venous grafts, 6 months</NAME>
<GROUP_LABEL_1>ASA or ASA/DIP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo or nothing</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ASA or ASA/DIP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo/nothing</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6008208208266974" CI_START="0.22488463125691255" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="12" LOG_CI_END="0.20434272424843172" LOG_CI_START="-0.6480402234811445" LOG_EFFECT_SIZE="-0.2218487496163564" ORDER="4484" O_E="0.0" SE="0.5006939628599933" STUDY_ID="STD-Clyne-1987" TOTAL_1="49" TOTAL_2="44" VAR="0.25069444444444444" WEIGHT="20.279395773740674"/>
<DICH_DATA CI_END="1.4762210118417485" CI_START="0.61158365755534" EFFECT_SIZE="0.9501750605978992" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="47" LOG_CI_END="0.16915138258040224" LOG_CI_START="-0.21354412811315582" LOG_EFFECT_SIZE="-0.022196372766376784" ORDER="4485" O_E="0.0" SE="0.224797237354726" STUDY_ID="STD-McCollum-1991" TOTAL_1="286" TOTAL_2="263" VAR="0.05053379792231703" WEIGHT="79.72060422625933"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.35263175163508315" CI_END="0.9926339808848774" CI_START="0.48162794086959554" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="0.6914334821591828" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="86" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="-0.003210861661172891" LOG_CI_START="-0.31728832612420516" LOG_EFFECT_SIZE="-0.16024959389268903" METHOD="MH" MODIFIED="2014-09-22 15:18:51 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.5526273409025363" P_Q="1.0" P_Z="0.04549616030599176" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="335" TOTAL_2="307" WEIGHT="100.0" Z="2.0000380040243786">
<NAME>Primary graft patency, venous grafts, 12 months</NAME>
<GROUP_LABEL_1>ASA or ASA/DIP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo or nothing</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ASA or ASA/DIP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo/nothing</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4243222122063286" CI_START="0.19008221231057343" EFFECT_SIZE="0.5203252032520326" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" LOG_CI_END="0.15360824713361196" LOG_CI_START="-0.7210585220446335" LOG_EFFECT_SIZE="-0.2837251374555107" ORDER="4486" O_E="0.0" SE="0.5137835898856369" STUDY_ID="STD-Clyne-1987" TOTAL_1="49" TOTAL_2="44" VAR="0.26397357723577236" WEIGHT="14.966140179987299"/>
<DICH_DATA CI_END="1.0634400895582903" CI_START="0.48957418924496543" EFFECT_SIZE="0.7215489031632529" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="74" LOG_CI_END="0.026713028317608273" LOG_CI_START="-0.3101814866222303" LOG_EFFECT_SIZE="-0.14173422915231101" ORDER="4487" O_E="0.0" SE="0.19789350573040568" STUDY_ID="STD-McCollum-1991" TOTAL_1="286" TOTAL_2="263" VAR="0.0391618396102701" WEIGHT="85.0338598200127"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.827334784897543" CI_END="3.280827438149691" CI_START="0.3232294978292823" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="1.0297864852956924" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="110" I2="79.28463542390868" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="0.5159833883774457" LOG_CI_START="-0.4904890125016741" LOG_EFFECT_SIZE="0.0127471879378858" METHOD="MH" MODIFIED="2015-01-23 09:46:12 +0000" MODIFIED_BY="Kate Cahill" NO="5" P_CHI2="0.02801201341329207" P_Q="1.0" P_Z="0.960403911334646" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.5689076006696191" TOTALS="YES" TOTAL_1="322" TOTAL_2="298" WEIGHT="100.0" Z="0.04964672501818618">
<NAME>Primary graft patency, venous grafts, 24 months</NAME>
<GROUP_LABEL_1>ASA or ASA/DIP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo or nothing</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ASA or ASA/DIP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo/nothing</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.647298425838918" CI_START="0.7539887526772946" EFFECT_SIZE="2.0634920634920637" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="9" LOG_CI_END="0.7518407382009529" LOG_CI_START="-0.1226351324944426" LOG_EFFECT_SIZE="0.3146028028532551" ORDER="4488" O_E="0.0" SE="0.513671455171848" STUDY_ID="STD-Kohler-1984" TOTAL_1="36" TOTAL_2="35" VAR="0.2638583638583638" WEIGHT="41.97164371391153"/>
<DICH_DATA CI_END="0.8913429223806512" CI_START="0.43529932568925706" EFFECT_SIZE="0.6228972411804288" ESTIMABLE="YES" EVENTS_1="80" EVENTS_2="101" LOG_CI_END="-0.049955179638196366" LOG_CI_START="-0.36121200559624644" LOG_EFFECT_SIZE="-0.20558359261722142" MODIFIED="2014-12-10 12:00:16 +0000" MODIFIED_BY="[Empty name]" ORDER="4489" O_E="0.0" SE="0.18283380031389596" STUDY_ID="STD-McCollum-1991" TOTAL_1="286" TOTAL_2="263" VAR="0.03342819853722158" WEIGHT="58.02835628608847"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.8790931806212112" CI_END="0.5115149742271088" CI_START="0.03900753920683143" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="0.14125487748055043" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="-0.29114164811210524" LOG_CI_START="-1.408851446319926" LOG_EFFECT_SIZE="-0.8499965472160156" METHOD="MH" MODIFIED="2015-01-23 10:03:08 +0000" MODIFIED_BY="Kate Cahill" NO="6" P_CHI2="0.6443285230497582" P_Q="1.0" P_Z="0.002872816560915601" Q="0.0" RANDOM="NO" SCALE="224.34" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="83" TOTAL_2="74" WEIGHT="100.0" Z="2.9810289257516747">
<NAME>Primary graft patency, prosthetic grafts, 1 month</NAME>
<GROUP_LABEL_1>ASA or ASA/DIP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo or nothing</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ASA or ASA/DIP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo/nothing</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.5803434523690243" CI_START="0.007841726159345076" EFFECT_SIZE="0.06746031746031746" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="9" LOG_CI_END="-0.23631491105256197" LOG_CI_START="-2.1055883277539786" LOG_EFFECT_SIZE="-1.17095161940327" MODIFIED="2015-01-23 10:03:08 +0000" MODIFIED_BY="Kate Cahill" ORDER="4490" O_E="0.0" SE="1.098020458023056" STUDY_ID="STD-Clyne-1987" TOTAL_1="29" TOTAL_2="26" VAR="1.2056489262371617" WEIGHT="58.52923000423021"/>
<DICH_DATA CI_END="2.2860901692923843" CI_START="0.02682098613929262" EFFECT_SIZE="0.24761904761904763" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.35909335609155657" LOG_CI_START="-1.571525258289797" LOG_EFFECT_SIZE="-0.6062159510991201" MODIFIED="2015-01-23 09:59:35 +0000" MODIFIED_BY="Kate Cahill" ORDER="4492" O_E="0.0" SE="1.134054930803877" STUDY_ID="STD-Goldman-1984" TOTAL_1="22" TOTAL_2="31" VAR="1.2860805860805862" WEIGHT="25.30745008044545"/>
<DICH_DATA CI_END="2.8842437890663692" CI_START="0.020293977429288797" EFFECT_SIZE="0.24193548387096775" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.46003196609301616" LOG_CI_START="-1.6926328269781614" LOG_EFFECT_SIZE="-0.6163004304425727" MODIFIED="2015-01-23 10:02:44 +0000" MODIFIED_BY="Kate Cahill" ORDER="4493" O_E="0.0" SE="1.264485955312591" STUDY_ID="STD-Green-1982" TOTAL_1="32" TOTAL_2="17" VAR="1.5989247311827957" WEIGHT="16.163319915324344"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.6319129110118032" CI_END="0.6636572168923552" CI_START="0.14180879433892213" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="OR" EFFECT_SIZE="0.30677749229992324" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="27" I2="0.0" I2_Q="0.0" ID="CMP-002.07" LOG_CI_END="-0.1780561785406558" LOG_CI_START="-0.8482968353417071" LOG_EFFECT_SIZE="-0.5131765069411814" METHOD="MH" MODIFIED="2015-01-23 10:04:21 +0000" MODIFIED_BY="Kate Cahill" NO="7" P_CHI2="0.8890893453329866" P_Q="1.0" P_Z="0.0026880103922817616" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="116" TOTAL_2="106" WEIGHT="100.0" Z="3.0013323158202274">
<NAME>Primary graft patency, prosthetic grafts, 3 months</NAME>
<GROUP_LABEL_1>ASA or ASA/DIP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo or nothing</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ASA or ASA/DIP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo/nothing</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1588373849588438" CI_START="0.09588153830147375" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" LOG_CI_END="0.06402249742181323" LOG_CI_START="-1.0182650068611383" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2015-01-23 10:04:20 +0000" MODIFIED_BY="Kate Cahill" ORDER="4494" O_E="0.0" SE="0.635741037425355" STUDY_ID="STD-Clyne-1987" TOTAL_1="29" TOTAL_2="26" VAR="0.4041666666666667" WEIGHT="35.52155637887083"/>
<DICH_DATA CI_END="1.5046218505303213" CI_START="0.05194615826553547" EFFECT_SIZE="0.27956989247311825" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.17742736447229535" LOG_CI_START="-1.2844465656385295" LOG_EFFECT_SIZE="-0.5535096005831172" MODIFIED="2015-01-23 10:04:21 +0000" MODIFIED_BY="Kate Cahill" ORDER="4495" O_E="0.0" SE="0.8587119829397597" STUDY_ID="STD-Donaldson-1985" TOTAL_1="33" TOTAL_2="32" VAR="0.7373862696443341" WEIGHT="23.293943702297984"/>
<DICH_DATA CI_END="1.4379508844005788" CI_START="0.018537184039056073" EFFECT_SIZE="0.16326530612244897" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="0.15774405225125085" LOG_CI_START="-1.731956238324391" LOG_EFFECT_SIZE="-0.7871060930365701" ORDER="4496" O_E="0.0" SE="1.1100193048514324" STUDY_ID="STD-Goldman-1984" TOTAL_1="22" TOTAL_2="31" VAR="1.2321428571428572" WEIGHT="22.577970387041717"/>
<DICH_DATA CI_END="2.1529334030110436" CI_START="0.10012442753144007" EFFECT_SIZE="0.4642857142857143" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.33303059593953666" LOG_CI_START="-0.9994599540103015" LOG_EFFECT_SIZE="-0.33321467903538243" ORDER="4497" O_E="0.0" SE="0.782711544975135" STUDY_ID="STD-Green-1982" TOTAL_1="32" TOTAL_2="17" VAR="0.6126373626373627" WEIGHT="18.60652953178948"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.7527616534068566" CI_END="0.4071211120829192" CI_START="0.10771941983031828" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="OR" EFFECT_SIZE="0.20941549607000443" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="47" I2="0.0" I2_Q="0.0" ID="CMP-002.08" LOG_CI_END="-0.3902763758240534" LOG_CI_START="-0.9677059943356281" LOG_EFFECT_SIZE="-0.6789911850798407" METHOD="MH" MODIFIED="2015-01-23 10:05:01 +0000" MODIFIED_BY="Kate Cahill" NO="8" P_CHI2="0.6252681856764456" P_Q="1.0" P_Z="4.0385809825247645E-6" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="116" TOTAL_2="106" WEIGHT="100.0" Z="4.60938693102381">
<NAME>Primary graft patency, prosthetic grafts, 6 months</NAME>
<GROUP_LABEL_1>ASA or ASA/DIP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo or nothing</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ASA or ASA/DIP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo/nothing</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.47783552346241304" CI_START="0.027862326708120704" EFFECT_SIZE="0.11538461538461539" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="13" LOG_CI_END="-0.3207215668711441" LOG_CI_START="-1.5549826196311667" LOG_EFFECT_SIZE="-0.9378520932511555" MODIFIED="2015-01-23 10:05:01 +0000" MODIFIED_BY="Kate Cahill" ORDER="4498" O_E="0.0" SE="0.7250110520819842" STUDY_ID="STD-Clyne-1987" TOTAL_1="29" TOTAL_2="26" VAR="0.5256410256410257" WEIGHT="30.74299476686689"/>
<DICH_DATA CI_END="0.7125710960984812" CI_START="0.028271819741200258" EFFECT_SIZE="0.14193548387096774" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="10" LOG_CI_END="-0.14717179784175355" LOG_CI_START="-1.548646236854417" LOG_EFFECT_SIZE="-0.8479090173480852" MODIFIED="2015-01-23 10:05:00 +0000" MODIFIED_BY="Kate Cahill" ORDER="4499" O_E="0.0" SE="0.8232330228863967" STUDY_ID="STD-Donaldson-1985" TOTAL_1="33" TOTAL_2="32" VAR="0.6777126099706744" WEIGHT="23.858355064864835"/>
<DICH_DATA CI_END="1.1364226320852957" CI_START="0.1087590020795831" EFFECT_SIZE="0.3515625" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="16" LOG_CI_END="0.0555398741989835" LOG_CI_START="-0.963534785944033" LOG_EFFECT_SIZE="-0.4539974558725247" ORDER="4500" O_E="0.0" SE="0.5986094998689323" STUDY_ID="STD-Goldman-1984" TOTAL_1="22" TOTAL_2="31" VAR="0.3583333333333333" WEIGHT="24.16330056478094"/>
<DICH_DATA CI_END="0.95443918328068" CI_START="0.07061754076076437" EFFECT_SIZE="0.25961538461538464" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="-0.02025173956689505" LOG_CI_START="-1.1510874107126912" LOG_EFFECT_SIZE="-0.585669575139793" ORDER="4501" O_E="0.0" SE="0.6642584709578917" STUDY_ID="STD-Green-1982" TOTAL_1="32" TOTAL_2="17" VAR="0.4412393162393162" WEIGHT="21.235349603487332"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-002.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-09-22 15:20:44 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="33" TOTAL_2="32" WEIGHT="0.0" Z="0.0">
<NAME>Primary graft patency, prosthetic grafts, 9 months</NAME>
<GROUP_LABEL_1>ASA or ASA/DIP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo or nothing</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ASA or ASA/DIP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo/control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.6664063596528969" CI_START="0.041682942209984405" EFFECT_SIZE="0.16666666666666666" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="12" LOG_CI_END="-0.17626086701996496" LOG_CI_START="-1.3800416337473222" LOG_EFFECT_SIZE="-0.7781512503836436" MODIFIED="2014-05-01 10:41:54 +0100" MODIFIED_BY="[Empty name]" ORDER="4499" O_E="0.0" SE="0.7071067811865475" STUDY_ID="STD-Donaldson-1985" TOTAL_1="33" TOTAL_2="32" VAR="0.49999999999999994" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.775995751032991" CI_END="0.3550076308236773" CI_START="0.10212650898452563" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="OR" EFFECT_SIZE="0.19040926972941585" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="57" I2="0.0" I2_Q="0.0" ID="CMP-002.10" LOG_CI_END="-0.44976231176462983" LOG_CI_START="-0.9908615134332253" LOG_EFFECT_SIZE="-0.7203119125989276" METHOD="MH" MODIFIED="2015-01-23 10:05:31 +0000" MODIFIED_BY="Kate Cahill" NO="10" P_CHI2="0.8551995339116606" P_Q="1.0" P_Z="1.8065777667999652E-7" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="116" TOTAL_2="106" WEIGHT="100.00000000000001" Z="5.218212859954398">
<NAME>Primary graft patency, prosthetic grafts, 12 months</NAME>
<GROUP_LABEL_1>ASA or ASA/DIP</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo or nothing</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ASA or ASA/DIP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo/nothing</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.5904805544244628" CI_START="0.043354518295614555" EFFECT_SIZE="0.16" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="13" LOG_CI_END="-0.2287943999051792" LOG_CI_START="-1.3629656347829713" LOG_EFFECT_SIZE="-0.7958800173440752" MODIFIED="2015-01-23 10:05:31 +0000" MODIFIED_BY="Kate Cahill" ORDER="4502" O_E="0.0" SE="0.666217797605373" STUDY_ID="STD-Clyne-1987" TOTAL_1="29" TOTAL_2="26" VAR="0.44384615384615383" WEIGHT="25.377373753213277"/>
<DICH_DATA CI_END="0.5483231756050849" CI_START="0.04456590284831751" EFFECT_SIZE="0.15632183908045977" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="15" LOG_CI_END="-0.26096339769723387" LOG_CI_START="-1.3509972907995682" LOG_EFFECT_SIZE="-0.805980344248401" MODIFIED="2015-01-23 10:05:31 +0000" MODIFIED_BY="Kate Cahill" ORDER="4503" O_E="0.0" SE="0.6402913045631036" STUDY_ID="STD-Donaldson-1985" TOTAL_1="33" TOTAL_2="32" VAR="0.40997295469912104" WEIGHT="28.74100199032557"/>
<DICH_DATA CI_END="0.9327303881689337" CI_START="0.09313495860761983" EFFECT_SIZE="0.29473684210526313" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="19" LOG_CI_END="-0.030243873779553624" LOG_CI_START="-1.0308872741137034" LOG_EFFECT_SIZE="-0.5305655739466286" ORDER="4504" O_E="0.0" SE="0.5877828866209965" STUDY_ID="STD-Goldman-1984" TOTAL_1="22" TOTAL_2="31" VAR="0.34548872180451123" WEIGHT="23.093778437249238"/>
<DICH_DATA CI_END="0.599790620869713" CI_START="0.04350630644803185" EFFECT_SIZE="0.16153846153846155" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" LOG_CI_END="-0.22200032973417147" LOG_CI_START="-1.3614477854116636" LOG_EFFECT_SIZE="-0.7917240575729175" ORDER="4505" O_E="0.0" SE="0.669317075820831" STUDY_ID="STD-Green-1982" TOTAL_1="32" TOTAL_2="17" VAR="0.447985347985348" WEIGHT="22.78784581921192"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2014-09-25 12:28:24 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>ASA or ASA/DIP versus pentoxifylline (PTX), all grafts</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-09-22 15:21:33 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="59" TOTAL_2="59" WEIGHT="0.0" Z="0.0">
<NAME>Primary graft patency, 1 month</NAME>
<GROUP_LABEL_1>ASA or ASA/DIP</GROUP_LABEL_1>
<GROUP_LABEL_2>PTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ASA or ASA/DIP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours pentoxifylline</GRAPH_LABEL_2>
<DICH_DATA CI_END="23.07312953280059" CI_START="0.17949806155904835" EFFECT_SIZE="2.0350877192982457" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3631065042154327" LOG_CI_START="-0.7459402371065783" LOG_EFFECT_SIZE="0.3085831335544271" ORDER="4506" O_E="0.0" SE="1.238864495802292" STUDY_ID="STD-Raithel-1987" TOTAL_1="59" TOTAL_2="59" VAR="1.5347852389594676" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-09-22 15:21:53 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="59" TOTAL_2="59" WEIGHT="0.0" Z="0.0">
<NAME>Primary graft patency, 3 months</NAME>
<GROUP_LABEL_1>ASA or ASA/DIP</GROUP_LABEL_1>
<GROUP_LABEL_2>PTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ASA or ASA/DIP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours pentoxifylline</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.6535825835764735" CI_START="0.27370395416684545" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.5627189283464096" LOG_CI_START="-0.5627189283464097" LOG_EFFECT_SIZE="0.0" ORDER="4507" O_E="0.0" SE="0.6610877680286007" STUDY_ID="STD-Raithel-1987" TOTAL_1="59" TOTAL_2="59" VAR="0.437037037037037" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.36660527815653965" CI_END="3.1103362704438786" CI_START="0.5606131227620704" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="1.3204905639245115" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.4928073448157198" LOG_CI_START="-0.2513367405456728" LOG_EFFECT_SIZE="0.1207353021350235" METHOD="MH" MODIFIED="2014-09-22 15:22:18 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.5448607858817758" P_Q="1.0" P_Z="0.5247781342756699" Q="0.0" RANDOM="NO" SCALE="34.43796297861948" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="78" TOTAL_2="73" WEIGHT="100.00000000000001" Z="0.6359973787395907">
<NAME>Primary graft patency, 6 months</NAME>
<GROUP_LABEL_1>ASA or ASA/DIP</GROUP_LABEL_1>
<GROUP_LABEL_2>PTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ASA or ASA/DIP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours pentoxifylline</GRAPH_LABEL_2>
<DICH_DATA CI_END="13.12071277526136" CI_START="0.34996854312302467" EFFECT_SIZE="2.142857142857143" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.1179574284812963" LOG_CI_START="-0.45597099039844763" LOG_EFFECT_SIZE="0.3309932190414244" ORDER="4508" O_E="0.0" SE="0.9245333443212878" STUDY_ID="STD-Lucas-1984" TOTAL_1="19" TOTAL_2="14" VAR="0.8547619047619048" WEIGHT="18.502548020384165"/>
<DICH_DATA CI_END="3.029866102715099" CI_START="0.4242671369901094" EFFECT_SIZE="1.1337868480725624" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" LOG_CI_END="0.4814234363779253" LOG_CI_START="-0.37236060664156473" LOG_EFFECT_SIZE="0.05453141486818027" ORDER="4509" O_E="0.0" SE="0.5015169731688223" STUDY_ID="STD-Raithel-1987" TOTAL_1="59" TOTAL_2="59" VAR="0.25151927437641725" WEIGHT="81.49745197961585"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="13" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-09-22 15:22:44 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="59" TOTAL_2="59" WEIGHT="0.0" Z="0.0">
<NAME>Primary graft patency, 12 months</NAME>
<GROUP_LABEL_1>ASA or ASA/DIP</GROUP_LABEL_1>
<GROUP_LABEL_2>PTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ASA or ASA/DIP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours pentoxifylline</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.145614624386487" CI_START="0.384581400644228" EFFECT_SIZE="0.9083850931677019" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="14" LOG_CI_END="0.3315517206439459" LOG_CI_START="-0.4150117231992092" LOG_EFFECT_SIZE="-0.04173000127763164" MODIFIED="2014-05-05 10:45:44 +0100" MODIFIED_BY="[Empty name]" ORDER="4510" O_E="0.0" SE="0.4385350624621174" STUDY_ID="STD-Raithel-1987" TOTAL_1="59" TOTAL_2="59" VAR="0.1923130010086532" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="34" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-003.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-09-22 14:43:32 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="177" TOTAL_2="177" WEIGHT="0.0" Z="0.0">
<NAME>Side effects</NAME>
<GROUP_LABEL_1>ASA or ASA/DIP</GROUP_LABEL_1>
<GROUP_LABEL_2>PTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ASA or ASA/DIP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours pentoxifylline</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="29" EVENTS_2="3" I2="0.0" ID="CMP-003.05.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-05-05 10:42:21 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="59" TOTAL_2="59" WEIGHT="0.0" Z="0.0">
<NAME>Gastric intolerance</NAME>
<DICH_DATA CI_END="64.17004956632198" CI_START="5.074048991845034" EFFECT_SIZE="18.044444444444444" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="3" LOG_CI_END="1.8073323747496883" LOG_CI_START="0.7053546561819748" LOG_EFFECT_SIZE="1.2563435154658316" MODIFIED="2014-05-05 10:42:21 +0100" MODIFIED_BY="[Empty name]" ORDER="279" O_E="0.0" SE="0.6473071667643571" STUDY_ID="STD-Raithel-1987" TOTAL_1="59" TOTAL_2="59" VAR="0.41900656814449916" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="1" I2="0.0" ID="CMP-003.05.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-05-05 10:43:14 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="59" TOTAL_2="59" WEIGHT="0.0" Z="0.0">
<NAME>Gastric haemorrhage</NAME>
<DICH_DATA CI_END="30.767819521181146" CI_START="0.3137803355888659" EFFECT_SIZE="3.107142857142857" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.488096719403992" LOG_CI_START="-0.5033742768511934" LOG_EFFECT_SIZE="0.4923612212763993" MODIFIED="2014-05-05 10:43:14 +0100" MODIFIED_BY="[Empty name]" ORDER="280" O_E="0.0" SE="1.1697999211407142" STUDY_ID="STD-Raithel-1987" TOTAL_1="59" TOTAL_2="59" VAR="1.368431855500821" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="4" I2="0.0" ID="CMP-003.05.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-05-05 10:44:06 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="59" TOTAL_2="59" WEIGHT="0.0" Z="0.0">
<NAME>Vertigo</NAME>
<DICH_DATA CI_END="2.7414026835341594" CI_START="0.08490687222286913" EFFECT_SIZE="0.4824561403508772" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.43797283356647604" LOG_CI_START="-1.0710571572509333" LOG_EFFECT_SIZE="-0.3165421618422288" MODIFIED="2014-05-05 10:44:06 +0100" MODIFIED_BY="[Empty name]" ORDER="281" O_E="0.0" SE="0.8864116864250725" STUDY_ID="STD-Raithel-1987" TOTAL_1="59" TOTAL_2="59" VAR="0.785725677830941" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-003.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-09-25 12:28:24 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="59" TOTAL_2="59" WEIGHT="0.0" Z="0.0">
<NAME>Limb amputation</NAME>
<GROUP_LABEL_1>ASA or ASA/DIP</GROUP_LABEL_1>
<GROUP_LABEL_2>PTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ASA or ASA/DIP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours pentoxifylline</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.036382749962968" CI_START="0.07051773937677111" EFFECT_SIZE="0.37894736842105264" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.3088594095067139" LOG_CI_START="-1.1517016185498348" LOG_EFFECT_SIZE="-0.4214211045215605" MODIFIED="2014-06-20 09:24:49 +0100" MODIFIED_BY="[Empty name]" ORDER="115" O_E="0.0" SE="0.8579407777741079" STUDY_ID="STD-Raithel-1987" TOTAL_1="59" TOTAL_2="59" VAR="0.7360623781676413" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-003.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-09-22 14:44:11 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="59" TOTAL_2="59" WEIGHT="0.0" Z="0.0">
<NAME>Mortality</NAME>
<GROUP_LABEL_1>ASA or ASA/DIP</GROUP_LABEL_1>
<GROUP_LABEL_2>PTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ASA or ASA/DIP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours pentoxifylline</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.882707530178093" CI_START="0.5027347936700465" EFFECT_SIZE="2.1132075471698113" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.9485453628721231" LOG_CI_START="-0.2986610567333378" LOG_EFFECT_SIZE="0.32494215306939256" MODIFIED="2014-05-05 10:39:19 +0100" MODIFIED_BY="[Empty name]" ORDER="278" O_E="0.0" SE="0.7326152246475941" STUDY_ID="STD-Raithel-1987" TOTAL_1="59" TOTAL_2="59" VAR="0.5367250673854448" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2014-09-22 15:24:00 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>ASA/DIP versus indobufen, prosthetic grafts</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-09-22 15:23:09 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="57" TOTAL_2="56" WEIGHT="0.0" Z="0.0">
<NAME>Primary graft patency, 3 months</NAME>
<GROUP_LABEL_1>ASA/DIP</GROUP_LABEL_1>
<GROUP_LABEL_2>Indobufen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ASA/DIP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours indobufen</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.442027392007548" CI_START="0.5095976704452078" EFFECT_SIZE="1.6653061224489796" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.7357607234356145" LOG_CI_START="-0.2927725659849195" LOG_EFFECT_SIZE="0.2214940787253475" ORDER="4511" O_E="0.0" SE="0.604165545527516" STUDY_ID="STD-D_x0027_Addato-1992" TOTAL_1="57" TOTAL_2="56" VAR="0.365016006402561" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="12" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-09-22 15:23:30 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="57" TOTAL_2="56" WEIGHT="0.0" Z="0.0">
<NAME>Primary graft patency, 6 months</NAME>
<GROUP_LABEL_1>ASA/DIP</GROUP_LABEL_1>
<GROUP_LABEL_2>Indobufen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ASA/DIP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours indobufen</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.274657675977172" CI_START="0.5988783650178007" EFFECT_SIZE="1.6" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" LOG_CI_END="0.6309013411959187" LOG_CI_START="-0.22266137588406898" LOG_EFFECT_SIZE="0.2041199826559248" ORDER="4512" O_E="0.0" SE="0.5013869652163775" STUDY_ID="STD-D_x0027_Addato-1992" TOTAL_1="57" TOTAL_2="56" VAR="0.2513888888888889" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="18" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-09-22 15:23:46 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="57" TOTAL_2="56" WEIGHT="0.0" Z="0.0">
<NAME>Primary graft patency, 9 months</NAME>
<GROUP_LABEL_1>ASA/DIP</GROUP_LABEL_1>
<GROUP_LABEL_2>Indobufen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ASA/DIP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours indobufen</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.845629500607251" CI_START="0.5592714334741083" EFFECT_SIZE="1.2615384615384615" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="15" LOG_CI_END="0.45417835452680005" LOG_CI_START="-0.25237736304507785" LOG_EFFECT_SIZE="0.1009004957408611" ORDER="4513" O_E="0.0" SE="0.4150343260089301" STUDY_ID="STD-D_x0027_Addato-1992" TOTAL_1="57" TOTAL_2="56" VAR="0.17225349176568686" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="21" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-004.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-09-22 15:24:00 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="57" TOTAL_2="56" WEIGHT="0.0" Z="0.0">
<NAME>Primary graft patency, 12 months</NAME>
<GROUP_LABEL_1>ASA/DIP</GROUP_LABEL_1>
<GROUP_LABEL_2>Indobufen</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ASA/DIP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours indobufen</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.9299861905924103" CI_START="0.6112225744176804" EFFECT_SIZE="1.338235294117647" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="17" LOG_CI_END="0.46686557347231844" LOG_CI_START="-0.21380061424260388" LOG_EFFECT_SIZE="0.12653247961485725" ORDER="4514" O_E="0.0" SE="0.3998266880157148" STUDY_ID="STD-D_x0027_Addato-1992" TOTAL_1="57" TOTAL_2="56" VAR="0.15986138044961573" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2014-09-25 12:28:39 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>ASA or ASA/DIP versus vitamin K antagonists, all grafts</NAME>
<DICH_OUTCOME CHI2="0.03117345248276334" CI_END="1.141941377949414" CI_START="0.6836218103079282" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8835474135887155" ESTIMABLE="YES" EVENTS_1="122" EVENTS_2="136" I2="0.0" I2_Q="100.0" ID="CMP-005.01" LOG_CI_END="0.057643809788501345" LOG_CI_START="-0.16518408997517278" LOG_EFFECT_SIZE="-0.053770140093335694" METHOD="MH" MODIFIED="2014-09-22 15:24:23 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8598540139050456" P_Q="0.0" P_Z="0.3441946473891706" Q="1.1241548739860762E-32" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1381" TOTAL_2="1400" WEIGHT="99.99999999999999" Z="0.9459097190107937">
<NAME>Primary graft patency, 3 months</NAME>
<GROUP_LABEL_1>ASA or ASA/DIP</GROUP_LABEL_1>
<GROUP_LABEL_2>Vitamin K antagonist</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ASA or ASA/DIP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Vit K antagonist</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.14522689542777" CI_START="0.6843996734309847" EFFECT_SIZE="0.8853207967935388" ESTIMABLE="YES" EVENTS_1="122" EVENTS_2="135" LOG_CI_END="0.05889153878958052" LOG_CI_START="-0.1646902063593931" LOG_EFFECT_SIZE="-0.05289933378490625" MODIFIED="2014-05-05 13:48:20 +0100" MODIFIED_BY="[Empty name]" ORDER="4522" O_E="0.0" SE="0.131333023847995" STUDY_ID="STD-BOA-2000" TOTAL_1="1351" TOTAL_2="1339" VAR="0.017248363153058024" WEIGHT="99.20873005731148"/>
<DICH_DATA CI_END="16.716089614075692" CI_START="0.0261537441225757" EFFECT_SIZE="0.6612021857923497" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="1.2231346907076648" LOG_CI_START="-1.5824661295356237" LOG_EFFECT_SIZE="-0.1796657194139794" ORDER="4523" O_E="0.0" SE="1.6480238097589497" STUDY_ID="STD-Schneider-1979" TOTAL_1="30" TOTAL_2="61" VAR="2.715982477532403" WEIGHT="0.7912699426885046"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.55466697125083" CI_END="1.958667785891522" CI_START="0.2664557638432238" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="0.7224253047927109" ESTIMABLE="YES" EVENTS_1="205" EVENTS_2="212" I2="60.85595456262644" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="0.29196078056382524" LOG_CI_START="-0.5743748808716249" LOG_EFFECT_SIZE="-0.14120705015389987" METHOD="MH" MODIFIED="2014-09-22 15:24:42 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.10996932884251298" P_Q="1.0" P_Z="0.5228732646869189" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.3657733259687861" TOTALS="YES" TOTAL_1="1381" TOTAL_2="1400" WEIGHT="100.0" Z="0.6389226369977983">
<NAME>Primary graft patency, 6 months</NAME>
<GROUP_LABEL_1>ASA or ASA/DIP</GROUP_LABEL_1>
<GROUP_LABEL_2>Vitamin K antagonist</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ASA or ASA/DIP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Vit K antagonist</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2606311125756369" CI_START="0.8238998345291908" EFFECT_SIZE="1.0191338307864266" ESTIMABLE="YES" EVENTS_1="202" EVENTS_2="197" LOG_CI_END="0.10058802137850317" LOG_CI_START="-0.08412558436535324" LOG_EFFECT_SIZE="0.008231218506574952" MODIFIED="2014-05-05 13:48:31 +0100" MODIFIED_BY="[Empty name]" ORDER="4524" O_E="0.0" SE="0.1085016863610361" STUDY_ID="STD-BOA-2000" TOTAL_1="1351" TOTAL_2="1339" VAR="0.011772615943188649" WEIGHT="68.59268151191019"/>
<DICH_DATA CI_END="1.2851936005073186" CI_START="0.09033989303612901" EFFECT_SIZE="0.34074074074074073" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="15" LOG_CI_END="0.1089685543590338" LOG_CI_START="-1.044120427985898" LOG_EFFECT_SIZE="-0.46757593681343207" ORDER="4525" O_E="0.0" SE="0.6773301761119311" STUDY_ID="STD-Schneider-1979" TOTAL_1="30" TOTAL_2="61" VAR="0.4587761674718196" WEIGHT="31.40731848808981"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.0189291373187856" CI_END="1.688768490168873" CI_START="0.27037127013639023" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="0.6757177529510914" ESTIMABLE="YES" EVENTS_1="264" EVENTS_2="290" I2="66.87567165328915" I2_Q="0.0" ID="CMP-005.03" LOG_CI_END="0.22757011710594197" LOG_CI_START="-0.5680394587515841" LOG_EFFECT_SIZE="-0.17023467082282115" METHOD="MH" MODIFIED="2014-09-22 15:25:07 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.08229800141952226" P_Q="1.0" P_Z="0.4016165952587383" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.3235711239747563" TOTALS="YES" TOTAL_1="1381" TOTAL_2="1400" WEIGHT="100.0" Z="0.8387375764630317">
<NAME>Primary graft patency, 12 months</NAME>
<GROUP_LABEL_1>ASA or ASA/DIP</GROUP_LABEL_1>
<GROUP_LABEL_2>Vitamin K antagonist</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ASA or ASA/DIP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Vit K antagonist</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1466798022163844" CI_START="0.7834683235601334" EFFECT_SIZE="0.9478329506314581" ESTIMABLE="YES" EVENTS_1="259" EVENTS_2="268" LOG_CI_END="0.059442162849615864" LOG_CI_START="-0.10597855781841545" LOG_EFFECT_SIZE="-0.02326819748439978" MODIFIED="2014-05-05 13:48:41 +0100" MODIFIED_BY="[Empty name]" ORDER="4526" O_E="0.0" SE="0.09716895016617512" STUDY_ID="STD-BOA-2000" TOTAL_1="1351" TOTAL_2="1339" VAR="0.009441804876396623" WEIGHT="65.58644817779337"/>
<DICH_DATA CI_END="1.0578829102263974" CI_START="0.11882456756196337" EFFECT_SIZE="0.35454545454545455" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="22" LOG_CI_END="0.024437601294009025" LOG_CI_START="-0.9250937575574607" LOG_EFFECT_SIZE="-0.4503280781317258" ORDER="4527" O_E="0.0" SE="0.5577594204453844" STUDY_ID="STD-Schneider-1979" TOTAL_1="30" TOTAL_2="61" VAR="0.3110955710955711" WEIGHT="34.413551822206635"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.91792480122071" CI_END="1.6344285450328884" CI_START="0.25429877260521566" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="0.6446961865195047" ESTIMABLE="YES" EVENTS_1="342" EVENTS_2="379" I2="74.47628398359178" I2_Q="0.0" ID="CMP-005.04" LOG_CI_END="0.21336593857422792" LOG_CI_START="-0.5946557359787086" LOG_EFFECT_SIZE="-0.19064489870224033" METHOD="MH" MODIFIED="2014-09-22 15:25:29 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.04777387955836365" P_Q="1.0" P_Z="0.35503401771730125" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.3558495146318721" TOTALS="YES" TOTAL_1="1381" TOTAL_2="1400" WEIGHT="100.0" Z="0.9248690896798419">
<NAME>Primary graft patency, 24 months</NAME>
<GROUP_LABEL_1>ASA or ASA/DIP</GROUP_LABEL_1>
<GROUP_LABEL_2>Vitamin K antagonist</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ASA or ASA/DIP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Vit K antagonist</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1127159447196506" CI_START="0.7860597112965878" EFFECT_SIZE="0.9352332191819528" ESTIMABLE="YES" EVENTS_1="334" EVENTS_2="348" LOG_CI_END="0.04638431133769972" LOG_CI_START="-0.10454446248267114" LOG_EFFECT_SIZE="-0.029080075572485705" MODIFIED="2014-05-05 13:48:48 +0100" MODIFIED_BY="[Empty name]" ORDER="4528" O_E="0.0" SE="0.0886563088515655" STUDY_ID="STD-BOA-2000" TOTAL_1="1351" TOTAL_2="1339" VAR="0.007859941099184172" WEIGHT="61.93934851847962"/>
<DICH_DATA CI_END="0.9119675561033576" CI_START="0.1357920503436086" EFFECT_SIZE="0.3519061583577713" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="31" LOG_CI_END="-0.040020611732893945" LOG_CI_START="-0.8671256541568516" LOG_EFFECT_SIZE="-0.4535731329448729" ORDER="4529" O_E="0.0" SE="0.4858455961558238" STUDY_ID="STD-Schneider-1979" TOTAL_1="30" TOTAL_2="61" VAR="0.23604594330400783" WEIGHT="38.060651481520374"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="110" EVENTS_2="110" I2="0.0" I2_Q="0.0" ID="CMP-005.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-09-25 12:28:39 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="1351" TOTAL_2="1339" WEIGHT="0.0" Z="0.0">
<NAME>Limb amputation</NAME>
<GROUP_LABEL_1>ASA or ASA/DIP</GROUP_LABEL_1>
<GROUP_LABEL_2>Vitamin K antagonist</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ASA or ASA/DIP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Vit K antagonist</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.304844249263329" CI_START="0.7516255365978993" EFFECT_SIZE="0.9903303787268332" ESTIMABLE="YES" EVENTS_1="110" EVENTS_2="110" LOG_CI_END="0.11555867587177018" LOG_CI_START="-0.12399847309632173" LOG_EFFECT_SIZE="-0.004219898612275761" MODIFIED="2014-06-20 12:44:26 +0100" MODIFIED_BY="[Empty name]" ORDER="119" O_E="0.0" SE="0.14071705513086938" STUDY_ID="STD-BOA-2000" TOTAL_1="1351" TOTAL_2="1339" VAR="0.01980128960470413" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="89" EVENTS_2="64" I2="0.0" I2_Q="0.0" ID="CMP-005.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-09-22 14:45:41 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="2702" TOTAL_2="2678" WEIGHT="0.0" Z="0.0">
<NAME>Cardiovascular events</NAME>
<GROUP_LABEL_1>ASA or ASA/DIP</GROUP_LABEL_1>
<GROUP_LABEL_2>Vitamin K antagonist</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ASA or ASA/DIP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Vit K antagonist</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="42" EVENTS_2="29" I2="0.0" ID="CMP-005.06.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-06-20 14:14:05 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="1351" TOTAL_2="1339" WEIGHT="0.0" Z="0.0">
<NAME>Myocardial infarction</NAME>
<DICH_DATA CI_END="2.340831617489223" CI_START="0.8974199263442733" EFFECT_SIZE="1.4493822607412872" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="29" LOG_CI_END="0.3693701748135181" LOG_CI_START="-0.04700429160561237" LOG_EFFECT_SIZE="0.16118294160395286" MODIFIED="2014-06-20 14:14:05 +0100" MODIFIED_BY="[Empty name]" ORDER="122" O_E="0.0" SE="0.24458042266144678" STUDY_ID="STD-BOA-2000" TOTAL_1="1351" TOTAL_2="1339" VAR="0.05981958314925195" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="47" EVENTS_2="35" I2="0.0" ID="CMP-005.06.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-06-20 14:14:11 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="1351" TOTAL_2="1339" WEIGHT="0.0" Z="0.0">
<NAME>Stroke</NAME>
<DICH_DATA CI_END="2.0939982751272974" CI_START="0.8611589262234828" EFFECT_SIZE="1.3428571428571427" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="35" LOG_CI_END="0.32097631960499867" LOG_CI_START="-0.06491669243411513" LOG_EFFECT_SIZE="0.1280298135854418" MODIFIED="2014-06-20 14:14:11 +0100" MODIFIED_BY="[Empty name]" ORDER="119" O_E="0.0" SE="0.2266754654729924" STUDY_ID="STD-BOA-2000" TOTAL_1="1351" TOTAL_2="1339" VAR="0.05138176664739776" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="211" EVENTS_2="205" I2="0.0" I2_Q="0.0" ID="CMP-005.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-09-22 14:46:19 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="1351" TOTAL_2="1339" WEIGHT="0.0" Z="0.0">
<NAME>Mortality</NAME>
<GROUP_LABEL_1>ASA or ASA/DIP</GROUP_LABEL_1>
<GROUP_LABEL_2>Vitamin K antagonist</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ASA or ASA/DIP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Vit K antagonist</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2619036048444265" CI_START="0.8307061274802394" EFFECT_SIZE="1.0238510911424903" ESTIMABLE="YES" EVENTS_1="211" EVENTS_2="205" LOG_CI_END="0.10102618099126087" LOG_CI_START="-0.08055258606655388" LOG_EFFECT_SIZE="0.010236797462353512" MODIFIED="2014-06-20 12:45:32 +0100" MODIFIED_BY="[Empty name]" ORDER="120" O_E="0.0" SE="0.10666026659915345" STUDY_ID="STD-BOA-2000" TOTAL_1="1351" TOTAL_2="1339" VAR="0.01137641247100249" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2014-09-22 15:26:11 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>ASA/DIP versus LMWH, all grafts</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="21" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-09-22 15:25:52 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="106" TOTAL_2="94" WEIGHT="0.0" Z="0.0">
<NAME>Primary graft patency, 6 months</NAME>
<GROUP_LABEL_1>ASA/DIP</GROUP_LABEL_1>
<GROUP_LABEL_2>LMWH</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ASA/DIP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours LMWH</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.6513750183740377" CI_START="0.7805657852075871" EFFECT_SIZE="1.688235294117647" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="12" LOG_CI_END="0.5624564399194298" LOG_CI_START="-0.10759048920799298" LOG_EFFECT_SIZE="0.2274329753557184" ORDER="4515" O_E="0.0" SE="0.39358888295523975" STUDY_ID="STD-Edmondson-1994" TOTAL_1="106" TOTAL_2="94" VAR="0.1549122087859534" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="38" EVENTS_2="30" I2="0.0" I2_Q="0.0" ID="CMP-006.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-09-22 15:26:11 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="106" TOTAL_2="94" WEIGHT="0.0" Z="0.0">
<NAME>Primary graft patency, 12 months</NAME>
<GROUP_LABEL_1>ASA/DIP</GROUP_LABEL_1>
<GROUP_LABEL_2>LMWH</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ASA/DIP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours LMWH</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.1461768129958854" CI_START="0.6622184979280918" EFFECT_SIZE="1.192156862745098" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="30" LOG_CI_END="0.3316654984990953" LOG_CI_START="-0.1789986921494982" LOG_EFFECT_SIZE="0.07633340317479857" ORDER="4516" O_E="0.0" SE="0.2999666734154958" STUDY_ID="STD-Edmondson-1994" TOTAL_1="106" TOTAL_2="94" VAR="0.08998000515995871" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-006.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-09-22 14:47:02 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="64.69" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="106" TOTAL_2="94" WEIGHT="0.0" Z="0.0">
<NAME>Mortality</NAME>
<GROUP_LABEL_1>ASA/DIP</GROUP_LABEL_1>
<GROUP_LABEL_2>LMWH</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ASA/DIP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours LMWH</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8632325998812658" CI_START="0.03821363157864039" EFFECT_SIZE="0.18162393162393162" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="9" LOG_CI_END="-0.06387216693357438" LOG_CI_START="-1.4177816877860883" LOG_EFFECT_SIZE="-0.7408269273598314" MODIFIED="2014-06-20 14:27:10 +0100" MODIFIED_BY="[Empty name]" ORDER="4516" O_E="0.0" SE="0.7952931545089827" STUDY_ID="STD-Edmondson-1994" TOTAL_1="106" TOTAL_2="94" VAR="0.6324912016088486" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" MODIFIED="2014-09-22 15:27:55 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Ticlopidine versus placebo, venous grafts</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-007.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-09-22 15:26:51 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="122" TOTAL_2="121" WEIGHT="0.0" Z="0.0">
<NAME>Primary graft patency, 1 month</NAME>
<GROUP_LABEL_1>Ticlopidine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ticlopidine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="74.37228019484539" CI_START="0.12101282865633818" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8714110968143405" LOG_CI_START="-0.9171685873750156" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="4517" O_E="0.0" SE="1.6380255101848875" STUDY_ID="STD-Becquemin-1997" TOTAL_1="122" TOTAL_2="121" VAR="2.683127572016461" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-007.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-09-22 15:27:10 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="122" TOTAL_2="121" WEIGHT="0.0" Z="0.0">
<NAME>Primary graft patency, 6 months</NAME>
<GROUP_LABEL_1>Ticlopidine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ticlopidine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.6302564432544002" CI_START="0.1067282981566014" EFFECT_SIZE="0.2593572778827977" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="23" LOG_CI_END="-0.200482705737946" LOG_CI_START="-0.9717204155909598" LOG_EFFECT_SIZE="-0.5861015606644528" ORDER="4518" O_E="0.0" SE="0.4530288484558949" STUDY_ID="STD-Becquemin-1997" TOTAL_1="122" TOTAL_2="121" VAR="0.2052351375332742" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="14" EVENTS_2="31" I2="0.0" I2_Q="0.0" ID="CMP-007.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-09-22 15:27:30 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="122" TOTAL_2="121" WEIGHT="0.0" Z="0.0">
<NAME>Primary graft patency, 12 months</NAME>
<GROUP_LABEL_1>Ticlopidine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ticlopidine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.7505730745190672" CI_START="0.188702307465686" EFFECT_SIZE="0.3763440860215054" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="31" LOG_CI_END="-0.12460701918956656" LOG_CI_START="-0.7242227892177523" LOG_EFFECT_SIZE="-0.42441490420365946" ORDER="4519" O_E="0.0" SE="0.35221727146048765" STUDY_ID="STD-Becquemin-1997" TOTAL_1="122" TOTAL_2="121" VAR="0.12405700631507083" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="22" EVENTS_2="45" I2="0.0" I2_Q="0.0" ID="CMP-007.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-09-22 15:27:55 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="122" TOTAL_2="121" WEIGHT="0.0" Z="0.0">
<NAME>Primary graft patency, 24 months</NAME>
<GROUP_LABEL_1>Ticlopidine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ticlopidine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.6707575958918035" CI_START="0.20581732016116627" EFFECT_SIZE="0.37155555555555553" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="45" LOG_CI_END="-0.17343440052674028" LOG_CI_START="-0.686518080817952" LOG_EFFECT_SIZE="-0.42997624067234613" ORDER="4520" O_E="0.0" SE="0.30138789360823665" STUDY_ID="STD-Becquemin-1997" TOTAL_1="122" TOTAL_2="121" VAR="0.09083466241360978" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" MODIFIED="2014-09-22 15:28:24 +0100" MODIFIED_BY="[Empty name]" NO="8">
<NAME>ASA versus prostaglandin (PGE1), venous grafts</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-008.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-09-22 15:28:24 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="33.59" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="50" TOTAL_2="50" WEIGHT="0.0" Z="0.0">
<NAME>Early occlusion</NAME>
<GROUP_LABEL_1>ASA</GROUP_LABEL_1>
<GROUP_LABEL_2>PGE1</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ASA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PGE1</GRAPH_LABEL_2>
<DICH_DATA CI_END="19.83058782910775" CI_START="0.7697435603600763" EFFECT_SIZE="3.9069767441860463" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="1.2973355879901753" LOG_CI_START="-0.11365393569762276" LOG_EFFECT_SIZE="0.5918408261462763" ORDER="4521" O_E="0.0" SE="0.8288222307249996" STUDY_ID="STD-Gruss-1991" TOTAL_1="50" TOTAL_2="50" VAR="0.6869462901439646" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-009" MODIFIED="2014-09-25 12:29:08 +0100" MODIFIED_BY="[Empty name]" NO="9">
<NAME>ASA versus naftidrofuryl</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="10" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-009.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-09-22 15:28:53 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="49" TOTAL_2="50" WEIGHT="0.0" Z="0.0">
<NAME>Primary graft patency at 12 months</NAME>
<GROUP_LABEL_1>ASA</GROUP_LABEL_1>
<GROUP_LABEL_2>Naftidrofuryl</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ASA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours naftidrofuryl</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.540210482545058" CI_START="0.5464313778980923" EFFECT_SIZE="1.575091575091575" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.6570759870617124" LOG_CI_START="-0.26246436998405154" LOG_EFFECT_SIZE="0.19730580853883048" ORDER="4534" O_E="0.0" SE="0.5401425575268596" STUDY_ID="STD-Noppeney-1988" TOTAL_1="49" TOTAL_2="50" VAR="0.29175398245165685" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="46" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-009.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-09-22 14:48:05 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="375.72" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="196" TOTAL_2="200" WEIGHT="0.0" Z="0.0">
<NAME>Side effects</NAME>
<GROUP_LABEL_1>ASA</GROUP_LABEL_1>
<GROUP_LABEL_2>Naftidrofuryl</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ASA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours naftidrofuryl</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="23" EVENTS_2="3" I2="0.0" ID="CMP-009.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-06-20 12:42:57 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="49" TOTAL_2="50" WEIGHT="0.0" Z="0.0">
<NAME>Side effects- general</NAME>
<DICH_DATA CI_END="50.5983329356784" CI_START="3.795997993192254" EFFECT_SIZE="13.85897435897436" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="3" LOG_CI_END="1.7041362083662321" LOG_CI_START="0.5793259741594277" LOG_EFFECT_SIZE="1.14173109126283" ORDER="4530" O_E="0.0" SE="0.6607190994735341" STUDY_ID="STD-Noppeney-1988" TOTAL_1="49" TOTAL_2="50" VAR="0.4365497284091178" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="18" EVENTS_2="1" I2="0.0" ID="CMP-009.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="49" TOTAL_2="50" WEIGHT="0.0" Z="0.0">
<NAME>Gastrointestinal side effects</NAME>
<DICH_DATA CI_END="223.9673668360517" CI_START="3.614340286402395" EFFECT_SIZE="28.451612903225808" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="1" LOG_CI_END="2.350184744068651" LOG_CI_START="0.558029038526443" LOG_EFFECT_SIZE="1.454106891297547" ORDER="4531" O_E="0.0" SE="1.0527211327493102" STUDY_ID="STD-Noppeney-1988" TOTAL_1="49" TOTAL_2="50" VAR="1.1082217833369907" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-009.02.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="49" TOTAL_2="50" WEIGHT="0.0" Z="0.0">
<NAME>Vertigo</NAME>
<DICH_DATA CI_END="4.1880263816408645" CI_START="0.009169035662474255" EFFECT_SIZE="0.19595959595959597" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6220094087673024" LOG_CI_START="-2.0376763381019503" LOG_EFFECT_SIZE="-0.7078334646673239" ORDER="4532" O_E="0.0" SE="1.5623125733677787" STUDY_ID="STD-Noppeney-1988" TOTAL_1="49" TOTAL_2="50" VAR="2.440820576903051" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="0" I2="0.0" ID="CMP-009.02.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="49" TOTAL_2="50" WEIGHT="0.0" Z="0.0">
<NAME>Stomach bleeding</NAME>
<DICH_DATA CI_END="232.14221685779333" CI_START="0.671264959255107" EFFECT_SIZE="12.48314606741573" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.3657541274492058" LOG_CI_START="-0.17310602285729595" LOG_EFFECT_SIZE="1.0963240522959548" ORDER="4533" O_E="0.0" SE="1.4913390198504701" STUDY_ID="STD-Noppeney-1988" TOTAL_1="49" TOTAL_2="50" VAR="2.224092072128561" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-009.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-09-22 14:48:35 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="41.69" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="49" TOTAL_2="50" WEIGHT="0.0" Z="0.0">
<NAME>Mortality</NAME>
<GROUP_LABEL_1>ASA</GROUP_LABEL_1>
<GROUP_LABEL_2>Naftidrofuryl</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ASA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours naftidrofuryl</GRAPH_LABEL_2>
<DICH_DATA CI_END="14.781527738757934" CI_START="0.5031967371967077" EFFECT_SIZE="2.727272727272727" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.169719322707243" LOG_CI_START="-0.2982621835843683" LOG_EFFECT_SIZE="0.43572856956143735" ORDER="4535" O_E="0.0" SE="0.8622996034213434" STUDY_ID="STD-Noppeney-1988" TOTAL_1="49" TOTAL_2="50" VAR="0.7435606060606061" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-010" MODIFIED="2014-09-25 12:29:26 +0100" MODIFIED_BY="[Empty name]" NO="10">
<NAME>Clopidogrel and ASA versus ASA alone, all grafts</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="93" EVENTS_2="97" I2="0.0" I2_Q="0.0" ID="CMP-010.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-09-22 15:29:19 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="EFFECT_SIZE" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="425" TOTAL_2="426" WEIGHT="0.0" Z="0.0">
<NAME>Primary graft patency at 24 months</NAME>
<GROUP_LABEL_1>Clopidogrel/ASA</GROUP_LABEL_1>
<GROUP_LABEL_2>ASA alone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clopidogrel/ASA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ASA alone</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3119867786736539" CI_START="0.6880319382555684" EFFECT_SIZE="0.9500993665383182" ESTIMABLE="YES" EVENTS_1="93" EVENTS_2="97" LOG_CI_END="0.117929458532014" LOG_CI_START="-0.1623914014647575" LOG_EFFECT_SIZE="-0.02223097146637176" MODIFIED="2014-06-10 12:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="98" O_E="0.0" SE="0.16466186077273967" STUDY_ID="STD-CASPAR-2010" TOTAL_1="425" TOTAL_2="426" VAR="0.027113528393141108" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="144" EVENTS_2="61" I2="0.0" I2_Q="0.0" ID="CMP-010.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-09-22 14:49:31 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="191.41" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="2125" TOTAL_2="2130" WEIGHT="0.0" Z="0.0">
<NAME>Side effects</NAME>
<GROUP_LABEL_1>Clopidogrel/ASA</GROUP_LABEL_1>
<GROUP_LABEL_2>ASA alone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clopidogrel/ASA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ASA alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="71" EVENTS_2="30" I2="0.0" ID="CMP-010.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-06-12 15:21:04 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="425" TOTAL_2="426" WEIGHT="0.0" Z="0.0">
<NAME>Bleeding- total</NAME>
<DICH_DATA CI_END="4.15298988050277" CI_START="1.6877074322512315" EFFECT_SIZE="2.647457627118644" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="30" LOG_CI_END="0.618360872875551" LOG_CI_START="0.2272971629227236" LOG_EFFECT_SIZE="0.4228290178991373" MODIFIED="2014-06-12 15:21:04 +0100" MODIFIED_BY="[Empty name]" ORDER="171" O_E="0.0" SE="0.2297127590228752" STUDY_ID="STD-CASPAR-2010" TOTAL_1="425" TOTAL_2="426" VAR="0.05276795165790153" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="46" EVENTS_2="21" I2="0.0" ID="CMP-010.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-06-12 15:20:51 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="425" TOTAL_2="426" WEIGHT="0.0" Z="0.0">
<NAME>Bleeding- mild</NAME>
<DICH_DATA CI_END="3.9960772927507247" CI_START="1.371117962994255" EFFECT_SIZE="2.3407463249151905" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="21" LOG_CI_END="0.6016338798268406" LOG_CI_START="0.13707482056166154" LOG_EFFECT_SIZE="0.36935435019425106" MODIFIED="2014-06-12 15:18:55 +0100" MODIFIED_BY="[Empty name]" ORDER="171" O_E="0.0" SE="0.27288429101679706" STUDY_ID="STD-CASPAR-2010" TOTAL_1="425" TOTAL_2="426" VAR="0.07446583628373998" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="16" EVENTS_2="4" I2="0.0" ID="CMP-010.02.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-06-12 15:20:50 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="425" TOTAL_2="426" WEIGHT="0.0" Z="0.0">
<NAME>Bleeding- moderate</NAME>
<DICH_DATA CI_END="12.449067769971588" CI_START="1.3682373368925536" EFFECT_SIZE="4.127139364303178" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="4" LOG_CI_END="1.0951368311493788" LOG_CI_START="0.13616143741521008" LOG_EFFECT_SIZE="0.6156491342822944" MODIFIED="2014-06-12 15:19:30 +0100" MODIFIED_BY="[Empty name]" ORDER="171" O_E="0.0" SE="0.5633068932842085" STUDY_ID="STD-CASPAR-2010" TOTAL_1="425" TOTAL_2="426" VAR="0.31731465602150666" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="9" EVENTS_2="5" I2="0.0" ID="CMP-010.02.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-06-12 15:20:50 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="425" TOTAL_2="426" WEIGHT="0.0" Z="0.0">
<NAME>Bleeding- severe</NAME>
<DICH_DATA CI_END="5.481148448789634" CI_START="0.6054119320012625" EFFECT_SIZE="1.8216346153846155" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="5" LOG_CI_END="0.7388715644544538" LOG_CI_START="-0.21794902382999048" LOG_EFFECT_SIZE="0.26046127031223165" MODIFIED="2014-06-12 15:19:41 +0100" MODIFIED_BY="[Empty name]" ORDER="171" O_E="0.0" SE="0.5620411498965813" STUDY_ID="STD-CASPAR-2010" TOTAL_1="425" TOTAL_2="426" VAR="0.3158902541770713" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-010.02.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-06-12 15:20:49 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="425" TOTAL_2="426" WEIGHT="0.0" Z="0.0">
<NAME>Bleeding- fatal</NAME>
<DICH_DATA CI_END="22.244423959608834" CI_START="0.18152479414064193" EFFECT_SIZE="2.0094562647754137" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.347221163763433" LOG_CI_START="-0.7410640470849325" LOG_EFFECT_SIZE="0.3030785583392504" MODIFIED="2014-06-12 15:19:56 +0100" MODIFIED_BY="[Empty name]" ORDER="174" O_E="0.0" SE="1.2266690700308394" STUDY_ID="STD-CASPAR-2010" TOTAL_1="425" TOTAL_2="426" VAR="1.5047170073703242" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="31" EVENTS_2="45" I2="0.0" I2_Q="0.0" ID="CMP-010.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-09-25 12:29:26 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="425" TOTAL_2="426" WEIGHT="0.0" Z="0.0">
<NAME>Limb amputation</NAME>
<GROUP_LABEL_1>Clopidogrel/ASA</GROUP_LABEL_1>
<GROUP_LABEL_2>ASA alone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clopidrogrel/ASA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ASA alone</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0751219159305268" CI_START="0.41276052193728985" EFFECT_SIZE="0.6661590524534687" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="45" LOG_CI_END="0.03145771486904105" LOG_CI_START="-0.38430184705109266" LOG_EFFECT_SIZE="-0.1764220660910258" MODIFIED="2014-06-20 10:02:41 +0100" MODIFIED_BY="[Empty name]" ORDER="116" O_E="0.0" SE="0.24421922471490978" STUDY_ID="STD-CASPAR-2010" TOTAL_1="425" TOTAL_2="426" VAR="0.0596430297203516" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="24" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-010.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-09-22 14:50:30 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="425" TOTAL_2="426" WEIGHT="0.0" Z="0.0">
<NAME>Mortality</NAME>
<GROUP_LABEL_1>Clopidogre/ASA</GROUP_LABEL_1>
<GROUP_LABEL_2>ASA alone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clopidogrel/ASA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ASA alone</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.720977194455406" CI_START="0.762004629084401" EFFECT_SIZE="1.4399295877952178" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="17" LOG_CI_END="0.43472490180780626" LOG_CI_START="-0.11804239036682312" LOG_EFFECT_SIZE="0.1583412557204916" MODIFIED="2014-06-12 15:24:12 +0100" MODIFIED_BY="[Empty name]" ORDER="176" O_E="0.0" SE="0.3246982436656031" STUDY_ID="STD-CASPAR-2010" TOTAL_1="425" TOTAL_2="426" VAR="0.1054289494395274" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-011" MODIFIED="2014-09-25 12:30:02 +0100" MODIFIED_BY="[Empty name]" NO="11">
<NAME>Clopidogrel and ASA versus ASA alone, subgroups</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="52" EVENTS_2="38" I2="0.0" I2_Q="0.0" ID="CMP-011.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-09-22 15:29:45 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="EFFECT_SIZE" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="297" TOTAL_2="301" WEIGHT="0.0" Z="0.0">
<NAME>Primary graft patency, venous grafts, 24 months</NAME>
<GROUP_LABEL_1>Clopidogrel/ASA</GROUP_LABEL_1>
<GROUP_LABEL_2>ASA alone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clopidogrel/ASA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ASA alone</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.310813651062806" CI_START="0.9338000607052434" EFFECT_SIZE="1.4689581095596134" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="38" LOG_CI_END="0.3637649244586676" LOG_CI_START="-0.029746102172238758" LOG_EFFECT_SIZE="0.1670094111432144" MODIFIED="2014-06-12 15:30:52 +0100" MODIFIED_BY="[Empty name]" ORDER="98" O_E="0.0" SE="0.2311503249539917" STUDY_ID="STD-CASPAR-2010" TOTAL_1="297" TOTAL_2="301" VAR="0.053430472726335956" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="41" EVENTS_2="59" I2="0.0" I2_Q="0.0" ID="CMP-011.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-09-22 15:30:02 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="EFFECT_SIZE" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="128" TOTAL_2="125" WEIGHT="0.0" Z="0.0">
<NAME>Primary graft patency, prosthetic grafts, 24 months</NAME>
<GROUP_LABEL_1>Clopidogrel/ASA</GROUP_LABEL_1>
<GROUP_LABEL_2>ASA alone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clopidogrel/ASA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ASA alone</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8788171417610802" CI_START="0.3162383508517918" EFFECT_SIZE="0.527177089421391" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="59" LOG_CI_END="-0.056101480541193065" LOG_CI_START="-0.49998546345712397" LOG_EFFECT_SIZE="-0.2780434719991586" MODIFIED="2014-06-12 15:30:40 +0100" MODIFIED_BY="[Empty name]" ORDER="98" O_E="0.0" SE="0.2607396488259702" STUDY_ID="STD-CASPAR-2010" TOTAL_1="128" TOTAL_2="125" VAR="0.06798516446989028" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="72" EVENTS_2="31" I2="0.0" I2_Q="0.0" ID="CMP-011.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-09-22 14:51:12 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="191.41" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="1275" TOTAL_2="1278" WEIGHT="0.0" Z="0.0">
<NAME>Side effects</NAME>
<GROUP_LABEL_1>Clopidogrel/ASA</GROUP_LABEL_1>
<GROUP_LABEL_2>ASA alone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clopidogrel/ASA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ASA alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="36" EVENTS_2="16" I2="0.0" ID="CMP-011.03.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-08-11 10:58:28 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="297" TOTAL_2="301" WEIGHT="0.0" Z="0.0">
<NAME>Bleeding- mild, venous grafts</NAME>
<DICH_DATA CI_END="4.532472835339871" CI_START="1.3317985314348428" EFFECT_SIZE="2.456896551724138" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="16" LOG_CI_END="0.6563352098999568" LOG_CI_START="0.1244385316632267" LOG_EFFECT_SIZE="0.39038687078159173" MODIFIED="2014-06-12 15:36:59 +0100" MODIFIED_BY="[Empty name]" ORDER="171" O_E="0.0" SE="0.31243874172727587" STUDY_ID="STD-CASPAR-2010" TOTAL_1="297" TOTAL_2="301" VAR="0.0976179673321234" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="11" EVENTS_2="6" I2="0.0" ID="CMP-011.03.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-08-11 10:58:28 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="128" TOTAL_2="125" WEIGHT="0.0" Z="0.0">
<NAME>Bleeding- mild, prosthetic grafts</NAME>
<DICH_DATA CI_END="5.207048633727839" CI_START="0.6677492898858458" EFFECT_SIZE="1.8646723646723646" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="6" LOG_CI_END="0.716591633996222" LOG_CI_START="-0.175386565154321" LOG_EFFECT_SIZE="0.2706025344209505" MODIFIED="2014-06-12 15:36:59 +0100" MODIFIED_BY="[Empty name]" ORDER="171" O_E="0.0" SE="0.5239524095443249" STUDY_ID="STD-CASPAR-2010" TOTAL_1="128" TOTAL_2="125" VAR="0.2745261274673039" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="11" EVENTS_2="2" I2="0.0" ID="CMP-011.03.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-08-11 10:58:28 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="297" TOTAL_2="301" WEIGHT="0.0" Z="0.0">
<NAME>Bleeding- moderate, venous grafts</NAME>
<DICH_DATA CI_END="26.167868402283677" CI_START="1.2634770051470692" EFFECT_SIZE="5.75" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="2" LOG_CI_END="1.417768347063664" LOG_CI_START="0.10156734231559697" LOG_EFFECT_SIZE="0.7596678446896304" MODIFIED="2014-06-12 15:38:12 +0100" MODIFIED_BY="[Empty name]" ORDER="171" O_E="0.0" SE="0.7731429854890656" STUDY_ID="STD-CASPAR-2010" TOTAL_1="297" TOTAL_2="301" VAR="0.5977500760109455" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="2" I2="0.0" ID="CMP-011.03.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-08-11 10:58:28 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="128" TOTAL_2="125" WEIGHT="0.0" Z="0.0">
<NAME>Bleeding- moderate, prosthetic grafts</NAME>
<DICH_DATA CI_END="13.131980113522562" CI_START="0.4759373640509939" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.1183302163818567" LOG_CI_START="-0.3224501990377814" LOG_EFFECT_SIZE="0.3979400086720376" MODIFIED="2014-06-12 15:38:18 +0100" MODIFIED_BY="[Empty name]" ORDER="171" O_E="0.0" SE="0.8463215479955748" STUDY_ID="STD-CASPAR-2010" TOTAL_1="128" TOTAL_2="125" VAR="0.7162601626016261" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="3" I2="0.0" ID="CMP-011.03.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-08-11 10:58:28 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="297" TOTAL_2="301" WEIGHT="0.0" Z="0.0">
<NAME>Bleeding- severe, venous grafts</NAME>
<DICH_DATA CI_END="10.46700328204323" CI_START="0.7223571017340029" EFFECT_SIZE="2.7497116493656284" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="1.019822360345574" LOG_CI_START="-0.1412480531615971" LOG_EFFECT_SIZE="0.4392871535919885" MODIFIED="2014-06-12 15:38:26 +0100" MODIFIED_BY="[Empty name]" ORDER="171" O_E="0.0" SE="0.6820185082853519" STUDY_ID="STD-CASPAR-2010" TOTAL_1="297" TOTAL_2="301" VAR="0.46514924564377663" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-011.03.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-08-11 10:58:28 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="128" TOTAL_2="125" WEIGHT="0.0" Z="0.0">
<NAME>Bleeding- severe, prosthetic grafts</NAME>
<DICH_DATA CI_END="5.4090726257835176" CI_START="0.043353081983433364" EFFECT_SIZE="0.484251968503937" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7331228126059172" LOG_CI_START="-1.3629800229669975" LOG_EFFECT_SIZE="-0.31492860518054017" MODIFIED="2014-06-12 15:38:33 +0100" MODIFIED_BY="[Empty name]" ORDER="171" O_E="0.0" SE="1.231261181491906" STUDY_ID="STD-CASPAR-2010" TOTAL_1="128" TOTAL_2="125" VAR="1.5160040970488444" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="31" EVENTS_2="45" I2="0.0" I2_Q="0.0" ID="CMP-011.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-09-25 12:29:40 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="425" TOTAL_2="426" WEIGHT="0.0" Z="0.0">
<NAME>Limb amputation</NAME>
<GROUP_LABEL_1>Clopidogrel/ASA</GROUP_LABEL_1>
<GROUP_LABEL_2>ASA alone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clopidogrel/ASA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ASA alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="19" EVENTS_2="21" I2="0.0" ID="CMP-011.04.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-06-20 10:05:21 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="297" TOTAL_2="301" WEIGHT="0.0" Z="0.0">
<NAME>Amputation, venous grafts</NAME>
<DICH_DATA CI_END="1.7323183195009266" CI_START="0.4793661739292862" EFFECT_SIZE="0.9112709832134293" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="21" LOG_CI_END="0.23862769813197002" LOG_CI_START="-0.3193326148458648" LOG_EFFECT_SIZE="-0.04035245835694736" MODIFIED="2014-06-20 10:05:21 +0100" MODIFIED_BY="[Empty name]" ORDER="117" O_E="0.0" SE="0.32774864979127355" STUDY_ID="STD-CASPAR-2010" TOTAL_1="297" TOTAL_2="301" VAR="0.10741917744000289" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="12" EVENTS_2="24" I2="0.0" ID="CMP-011.04.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-06-20 10:05:29 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="128" TOTAL_2="125" WEIGHT="0.0" Z="0.0">
<NAME>Amputation, prosthetic grafts</NAME>
<DICH_DATA CI_END="0.9147549208261263" CI_START="0.20718677166000027" EFFECT_SIZE="0.4353448275862069" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="24" LOG_CI_END="-0.03869524559441865" LOG_CI_START="-0.6836379766220955" LOG_EFFECT_SIZE="-0.3611666111082571" MODIFIED="2014-06-20 10:05:29 +0100" MODIFIED_BY="[Empty name]" ORDER="118" O_E="0.0" SE="0.37884255272366424" STUDY_ID="STD-CASPAR-2010" TOTAL_1="128" TOTAL_2="125" VAR="0.1435216797541823" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="24" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-011.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-09-25 12:30:02 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="425" TOTAL_2="426" WEIGHT="0.0" Z="0.0">
<NAME>Mortality</NAME>
<GROUP_LABEL_1>Clopidogrel/ASA</GROUP_LABEL_1>
<GROUP_LABEL_2>ASA alone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours clopidogrel/ASA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ASA alone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="18" EVENTS_2="13" I2="0.0" ID="CMP-011.05.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-09-25 12:29:54 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="297" TOTAL_2="301" WEIGHT="0.0" Z="0.0">
<NAME>Mortality, venous grafts</NAME>
<DICH_DATA CI_END="2.972204077893815" CI_START="0.6873156754296396" EFFECT_SIZE="1.4292803970223324" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="13" LOG_CI_END="0.47307862570103204" LOG_CI_START="-0.16284375113682684" LOG_EFFECT_SIZE="0.1551174372821026" MODIFIED="2014-06-12 15:39:42 +0100" MODIFIED_BY="[Empty name]" ORDER="176" O_E="0.0" SE="0.37354395202109175" STUDY_ID="STD-CASPAR-2010" TOTAL_1="297" TOTAL_2="301" VAR="0.1395350840915357" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="4" I2="0.0" ID="CMP-011.05.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-09-25 12:30:02 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="128" TOTAL_2="125" WEIGHT="0.0" Z="0.0">
<NAME>Mortality, prosthetic grafts</NAME>
<DICH_DATA CI_END="5.4039756616402395" CI_START="0.409562526132318" EFFECT_SIZE="1.4877049180327868" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.7327133843842001" LOG_CI_START="-0.38767978698943384" LOG_EFFECT_SIZE="0.17251679869738307" MODIFIED="2014-06-12 15:39:53 +0100" MODIFIED_BY="[Empty name]" ORDER="176" O_E="0.0" SE="0.658124494900516" STUDY_ID="STD-CASPAR-2010" TOTAL_1="128" TOTAL_2="125" VAR="0.4331278507880594" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2015-01-27 14:42:47 +0000" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2015-01-27 14:42:47 +0000" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAApcAAARQCAYAAAC4UXqnAACAAElEQVR42uy9D0Se3+P//2ZmMjMj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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2015-01-27 14:25:06 +0000" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAl4AAAEACAMAAABVk4iuAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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=
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2015-01-27 14:25:06 +0000" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAU4AAAM1CAIAAACQS48VAAAqtUlEQVR42u3dsW4cyfn1YQIGDAcM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==
</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2014-04-24 19:34:22 +0100" MODIFIED_BY="[Empty name]">
<FEEDBACK_ITEM ID="FBK-01" MODIFIED="2014-04-24 19:34:22 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2011-02-14 11:09:32 +0000" MODIFIED_BY="Marlene Stewart">Anticoagulant feedback</TITLE>
<DATE_SUBMITTED>
<DATE DAY="14" MONTH="2" YEAR="2011"/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY MODIFIED="2011-02-14 11:10:22 +0000" MODIFIED_BY="Marlene Stewart">
<P>Feedback received on this review, and other reviews and protocols on anticoagulants, is available on the Cochrane Editorial Unit website at <A HREF="http://www.editorial-unit.cochrane.org/anticoagulants-feedback">http://www.editorial-unit.cochrane.org/anticoagulants-feedback</A>.</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY MODIFIED="2014-04-24 19:34:22 +0100" MODIFIED_BY="[Empty name]"/>
<FEEDBACK_CONTRIBUTORS/>
</FEEDBACK_ITEM>
</FEEDBACK>
<APPENDICES MODIFIED="2014-09-01 15:23:28 +0100" MODIFIED_BY="Karen Welch">
<APPENDIX ID="APP-01" MODIFIED="2014-09-01 15:23:28 +0100" MODIFIED_BY="Karen Welch" NO="1">
<TITLE MODIFIED="2014-04-02 13:34:27 +0100" MODIFIED_BY="Karen Welch">CENTRAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-09-01 15:23:28 +0100" MODIFIED_BY="Karen Welch">
<TABLE COLS="3" ROWS="66">
<TR>
<TD>
<P>#1</P>
</TD>
<TD>
<P>MeSH descriptor: [Arteriosclerosis] this term only</P>
</TD>
<TD ALIGN="RIGHT">
<P>895</P>
</TD>
</TR>
<TR>
<TD>
<P>#2</P>
</TD>
<TD>
<P>MeSH descriptor: [Arteriolosclerosis] this term only</P>
</TD>
<TD ALIGN="RIGHT">
<P>0</P>
</TD>
</TR>
<TR>
<TD>
<P>#3</P>
</TD>
<TD>
<P>MeSH descriptor: [Arteriosclerosis Obliterans] this term only</P>
</TD>
<TD ALIGN="RIGHT">
<P>73</P>
</TD>
</TR>
<TR>
<TD>
<P>#4</P>
</TD>
<TD>
<P>MeSH descriptor: [Atherosclerosis] this term only</P>
</TD>
<TD ALIGN="RIGHT">
<P>513</P>
</TD>
</TR>
<TR>
<TD>
<P>#5</P>
</TD>
<TD>
<P>MeSH descriptor: [Arterial Occlusive Diseases] this term only</P>
</TD>
<TD ALIGN="RIGHT">
<P>810</P>
</TD>
</TR>
<TR>
<TD>
<P>#6</P>
</TD>
<TD>
<P>MeSH descriptor: [Intermittent Claudication] this term only</P>
</TD>
<TD ALIGN="RIGHT">
<P>768</P>
</TD>
</TR>
<TR>
<TD>
<P>#7</P>
</TD>
<TD>
<P>MeSH descriptor: [Ischemia] this term only</P>
</TD>
<TD ALIGN="RIGHT">
<P>814</P>
</TD>
</TR>
<TR>
<TD>
<P>#8</P>
</TD>
<TD>
<P>MeSH descriptor: [Peripheral Vascular Diseases] explode all trees</P>
</TD>
<TD ALIGN="RIGHT">
<P>2293</P>
</TD>
</TR>
<TR>
<TD>
<P>#9</P>
</TD>
<TD>
<P>MeSH descriptor: [Vascular Diseases] this term only</P>
</TD>
<TD ALIGN="RIGHT">
<P>424</P>
</TD>
</TR>
<TR>
<TD>
<P>#10</P>
</TD>
<TD>
<P>MeSH descriptor: [Leg] explode all trees and with qualifier(s): [Blood supply - BS]</P>
</TD>
<TD ALIGN="RIGHT">
<P>1145</P>
</TD>
</TR>
<TR>
<TD>
<P>#11</P>
</TD>
<TD>
<P>MeSH descriptor: [Femoral Artery] explode all trees</P>
</TD>
<TD ALIGN="RIGHT">
<P>796</P>
</TD>
</TR>
<TR>
<TD>
<P>#12</P>
</TD>
<TD>
<P>MeSH descriptor: [Popliteal Artery] explode all trees</P>
</TD>
<TD ALIGN="RIGHT">
<P>289</P>
</TD>
</TR>
<TR>
<TD>
<P>#13</P>
</TD>
<TD>
<P>MeSH descriptor: [Iliac Artery] explode all trees</P>
</TD>
<TD ALIGN="RIGHT">
<P>159</P>
</TD>
</TR>
<TR>
<TD>
<P>#14</P>
</TD>
<TD>
<P>MeSH descriptor: [Tibial Arteries] explode all trees</P>
</TD>
<TD ALIGN="RIGHT">
<P>32</P>
</TD>
</TR>
<TR>
<TD>
<P>#15</P>
</TD>
<TD>
<P>(atherosclero* or arteriosclero* or PVD or PAOD or PAD)</P>
</TD>
<TD ALIGN="RIGHT">
<P>19399</P>
</TD>
</TR>
<TR>
<TD>
<P>#16</P>
</TD>
<TD>
<P>(arter*) near (*occlus* or steno* or obstruct* or lesio* or block* or obliter*)</P>
</TD>
<TD ALIGN="RIGHT">
<P>6127</P>
</TD>
</TR>
<TR>
<TD>
<P>#17</P>
</TD>
<TD>
<P>(vascular) near (*occlus* or steno* or obstruct* or lesio* or block* or obliter*)</P>
</TD>
<TD ALIGN="RIGHT">
<P>1656</P>
</TD>
</TR>
<TR>
<TD>
<P>#18</P>
</TD>
<TD>
<P>(vein*) near (*occlus* or steno* or obstruct* or lesio* or block* or obliter*)</P>
</TD>
<TD ALIGN="RIGHT">
<P>951</P>
</TD>
</TR>
<TR>
<TD>
<P>#19</P>
</TD>
<TD>
<P>(veno*) near (*occlus* or steno* or obstruct* or lesio* or block* or obliter*)</P>
</TD>
<TD ALIGN="RIGHT">
<P>1174</P>
</TD>
</TR>
<TR>
<TD>
<P>#20</P>
</TD>
<TD>
<P>(peripher*) near (*occlus* or steno* or obstruct* or lesio* or block* or obliter*)</P>
</TD>
<TD ALIGN="RIGHT">
<P>1631</P>
</TD>
</TR>
<TR>
<TD>
<P>#21</P>
</TD>
<TD>
<P>peripheral near/3 dis*</P>
</TD>
<TD ALIGN="RIGHT">
<P>3705</P>
</TD>
</TR>
<TR>
<TD>
<P>#22</P>
</TD>
<TD>
<P>arteriopathic</P>
</TD>
<TD ALIGN="RIGHT">
<P>25</P>
</TD>
</TR>
<TR>
<TD>
<P>#23</P>
</TD>
<TD>
<P>(claudic* or hinken*)</P>
</TD>
<TD ALIGN="RIGHT">
<P>1600</P>
</TD>
</TR>
<TR>
<TD>
<P>#24</P>
</TD>
<TD>
<P>(isch* or CLI)</P>
</TD>
<TD ALIGN="RIGHT">
<P>20013</P>
</TD>
</TR>
<TR>
<TD>
<P>#25</P>
</TD>
<TD>
<P>dysvascular*</P>
</TD>
<TD ALIGN="RIGHT">
<P>35</P>
</TD>
</TR>
<TR>
<TD>
<P>#26</P>
</TD>
<TD>
<P>leg near/4 (obstruct* or occlus* or steno* or block* or obliter*)</P>
</TD>
<TD ALIGN="RIGHT">
<P>201</P>
</TD>
</TR>
<TR>
<TD>
<P>#27</P>
</TD>
<TD>
<P>limb near/4 (obstruct* or occlus* or steno* or block* or obliter*)</P>
</TD>
<TD ALIGN="RIGHT">
<P>261</P>
</TD>
</TR>
<TR>
<TD>
<P>#28</P>
</TD>
<TD>
<P>(lower near/3 extrem*) near/4 (obstruct* or occlus* or steno* or block* or obliter*)</P>
</TD>
<TD ALIGN="RIGHT">
<P>158</P>
</TD>
</TR>
<TR>
<TD>
<P>#29</P>
</TD>
<TD>
<P>(aort* or iliac or femoral or popliteal or femoro* or fempop* or crural or *inguinal) near/3 (obstruct* or occlus*)</P>
</TD>
<TD ALIGN="RIGHT">
<P>402</P>
</TD>
</TR>
<TR>
<TD>
<P>#30</P>
</TD>
<TD>
<P>#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29</P>
</TD>
<TD ALIGN="RIGHT">
<P>46395</P>
</TD>
</TR>
<TR>
<TD>
<P>#31</P>
</TD>
<TD>
<P>bypass*:ti,ab,kw (Word variations have been searched)</P>
</TD>
<TD ALIGN="RIGHT">
<P>11328</P>
</TD>
</TR>
<TR>
<TD>
<P>#32</P>
</TD>
<TD>
<P>MeSH descriptor: [Vascular Grafting] explode all trees</P>
</TD>
<TD ALIGN="RIGHT">
<P>6012</P>
</TD>
</TR>
<TR>
<TD>
<P>#33</P>
</TD>
<TD>
<P>MeSH descriptor: [Blood Vessel Prosthesis] explode all trees</P>
</TD>
<TD ALIGN="RIGHT">
<P>472</P>
</TD>
</TR>
<TR>
<TD>
<P>#34</P>
</TD>
<TD>
<P>MeSH descriptor: [Blood Vessel Prosthesis Implantation] explode all trees</P>
</TD>
<TD ALIGN="RIGHT">
<P>536</P>
</TD>
</TR>
<TR>
<TD>
<P>#35</P>
</TD>
<TD>
<P>revascul*:ti,ab,kw (Word variations have been searched)</P>
</TD>
<TD ALIGN="RIGHT">
<P>4850</P>
</TD>
</TR>
<TR>
<TD>
<P>#36</P>
</TD>
<TD>
<P>graft*:ti,ab,kw (Word variations have been searched)</P>
</TD>
<TD ALIGN="RIGHT">
<P>13673</P>
</TD>
</TR>
<TR>
<TD>
<P>#37</P>
</TD>
<TD>
<P>reconstruct*:ti,ab,kw (Word variations have been searched)</P>
</TD>
<TD ALIGN="RIGHT">
<P>9</P>
</TD>
</TR>
<TR>
<TD>
<P>#38</P>
</TD>
<TD>
<P>#31 or #32 or #33 or #34 or #35 or #36 or #37</P>
</TD>
<TD ALIGN="RIGHT">
<P>23761</P>
</TD>
</TR>
<TR>
<TD>
<P>#39</P>
</TD>
<TD>
<P>#30 and #38 in Trials</P>
</TD>
<TD ALIGN="RIGHT">
<P>5278</P>
</TD>
</TR>
<TR>
<TD>
<P>#40</P>
</TD>
<TD>
<P>MeSH descriptor: [Platelet Aggregation Inhibitors] explode all trees</P>
</TD>
<TD ALIGN="RIGHT">
<P>3038</P>
</TD>
</TR>
<TR>
<TD>
<P>#41</P>
</TD>
<TD>
<P>MeSH descriptor: [Phosphodiesterase Inhibitors] explode all trees</P>
</TD>
<TD ALIGN="RIGHT">
<P>970</P>
</TD>
</TR>
<TR>
<TD>
<P>#42</P>
</TD>
<TD>
<P>MeSH descriptor: [Tetrazoles] this term only</P>
</TD>
<TD ALIGN="RIGHT">
<P>1681</P>
</TD>
</TR>
<TR>
<TD>
<P>#43</P>
</TD>
<TD>
<P>antiplatelet* or anti-platelet* or antiaggreg* or anti-aggreg*:ti,ab,kw (Word variations have been searched)</P>
</TD>
<TD ALIGN="RIGHT">
<P>2314</P>
</TD>
</TR>
<TR>
<TD>
<P>#44</P>
</TD>
<TD>
<P>((platelet or thromboxane or thrombocyte or cyclooxygenase or cyclo-oxygenase or phosphodiesterase or fibrinogen or PAR-1) near/3 (antagonist or inhibitor)):ti,ab,kw (Word variations have been searched)</P>
</TD>
<TD ALIGN="RIGHT">
<P>6624</P>
</TD>
</TR>
<TR>
<TD>
<P>#45</P>
</TD>
<TD>
<P>(gp* or glycoprotein* or protease or P2Y12 or TXA2) near/3 inhibit*:ti,ab,kw (Word variations have been searched)</P>
</TD>
<TD ALIGN="RIGHT">
<P>2401</P>
</TD>
</TR>
<TR>
<TD>
<P>#46</P>
</TD>
<TD>
<P>thienopyridine:ti,ab,kw (Word variations have been searched)</P>
</TD>
<TD ALIGN="RIGHT">
<P>144</P>
</TD>
</TR>
<TR>
<TD>
<P>#47</P>
</TD>
<TD>
<P>ticlopidine or Ticlid:ti,ab,kw (Word variations have been searched)</P>
</TD>
<TD ALIGN="RIGHT">
<P>1583</P>
</TD>
</TR>
<TR>
<TD>
<P>#48</P>
</TD>
<TD>
<P>clopidogrel or Plavix:ti,ab,kw (Word variations have been searched)</P>
</TD>
<TD ALIGN="RIGHT">
<P>1849</P>
</TD>
</TR>
<TR>
<TD>
<P>#49</P>
</TD>
<TD>
<P>Prasugrel or Effient or Efient or Prasita:ti,ab,kw (Word variations have been searched)</P>
</TD>
<TD ALIGN="RIGHT">
<P>182</P>
</TD>
</TR>
<TR>
<TD>
<P>#50</P>
</TD>
<TD>
<P>ticagrelor or AZD6140 or Brilinta:ti,ab,kw (Word variations have been searched)</P>
</TD>
<TD ALIGN="RIGHT">
<P>126</P>
</TD>
</TR>
<TR>
<TD>
<P>#51</P>
</TD>
<TD>
<P>elinogrel or PRT060128 or PRT-060128:ti,ab,kw (Word variations have been searched)</P>
</TD>
<TD ALIGN="RIGHT">
<P>7</P>
</TD>
</TR>
<TR>
<TD>
<P>#52</P>
</TD>
<TD>
<P>cangrelor or AR-C6993* or ARC6993*:ti,ab,kw (Word variations have been searched)</P>
</TD>
<TD ALIGN="RIGHT">
<P>25</P>
</TD>
</TR>
<TR>
<TD>
<P>#53</P>
</TD>
<TD>
<P>SCH530348 or SCH-530348:ti,ab,kw (Word variations have been searched)</P>
</TD>
<TD ALIGN="RIGHT">
<P>11</P>
</TD>
</TR>
<TR>
<TD>
<P>#54</P>
</TD>
<TD>
<P>E5555:ti,ab,kw (Word variations have been searched)</P>
</TD>
<TD ALIGN="RIGHT">
<P>3</P>
</TD>
</TR>
<TR>
<TD>
<P>#55</P>
</TD>
<TD>
<P>terutroban or Triplion:ti,ab,kw (Word variations have been searched)</P>
</TD>
<TD ALIGN="RIGHT">
<P>11</P>
</TD>
</TR>
<TR>
<TD>
<P>#56</P>
</TD>
<TD>
<P>(aspirin* or nitroaspirin or ASA or "acetyl salicylic acid*" or "acetylsalicylic acid" or "acetyl-salicylic acid"):ti,ab,kw (Word variations have been searched)</P>
</TD>
<TD ALIGN="RIGHT">
<P>15346</P>
</TD>
</TR>
<TR>
<TD>
<P>#57</P>
</TD>
<TD>
<P>triflusal or disgren:ti,ab,kw (Word variations have been searched)</P>
</TD>
<TD ALIGN="RIGHT">
<P>88</P>
</TD>
</TR>
<TR>
<TD>
<P>#58</P>
</TD>
<TD>
<P>Cilostazol or Pletal or Pletaal:ti,ab,kw (Word variations have been searched)</P>
</TD>
<TD ALIGN="RIGHT">
<P>356</P>
</TD>
</TR>
<TR>
<TD>
<P>#59</P>
</TD>
<TD>
<P>dipyridamol* or Persantine:ti,ab,kw (Word variations have been searched)</P>
</TD>
<TD ALIGN="RIGHT">
<P>1086</P>
</TD>
</TR>
<TR>
<TD>
<P>#60</P>
</TD>
<TD>
<P>OPC-13013 or OPC13013:ti,ab,kw (Word variations have been searched)</P>
</TD>
<TD ALIGN="RIGHT">
<P>5</P>
</TD>
</TR>
<TR>
<TD>
<P>#61</P>
</TD>
<TD>
<P>picotamide or picotinamide:ti,ab,kw (Word variations have been searched)</P>
</TD>
<TD ALIGN="RIGHT">
<P>43</P>
</TD>
</TR>
<TR>
<TD>
<P>#62</P>
</TD>
<TD>
<P>satigrel:ti,ab,kw (Word variations have been searched)</P>
</TD>
<TD ALIGN="RIGHT">
<P>4</P>
</TD>
</TR>
<TR>
<TD>
<P>#63</P>
</TD>
<TD>
<P>vorapaxar:ti,ab,kw (Word variations have been searched)</P>
</TD>
<TD ALIGN="RIGHT">
<P>22</P>
</TD>
</TR>
<TR>
<TD>
<P>#64</P>
</TD>
<TD>
<P>indobufen</P>
</TD>
<TD ALIGN="RIGHT">
<P>102</P>
</TD>
</TR>
<TR>
<TD>
<P>#65</P>
</TD>
<TD>
<P>#40 or #41 or #42 or #43 or #44 or #45 or #46 or #47 or #48 or #49 or #50 or #51 or #52 or #53 or #54 or #55 or #56 or #57 or #58 or #59 or #60 or #61 or #62 or #63 or #64</P>
</TD>
<TD ALIGN="RIGHT">
<P>25325</P>
</TD>
</TR>
<TR>
<TD>
<P>#66</P>
</TD>
<TD>
<P>39 and #65 in Trials</P>
</TD>
<TD ALIGN="RIGHT">
<P>1259</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;16 studies included in quatitative analysis (meta-analysis)&lt;/p&gt;" WIDTH="145">
<FLOWCHARTBOX TEXT="&lt;p&gt;16 studies included in qualitative analysis&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;15 studies included in previous version of review&lt;/p&gt;"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;1 NEW study included (4 reports)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;19 full-text reports assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;1225 records screened by TSC&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;1225 records after duplicates removed&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;1259 reports from CENTRAL&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;19 reports identified from the Specialised Register&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;1206 not relevant&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;3 new studies excluded, with reasons (4 reports)&lt;/p&gt;&lt;p&gt;4 additional reports added to BOA study&lt;/p&gt;&lt;p&gt;1 additional report added to McCollum study &lt;/p&gt;&lt;p&gt;6 not relevant&lt;/p&gt;&lt;p&gt;(In addition 6 reports to the BOA study and 2 reports to the McCollum study previously recorded as excluded studies have now been added to the BOA and McCollum study IDs)&lt;/p&gt;" WIDTH="142"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>